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Welcome
Veistu ef þú vin átt,  Know, if you have a friend
þann er þú vel trúir,  in whom you have faith,
og vilt þú af honum gott geta,  and you wish to get something good from him,
geði skaltu við þann blanda  you must share with his mind
og gjöfum skipta,  and exchange gifts,
fara að finna oft and go often to seek him out
(Hávamál)
Dear Participant
On behalf of the organizing Icelandic societies of pulmonary physicians and nurses, we are pleased to welcome you to 
Reykjavik and to the 46th Nordic Lung Congress.
A profound change has occurred in just a few years in the way we access information. To gain knowledge of the most 
recent advances in medicine it is no longer necessary to travel the world.  In some aspects the need for medical conferences 
as a source of explicit information has lessened.
What has not lessened and has perhaps become more important than ever before, is the way we process this immense 
amount of information,  digest it and turn it into the know-how that we can use for our own work and for the benefit of 
our patients. 
This is the kind of tacit knowledge that can only be transmitted by personal contact with people that you know or share 
a background with, be it cultural, scientific or social.
Therein one finds the value of Nordic collaboration. 
The ambition of the NLC is to facilitate this collaboration by bringing together Nordic academic and clinical researchers 
with shared interests in respiratory medicine and nursing.  If fruitful, such contacts can be of crucial importance in the 
everyday work, also in the interval between the conferences. The general vision for Nordic collaboration is that the Nordic 
Countries comprise a leading region in the areas of innovation, green growth and welfare.  Working together in health 
care, will help us along that path.
We are thankful to the session Chairs, and Plenary, Invited and Featured Speakers and to all of you who have come to 
Reykjavik to present and share your work.
The associated exhibition runs in parallel with the conference and offers you the chance to get up-to-date information 
from companies active in respiratory medicine. We are grateful to our sponsors and exhibitors for their interest and support 
for the conference
Special thanks go to the dedicated team of Congress Reykjavik who run all aspects of the technical organisation, marketing 
and exhibition of this conference.
We hope you find the conference stimulating and that you enjoy meeting up with old friends and making new ones. We 
look forward to receiving your feedback and to seeing you again at the next NLC in 2015.
Best wishes,
Eyþór Björnsson,  
The Icelandic Society of Respiratory Physicians
Bryndís Halldórsdóttir, 
The Icelandic Society of Respiratory Nurses
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Something is missing ...
To find out what is missing,  
visit the flutiform® stand and learn more.
oncology
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Practical Information
Chairs
Please be present in your session hall at least 10 minutes prior to your session. It is important that the session 
stay on schedule so that individuals who want to hear a specific talk may do so without concerns of time. 
Please keep time with a gentle but firm hand.
It is vital that all speakers observe their time allotment.
Congress Badges
Your personal badge is your entrance ticket to the sessions and you are asked to wear it throughout the congress. 
Should you misplace your badge a replacement can be obtained at the Congress hospitality desk.
Excursions
Excursions for participants and accompanying persons are available and information and tickets can be obtained 
at the Congress hospitality desk.
Hospitality and Registration Desk 
Congress Reykjavík is in charge of the registration, accommodation bookings and social arrangements. 
Opening hours: Thursday June 13 10:00–16:30
 Friday June 14  08:00–16:30 
 Saturday June 15 08:00–12:00
Telephone / mobile: Kristjana 820 4339, Bryndis: 696 5169, Lara: 896 6075
Poster Display, set –up and removal 
All posters are to be put up at the beginning of the Congress and dismantled in the end. Poster left on poster 
boards after the congress will be removed by the organiser who can not be held liable for any loss or damage to 
posters.
Please refer to the Programme book that you will receive upon arrival at the Congress for the poster board 
number assigned to you. 
Please use the board with the same number. 
Professional Congress Organizer – PCO 
Congress Reykjavík, Conference Management Services Ltd. is the official organizing agency for the congress. 
The address is: Congress Reykjavik, Engjateigur 5, IS-105 Reykjavík, 
tel: +354 585 3900, fax: +354 585 3901, www.congress.is.
Speakers 
All speakers are asked to bring their presentation on a memory stick in time before the beginning of their session 
and load it on the computer in the session hall.
6 NLC 2013
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gratefully acknowledges the following benefactors
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Social Programme
Thursday, June 13
17:00–18:30 Welcome Reception – Reykjavik City Hall
Welcome reception will be held at the City Hall.
•	 Light refreshment will be served and musical artists will perform during the reception.
•	 The City Hall is located in the city centre by the lake Tjörnin.
•	 Included in the registration fee.
 
Friday, June 14
20:00–23:30 Congress Dinner at The Blue Lagoon 
The Blue Lagoon is a unique experience – an unforgettable opportunity to energize with the 
forces of nature. Set in the pure heart of the Icelandic landscape, Blue Lagoon is a truly 
special world. 
•	 After optional bath a three course dinner with wine will be served at the Lava 
restaurant. Musical artists will perform during the dinner and a dance band will play 
for you into the summer night.
•	 Tickets can be bought when registering for the conference. 
Transfer from the venue Harpa:
17:30 Bus departure for Congress dinner with bath entrance
Price ISK 17.500
19:00 Bus departure for Congress dinner 
Price ISK 13.000
23:30/24:00  Bus departure to Reykjavik
10 NLC 2013
Programme Overview
Thursday, June 13
NORÐURLJÓS KALDALÓN RÍMA STEMMA
12:00–12:20 Opening Act
12:20–13:00 Light lunch in the exhibition area
13:00–14:30 Session 1 – Sleep 1  Session 2 – Occupational Medicine Session 3 – Palliative Care
14:30–15:00 Coffee Break
15:00–16:00 Session 4 – Pulmonary 
interventions
15:00–17:00 Session 5 – Pulmonary Rehabilitation
15:00–16:30 Session 6 – RHINE study: 
New data
17:00–18:30 Reception City Hall – Musical Event
Friday, June 14
KALDALÓN RÍMA STEMMA BJÖRTU LOFT
08:30–10:00 Session 7 – Diagnosis and 
staging of lung cancer
Session 8 – COPD 1 Aspects 
on disease progression
Session 9 – Home 
mechanical ventilation
10:00–10:30 Coffee Break and Guided Poster Discussion
10:30–12:00 Session 10 – Beginning COPD Session 11 – Lung infections: 
Broken defences-vulnerable 
lungs 
12:00–13:00 Lunch
13:00–14:45 Session 12 – Difficult to treat 
astma; what do we know and 
where are we going?
Session 13 – Tuberculosis in 
the Nordic countries
13:00–14:30 Session 14 – Partnership 
with individuals and 
families facing the 
existence of COPD
14:30–15:00 Coffee Break and Guided Poster Discussion
15:00–16:40 Session 15 – Biomarkers in 
asthma – diagnosis and 
management 
15:00–16:20 Session 16 – Person centered 
care  
15:00–16:30 Session 17 – Pulmonary 
Hypertension
20:00–23:30 Congress dinner at the Blue Lagoon
Saturday, June 15
KALDALÓN RÍMA
08:30–09:30 Session 18 – Treatment guidelines on COPD  
08:30–09:45 Session 19 – Interstitial lung diseases
10:30–12:00 Session 20 – Nursing care for people with advanced 
lung diseases and their families
Session 21 – Sleep 2
NLC 2013 11
Programme
Thursday, June 13
12:00–12:20 Opening Act HALL: NORðuRLJÓS – 2ND FLOOR
12:20–13:00    Light lunch served in the exhibition area
13:00–14:30 Session 1 – Sleep 1  HALL: KALDALÓN 
Aim: To describe the many faces of obstructive sleep apnea in association with other common clinical  
problems including RLS, nGER and insomnia
Chair: Stefán Þorvaldsson
13:00–13:30 O01 Is sleep apnea also a major health problem among women? 
Eva Lindberg
University of Uppsala, UPPSALA, Sweden
13:30–13:50 O02 RLS among sleep apnea patients before and after PAP treatment and compared to the general 
population
Erna Arnardottir1, Bryndis Benediktsdottir1, Christer Janson2, Allan I. Pack3, Sigurdur Juliusson4, Thorarinn Gislason1
1University Hospital of Iceland, REYKJAVIK, Iceland
2Uppsala University, UPPSALA, Sweden
3University of Pennsylvania School, PENNSYLVANIA, USA
4Landspitali University Hospital, REYKJAVIK, Iceland
13:50–14:10 O03 Sleep and Gastroesophageal Reflux Disease
Össur Ingi Emilsson1, Christer Janson2, Þórarinn Gíslason1
1Landspitali, REYKJAVIK, Iceland
2Uppsala University Hospital, UPPSALA, Sweden
14:10–14:30 O04 Symptoms of insomnia among OSA patients before and after 2 years of PAP treatment
Erla Björnsdóttir1, Christer Janson2, Jon Sigurdsson1, Philip Gherman3, Michael Perlis3, Sigurdur Juliusson4, Erna 
Arnardottir1, Samuel Kuna5, Allan Pack3, Thorarinn Gislason1, Bryndis Benediktsdottir1
1University of Iceland, REYKJAVIK, Iceland
2Uppsala university, UPPSALA, Sweden
3University of Pennsylvania, PENNSYLVANIA, United States of America
4Landspitali, REYKJAVIK, Iceland
5Veterans Affairs Medical Center, Philadelphia, PHILADELPHIA, United States of America
13:00–14:30 Session 2 – Occupational Medicine HALL: RíMA 
Aim: To describe the effect of different environmental exposure of lungs
Chair: Sigurður Þór Sigurðsson
13:00–13:30 O05 Farming exposure and respiratory health
Anna Rask-Andersen
Arbets- och miljömedicin, Akademiska sjukhuset, UPPSALA, Sweden
13:30–13:50 O06 Asthma and COPD in Norwegian farmers – associations with farming exposure depend on atopy
Wijnand Eduard
National Institute of Occupational Health, OSLO, Norge
13:50–14:10 O07 The exposure-window and gene-environment interaction as modifier for respiratory health in 
farming
Øyvind Omland
Aalborg University Hospital, AALBORG, Denmark
14:10–14:30 O08 Volcanic eruptions and respiratory health – the Icelandic experience
Hanne Krage Carlsen
University of Iceland, REYKJAVIK, Iceland
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13:00–14:30 Session 3 – Palliative Care  HALL: STEMMA 
Aim: Create an interdisciplinary dialogue on unique needs of people with COPD in palliative care
Chairs: Þorbjörg Sóley Ingadóttir, Guðrún Jónsdóttir
13:00–13:30 O09 Palliative care and COPD
Abebaw Yohannes
RIHSC Research Centre, MANCHESTER, United Kingdom
13:30–14:00 O10 Characteristics of people with COPD admitted to nursing homes in Iceland
Ingibjörg Hjaltadóttir
Landspitali University Hospital, REYKJAVÍK, Iceland
14:00–14:30 Panel discussions; Abebaw Yohannes, Ingibjorg Hjaltadottir, Jon Eyjolfur Jonsson and Dóra Lúðvíksdóttir
14:30–15:00 Coffee Break
15:00–16:00 Session 4 – Pulmonary interventions HALL: KALDALÓN 
Aim: To provide insight into recent developments in pulmonary interventions 
Chair: Óskar Einarsson
15:00–15:30 O11 State of the art : New frontiers in interventional pulmonology
Erik van der Heijden
Radboud University Nijmegen Medical Center, NIJMEGEN, Nederland
15:30–16:00 O12 The use of prosthetics and biomedical engineering in modern pulmonology
Tómas Guðbjartsson 
University of Iceland, REYKJAVÍK, Iceland
15:00–17:00 Session 5 – Pulmonary Rehabilitation HALL: RíMA 
Aim: To review latest knowledge regarding outcome measures, early intervention and  
patient involvement in pulmonary rehabilitation
Chairs: Magdalena Ásgeirsdóttir, Marta Guðjónsdóttir 
15:00–15:20 O13 Early pulmonary rehabilitation (PR) COPD
Thomas Ringbæk
Hvidovre Hospital, HVIDOVRE, Denmark
15:20–15:40 O14 The pros of patient involvement in PR as experienced by patients
Anne-Grethe Halding
Sogn og Fjordane University College, FØRDE, Norway
15:40–16:00 O15 The pros and cons of the different dyspnoea instruments as an outcome measure in pulmonary 
rehabilitation
Elfa Dröfn Ingólfsdóttir
Reykjalundur, MOSFELLSBÆR, Iceland
16:00–16:20 O16 The pros and cons of different walk tests as outcome measure in pulmonary rehabilitation
Ragnheiður Harpa Arnardóttir
University of Akureyri and Akureyri Hospital, AKUREYRI, Iceland
16:20–16:40 O17 The pros and cons of different activity monitors and self-rated activity scales
Margareta Emtner
Uppsala University, UPPSALA, Sweden
16:40–17:00 Questions and discussions
15:00–16:30 Session 6 – RHINE study: New data HALL: STEMMA 
Aim: To present and discuss the latest epidemiological data from the RHINE study group
Chair: María Gunnbjörnsdóttir 
15:00–15:20 O18 Changes in the prevalence of asthma, rhinitis and respiratory symptoms over a 20 year period
Christer Janson
Uppsala University, UPPSALA, Sverige
15:20–15:40 O19 The importance of childhood environment for adult heath in the Nordic countries
Francisco Gomez Real
University of Bergen, BERGEN, Norway
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15:40–16:00 O20 Gender and respiratory health in Northern Europe
Francisco Gomez Real
University of Bergen, BERGEN, Norway
16:00–16:20 O21 Respiratory health and co-morbidities: cardiovascular disease, diabetes and inflammatory bowel 
disease
Vivi Schlünssen
University of Aarhus, ÅRHUS, Denmark
16:20–16:30 Questions and discussions 
17:00–18:30 Reception City Hall – Musical Event
Friday, June 14
08:30–10:00 Session 7 – Diagnosis and staging of lung cancer  HALL: KALDALÓN 
Aim: To highlight the importance of staging in the diagnosis and treatment of Lung Cancer and  
discuss advances in minimally invasive staging techniques and recent Nordic data on screening
Chair: Steinn Jónsson
08:30–09:00 O22 Recent Advances in the Staging of Lung Cancer: the 7th edition of TNM
Peter Goldstraw
National Heart and Lung Institute, Imperial College, DARTMOUTH, United Kingdom
09:00–09:30 O23 Endosonographic staging of lung cancer
Erik van der Heijden
Radboud University Nijmegen Medical Center, NIJMEGEN, Nederland
09:30–10:00 O24 CT screening of lung cancer – Danish screening study
Asger Dirksen
Copenhagen University, COPENHAGEN, Denmark
08:30–10:00 Session 8 – COPD 1 Aspects on disease progression HALL: RíMA 
Aim: To illustrate the many facets of COPD
Chair: Andrés Sigvaldason
08:30–09:00 O25 Can we recognize the rapid decliners in COPD?
Tarja Laitinen
University Hospital of Turku, TURKU, Finland
09:00–09:30 O26 Why do COPD patients exacerbate?
Per Bakke
University og Bergen and Haukeland University Hospital, BERGEN, Norway
09:30–10:00 O27 What’s new in COPD treatment?
Christer Janson
Uppsala University, UPPSALA, Sverige
08:30–10:00 Session 9 – Home mechanical ventilation HALL: STEMMA 
Aim: To give overview of interdisciplinary management of HMV
Chairs: Sigríður Ólína Haraldsdóttir, Bryndís Halldórsdóttir 
08:30–09:00 O28 A life at home on a ventilator – reflections through the lens of caring science
Berit Lindahl
Borås University College, BORÅS, Sverige
09:00–09:15 O29 HMV at South West Hospital District in Finland
ulla Anttalainen
Turku University Hospital, TURKU, Finland
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09:15–09:30 O30 Management of airway secretions in home mechanical ventilation
Tiina Andersen
Haukeland University Hospital, BERGEN, Norway
09:30–09:45 O31 Choice of ventilator in LTMV (Long term mechanical ventilation)
Ove Fondenes
Haukeland University hospital, BERGEN, Norway
09:45–10:00 O32 Morbid Obesity and Ventilation
Eva Lindberg
Uppsala University, UPPSALA, Sweden
10:00–10:30 Guided Poster Discussion 1 – Poster P01–P32
 Coffee Break
10:30–12:00 Session 10 – Beginning COPD HALL: KALDALÓN 
Aim: Draw attention to the situation and experience with beginning COPD
Chairs: Jónína Sigurgeirsdóttir, Guðrún Jónsdóttir
10:30–11:00 O33 The challenge of experienced stigmatisation for self-infliction among persons living with COPD- 
can health care personnel make a difference?
Anne-Grethe Halding
Sogn og Fjordane University College, FØRDE, Norway
11:00–11:20 O34 The experience of families with beginning COPD
Guðrún Hlín Bragadóttir1, Helga Jónsdóttir2, Þorbjörg Sóley Ingadóttir2, Bryndís S. Halldórsdóttir2
1Háskóli Íslands, KÓPAVOGUR, Iceland
2University of Iceland, REYKJAVÍK, Iceland
11:20–11:40 O35 Bodily (dis)integration; physical aspects and phenomenal experience of smoking
Marianne Klinke, Helga Jónsdóttir
University of Iceland, REYKJAVÍK, Island
11:40–12:00 O36 The relationship between stress management/relaxation exercises and anxiety, depression, health 
related quality of life and smoking 
Kristín Rósa Ármannsdóttir, Helga Jónsdóttir
University of Iceland, REYKJAVÍK, Iceland
10:30–12:00 Session 11 – Lung infections: Broken defences-vulnerable lungs  HALL: RíMA 
Aim: To improve insight into the different clinical aspects of poor lung defence
Chair: Ólafur Baldursson
10:30–10:50 O37 Ventilator Induced Lung Injury – Mechanical strain and cellular endurance
Sigurbergur Kárason
Landspítali University Hospital, REYKJAVÍK, Iceland
10:50–11:10 O38 Lung infections in the immunocompromized host
Paula Masilyta
University of Helsinki, HELSINKI, Finland
11:10–11:30 O39 Pneumonia due to influenza; is there a genetic susceptibility?
Magnús Gottfreðsson
Landspitali University Hospital, REYKJAVIK, Iceland
11:30–11:50 O40 Bronchiectasis and Cystic Fibrosis; pathogens and the airway epithelium
Ólafur Baldursson
Landspitali University Hospital, REYKJAVIK, Iceland
11:50–12:00 Questions and discussions
12:00–13:00 Lunch
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13:00–14:45 Session 12 – Difficult to treat astma; what do we know and where are we going? HALL: KALDALÓN 
Aim: To give a review of the current situation regarding the subject, with main focus on practical issues of value for the 
common chest physisian
Chairs: Friðrik Yngvason, Vibeke Backer
13:00–13:05 Welcome / Introduction
13:05–13:30 O41 Introducton with definition, prevalence numbers, characteristics and different phenotypes. What 
are the issues we are dealing with?
Anneke ten Brinke
Medical Centre Leeuwarden, MOLENEND, Nederland
13:30–13:55 O42 Evaluation of the difficult to treat patient in the clinic and treatment adherence
Leif Bjermer
Skåne University Hospital, LUND, Sweden
13:55–14:20 O43 Allergic and nonallergic factors in difficult to treat asthma
Paula Kauppi
Helsinki University Central Hospital, HELSINKI, Finland
14:20–14:45 O44 Allergic and nonallergic factors in difficult to treat astma with focus on allergens, work exposure, 
air pollution and comorbidites
Paula Kauppi
HUCH, Skin and Allergy Hospital, Finland
13:00–14:45 Session 13 – Tuberculosis in the Nordic countries  HALL: RíMA 
Aim: To highlight the importance of history, public health, migration and drug resistance in the fight against tuberculosis
Chairs: Haraldur Briem, Tuula Vasankari
13:00–13:30 O45 Our battle against tuberculosis in the mirror of time
Gunnar Boman
Uppsala lungmedicin, UPPSALA, Sverige
13:30–13:45 O46 Experience of program management of tuberculosis in Finland
Rauni Ruohonen
Filha, HELSINKI, Finland
13:45–14:00 O47 Tuberculosis among resident immigrants in Iceland
Thorsteinn Blöndal, L. Gudmundsson, K. Blöndal
REYKJAVÍK, Iceland
14:00–14:15 O48 Tuberculosis and Migration
Einar Heldal
OSLO, Norway
14:15–14:30 O49 Emergence of MDR-TBin Europe
Christoff Lange
Germany
14:30–14:45 O50 Novel Anti-TB Drugs: Experience of Estonia
Manfred Danilovits
Tartu University Hospital, TARTU, Estonia
13:00–14:30 Session 14 – Partnership with individuals and families facing the existence of COPD  HALL: STEMMA 
Aim: Facilitate development of health care for people with beginning COPD and their families
Chair: Helga Jónsdóttir 
13:00–13:30 O51 Partnership with individuals and families facing the existence of COPD
Helga Jónsdóttir1, Alda Gunnarsdóttir2, Bryndís S. Halldórsdóttir2, Gunnar Guðmundsson3, Ingibjörg K. Stefánsdóttir2,  
Jón Steinar Jónsson4, Rósa Jónsdóttir2, Þorbjörg Sóley Ingadóttir2
1Faculty of Nursing University of Iceland, REYKJAVIK, Iceland
2Landspítali Reykjavík, REYKJAVIK, Iceland
3Lungnadeild Landspítala, Læknadeild Háskóla Íslands, REYKJAVIK, Iceland
4Heilsugæsla höfuðborgarsvæðisins, Læknadeild Háskóla Íslands, REYKJAVIK, Iceland
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13:30–14:30 Panel discussions
Þorbjörg Sóley Ingadóttir, Ingibjörg K. Stefánsdóttir, Jón Steinar Jónsson and Ann-Grethe Halding
14:30–15:00 Guided Poster Discussion 2 – Posters P33–P62
 Coffee Break
15:00–16:40 Session 15 – Biomarkers in asthma – diagnosis and management  HALL: KALDALÓN 
Aim: To provide new insights in the use of biomarkers to detect airway inflammation and its role in asthma diagnosis 
and treatment. Future perspectives for new biomarkers
Chairs: Dóra Lúðvíksdóttir, Leif Bjermer
15:00–15:05 Welcome / Introduction
15:05–15:25 O52 Clinical significance of different phenotypes in asthma
Vibeke Backer
Bispebjerg University Hospital, COPENHAGEN, Denmark
15:25–15:45 O53 Clinical use of biomarkers in asthma mangement?
Andrei Malinovchi
Uppsala University, UPPSALA, Sweden
15:45–16:05 O54 Airway hyperresponsiveness in asthma
Maria Juusela
HUSMedical Imaging Center, HELSINKI, Finland
16:05–16:25 O55 Novel Therapies in Asthma – The Biomarker Era?
Andrew Menzies-Gow
Royal Brompton Hospital, LONDON, United Kingdom
16:25–16:40 Questions and discussions
15:00–16:20 Session 16 – Person centered care  HALL: RíMA 
Aim: Facilitate implementation of person-centered perspectives in respiratory care 
Chairs: Ragnheiður Alfreðsdóttir, Jónína Sigurgeirsdóttir
15:00–15:20 O56 Written Self Management Plan: a useful tool for asthma and COPD patients experiencing 
exacerbation at home?
Liv Hasund Eid, Helga Groa Sigurdardottir, Lena Kristin Jørgensen, Kari Hvinden
Glittreklinikken, HAKADAL, Norway
15:20–15:40 O57 Patient participation during hospitalization: Contributions and hindrances
Bente Bjørsland
Hedmark University College, ELVERUM, Norge
15:40–16:00 O58 Exercise training – nothing for me. An interview study in patients with chronic obstructive 
pulmonary disease
Karin Wadell, Petronella Nordwall Strömberg, Anncristine Fjellman-Wiklund
Umeå University, UMEÅ, Sweden
16:00–16:20 O59 The need of support to patients with lung cancer and their relatives
Maria Olin1, Cecilia Arving2
1Karolinska Institutet, Dept Medicine Solna, STOCKHOLM, Sweden
2Uppsala University, Department of Public Health and Caring Sciences, UPPSALA, Sverige
15:00–16:30 Session 17 – Pulmonary Hypertension  HALL: BJÖRTu LOFT – 6TH FLOOR 
Aim: understanding pulmonary arterial hypertension with special emphasis on Chronic thromboembolic pulmonary 
hypertension – CTEPH
Chairs: Hrönn Harðardóttir Guðmundur Þorgeirsson
15:00–15:30 O60 Pulmonary Hypertension – Causes and Diagnosis
Göran Rådegran
Skånes Universitetssjukhus, LUND, Sweden
15:30–16:00 O61 CTEPH, revealing a hidden disease – epidemiology in Sweden
Stefan Söderberg
Umeå University Hospital, UMEÅ, Sweden
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16:00–16:30 O62 Treatment of CTEPH. Is surgery the solution?
Søren Mellemkjær
Aarhus University Hospital, AARHUS, Denmark
17:30  Bus departure for Congress Dinner with bath entrance
19:00 Bus departure for Congress Dinner
20:00–23:30 Congress dinner at the Blue Lagoon 
Saturday, June 15
08:30–09:30 Session 18 – Treatment guidelines on COPD  HALL: KALDALÓN 
Aim: To provide an update on current international treatment guidelines
Chair: Magni Jónsson
08:30–09:00 O63 Updated GOLD guidelines – Pro
Jørgen Vestbo
Odense University Hospital, ODENSE, Denmark
09:00–09:30 O64 A case against GOLD
Peter Lange
University of Copenhagen and Respiratory Section, Hvidovre Hospital, COPENHAGEN, Denmark
09:30–10:00 Questions and discussions
08:30–09:45 Session 19 – Interstitial lung diseases HALL: RíMA 
Aim: To get new knowledge about idiopathic interstitial pneumonias. Learn about new pathogenetic mechanisms in 
idiopathic pulmonary fibrosis. Obtain information on registries for interstitial lung diseases in the Nordic countries
Chairs: Gunnar Guðmundsson, Elisabeth Bendstrup 
08:30–09:00 O65 State of the art 30–40 min
Gisli Jenkins
University of Nottingham, NOTTINGHAM, United Kingdom
09:00–09:15 O66 Human bronchial basal epithelial cells as candidate EMT precursors in idiopathic pulmonary 
fibrosis
Þórarinn Guðjónsson
University of Iceland, REYKJAVIK, Iceland
09:15–09:30 O67 The Danish Registry for Interstitial Lung Diseases, purpose and perspectives
Charlotte Hyldgaard
Aarhus University Hospital, AARHUS C, Danmark
09:30–09:45 O68 A national collaborative effort for the registration of idiopathic pulmonary fibrosis patient data in 
Finland
Marjukka Myllärniemi
University of Helsinki, HELSINKI, Finland
10:00–10:30 Coffee Break  
10:30–12:00 Session 20 – Nursing care for people with advanced lung diseases and their families  HALL: KALDALÓN 
Aim: Enhance healthcare for people with advanced lung diseases and their families
Chairs: Guðbjörg Pétursdóttir, Elfa D. Ingólfsdóttir
10:30–10:45 O69 Caring burden of home-dwellers with partners suffering from COPD or dementia in relation to 
aspects of social support
Bente Nordtug
Høgskolen i Nord-Trøndelag, LEVANGER, Norge
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10:45–11:00 O70 The effects of real-time telemedicine consultations between hospital-based nurses and severe 
COPD patients discharged after exacerbation admissions
Anne Dichmann Sorknæs1, Jest Peder1, Mickael Bech2, Lise Hounsgaard2, Finn Olesen3, Birte Østergaard2
1OUH-Odense University Hopsital & Svendborg Hospital, V. SKERNINGE, Danmark
2University of Southern Denmark, ODENSE, Denmark
3Aarhus University, AARHUS, Denmark
11:00–11:15 O71 Chronic Obstructive Pulmonary Disease – test of physical activity level in a home setting
Christina Nielsen, Lisbeth Marie Oestergaard, Nina Skavlan Godtfredsen
Bispebjerg University Hospital, COPENHAGEN, Denmark
11:15–12:00 O72 Family nursing practice for patients with lung diseases:  
Theoretical framework of partnership-based family nursing practice 
Helga Jónsdóttir, university of Iceland
 Addressing the diversity of patient needs in partnership-based family nursing practice
Þorbjörg Sóley Ingadóttir, Landspitali university Hospital, Iceland
 Working with families in partnership-based family nursing practice 
Bryndís S. Halldórsdóttir, Landspitali university Hospital, Iceland
10:30–12:00 Session 21 – Sleep 2  HALL: RíMA 
Aim: To describe new technical possibilities on how to assess and follow a very fast increasing patient population
Chair: Þórarinn Gíslason
10:30–11:10 O73 New technological approaches to a major public health problem
Samuel Kuna
University of Pennsylvania, PHILADELPHIA, USA
11:10–11:35 O74 Telemonitoring of CPAP therapy
Tarja Saaresranta
Turku University Hospital, TURKU, Finland
11:35–12:00 O75 Presentation of the first Norwegian Hospital based Centre of Sleep Medicine 
Trygve Muller Jonassen
University of Bergen, BERGEN, Norway
Abstracts
Oral Presentations
Poster Presentations
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Session 1 – Sleep 1
O01
Is sleep apnea also a major health problem 
among women?
Eva Lindberg
Uppsala University, UPPSALA, Sweden
In the literature, it is still often stated that obstructive sleep apnea 
is a male disorder and hence a majority of studies within this field 
has been performed in male populations. We have recently 
reported that in a population-based Swedish female sample 
investigated with full polysomnography, not less than 50% of 
women aged 20–70 years have an AHI of >5 and 5.9 % have 
severe sleep apnea defined as an AHI of >30. The prevalence of 
sleep apnea was strongly associated with both age and BMI. These 
findings raise the question whether sleep apnea has an impact on 
health or if it is merely a marker of an ageing process and obesity 
in women. However, in the same population, there was an 
association between AHI and insulin resistance, metabolic 
syndrome, inflammatory markers and Type B Natriuretic peptide 
levels.
Conclusion: Sleep apnea is a common finding in women that do 
have an impact on well-known cardiovascular risk factors.
O02
RLS among sleep apnea patients before and 
after PAP treatment and compared to the 
general population
Erna Arnardottir1, Bryndis Benediktsdottir1, Christer Janson2,  
Allan I. Pack3, Sigurdur Juliusson4, Thorarinn Gislason1
1University of Iceland, REYKJAVIK, Iceland
2Uppsala University, UPPSALA, Sweden
3University of Pennsylvania School, PENNSYLVANIA, USA
4Landspitali University Hospital, REYKJAVIK, Iceland
Objectives: To compare the prevalence of reported restless legs 
syndrome (RLS) between subjects with obstructive sleep apnea 
(OSA) and a randomly chosen sample from the general population 
as well as possible changes with CPAP treatment.
Materials and Methods: The OSA subjects (n = 822) were a 
part of the Icelandic Sleep Apnea Cohort. They were newly 
diagnosed with moderate or severe OSA (665 males, 157 females). 
The control subjects (n = 742) were randomly chosen Icelanders 
(394 males, 348 females) who participated in another 
epidemiological study (www.boldcopd.org). Measurements 
included a standardized RLS rating scale, questions about sleep 
and the Epworth Sleepiness scale. The change with CPAP 
treatment was assessed after 2 years (n = 538).
Results: Among OSA males 23.3% reported RLS but 12.9% of 
control males (p < 0.001). 35.8% of OSA females reported RLS 
but 24.4% of control females (p = 0.03). Both among OSA 
patients and controls those with RLS more commonly reported 
insomnia, daytime sleepiness, nocturnal sweating, snoring and 
gastro esophageal reflux (p < 0.05). They were more likely to be 
females and to have a smoking history. No relationship was found 
between RLS and age, BMI, hypertension or respiratory disease in 
a logistic regression adjusting for the presence of OSA and the 
other factors mentioned. No relationship was found between RLS 
and sleep apnea severity. Subjects using CPAP had a decreased 
prevalence of RLS from 25.7% to 13.8% while no change was 
observed in those subjects not using CPAP (p = 0.04 for difference 
between groups). Subjects that had persistent RLS were older on
average and had a lower physical quality of life at baseline.
Conclusions: RLS is more prevalent among OSA patients than 
controls. No relationship was found with sleep apnea severity or 
BMI. CPAP treatment of OSA decreases RLS symptoms 
significantly. RLS symptoms are significantly related with insomnia 
and daytime sleepiness in both OSA subjects and controls.
O03
Sleep and Gastroesophageal Reflux Disease
Össur Ingi Emilsson1, Christer Janson2, Þórarinn Gíslason1
1Landspitali, REYKJAVIK, Iceland
2Uppsala University Hospital, UPPSALA, Sweden
Gastroesophageal reflux (GER) is a common condition, which 
affects around 12% of the adult population on a weekly basis. It is 
associated with various sleep disturbances, and can even cause 
nocturnal awakenings, sometimes leading to daytime sleepiness. 
Its association with obstructive sleep apnea (OSA) has become of 
special interest. Even though GER and OSA share common risk 
factors, such as obesity, their association seems to remain 
significant after adjusting for these factors. This is especially 
evident in patients suffering from nocturnal GER (nGER), which is 
considered more harmful than daytime GER only.
Patients with persistent nGER have been shown to be more 
likely to develop symptoms of OSA than those without nGER. The 
incidence of observed apneas is notably significantly higher among 
those with persistent nGER. Edema in the upper airway caused by 
nGER has been hypothesized to make the upper airway more 
susceptible to intermittent collapse during sleep, i.e. apneas, but 
this remains to be studied further. Conversely, studies have shown 
that treating OSA with CPAP can greatly reduce symptoms of GER. 
Therefore, it is also hypothesized that OSA can induce GER.
Most likely, OSA and GER can aggravate each other, almost as 
in a vicious cycle. In turn, these two conditions can cause or 
aggravate other respiratory illnesses, such as asthma and chronic 
cough.
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O04
Symptoms of insomnia among OSA patients 
before and after 2 years of PAP treatment
Erla Björnsdóttir1, Christer Janson2, Jon Sigurdsson1, Philip 
Gherman3, Michael Perlis3, Sigurdur Juliusson4, Erna Arnardottir1, 
Samuel Kuna5, Allan Pack3, Thorarinn Gislason1, Bryndis 
Benediktsdottir1
1University of Iceland, REYKJAVIK, Iceland
2Uppsala university, UPPSALA, Sweden
3University of Pennsylvania, PENNSYLVANIA, United States of 
America
4Landspitali, REYKJAVIK, Iceland
5Veterans Affairs Medical Center, Philadelphia, PHILADELPHIA, 
United States of America
Study objectives: To assess the changes of insomnia symptoms 
among patients with obstructive sleep apnea (OSA) from starting 
treatment with positive airway pressure (PAP) to a two-year 
follow-up.
Design: Longitudinal cohort study.
Setting: Landspitali – The National university Hospital of Iceland.
Participants: 705 adults with OSA were assessed prior to and 
two years after starting PAP treatment.
Intervention: PAP treatment for OSA.
Measurements and results: All subjects underwent a medical 
examination, type 3 sleep study and answered questionnaires on 
health and sleep before and 2 years after starting PAP treatment. 
The change in prevalence of insomnia symptoms by subtype were 
assessed by questionnaire and compared between individuals who 
were using or not using PAP at follow-up. Symptoms of middle 
insomnia were most common at baseline and improved 
significantly among subjects using PAP (from 59.4% to 30.7%, 
p<0.001). Symptoms of initial insomnia tended to persist, 
regardless of PAP treatment and symptoms of late insomnia were 
more likely to improve among subjects not using PAP. Subjects 
with symptoms of initial and late insomnia at baseline were less 
likely to adhere with PAP (odds ratio (OR) 0.56, p = 0.007, and OR 
0.53, p<0.001, respectively).
Conclusion: PAP treatment significantly reduced symptoms of 
middle insomnia. Symptoms of initial and late insomnia, however, 
tended to persist regardless of PAP treatment and had a negative 
effect on adherence. Targeted treatment for insomnia may be 
beneficial for patients with OSA comorbid with insomnia and has 
the potential to positively affect adherence to PAP.
Session 2 – Occupational Medicine
O05
Farming exposure and respiratory health
Anna Rask-Andersen
Arbets- och miljömedicin, Akademiska sjukhuset, UPPSALA, 
Sweden
Exposure to fresh countryside air, physical work and lower rates of 
cigarette smoking have been thought to be the source of good 
health in farmers. But, respiratory health effects are well-
recognized problems caused by agricultural exposures with dust 
and irritant chemicals. Numerous studies have shown that a 
spectrum of different symptoms and diseases sometimes 
overlapping each other may affect farmers such as inhalation fever, 
allergic alveolitis, chronic bronchitis, COPD and toxic injuries such 
as silo filler’s disease. But the studies have been done on males; 
farm women have been underrepresented in most studies. 
However, a few studies of farm women have been carried out in 
the Nordic countries showing that females may be more sensitive 
to the effects of farm dust than men. While adult exposures on the 
farm are a known cause of occupational asthma, exposures to 
farm environments in early life reduce the incidence of asthma – 
an apparent contradiction that has been referred to as the 
“agricultural asthma paradox”.
O06
Asthma and COPD in Norwegian farmers – 
associations with farming exposure depend on 
atopy
Wijnand Eduard
National Institute of Occupational Health, OSLO, Norge
In a cross-sectional study of 8482 Norwegian farmers with and 
without livestock we assessed respiratory disease, lung function 
and atopy, and its associations with exposure to chemical and 
biological agents.
Methods: Asthma (current doctor diagnosed) and chronic 
bronchitis was recorded by a questionnaire and lung function by 
spirometry. COPD was defined by the 5% LLN prebronchodilator 
FEV1/FVC excluding asthma. Atopy was assessed in a sub-sample 
(n=2253) by a multiple RAST tests with common aeroallergens. 
Personal exposures to 13 chemical and biological agents were 
measured during predefined work tasks on 127 randomly selected 
farms.
Results: The prevalence of asthma was 2.7%, chronic bronchitis 
6.9%, COPD 13.5% and atopy 14%. Compared to crop farmers, 
livestock farmers were more likely to have chronic bronchitis (OR 
1.9, 95%CI 1.4-2.6) and COPD (OR 1.4, 95%CI 1.1-1.7). Asthma 
and atopy were not significantly elevated. In atopic farmers 
livestock production was associated with less asthma, higher 
COPD while chronic bronchitis was not significantly increased. In 
non-atopic farmers asthma and chronic bronchitis occurrence was 
significantly higher in livestock farmers, but not COPD. 
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Associations with estimated exposure showed similar associations 
with several of the agents. However, correlations between 
exposures prevented the identification of agents most strongly 
associated with respiratory disease.
Conclusions: Atopy seems to modulate the exposure-response 
associations of asthma and COPD in farmers differently. Atopic 
livestock farmers appear to have less asthma but more COPD than 
crop farmers, while non- atopic livestock farmers had more 
asthma, but not significantly more COPD. Associations with 
chronic bronchitis were independent from atopy although not 
significant in atopic farmers. Exposure to chemical and biological 
agents are likely causes of respiratory disease in farmers, but 
identification of specific agents was not possible.
O07
The exposure-window and gene-environment 
interaction as modifier for respiratory health in 
farming
Øyvind Omland
Aalborg University Hospital, AALBORG, Denmark
Many factors, including environmental exposures, have been 
related to the observed increase in the prevalence of asthma 
during the last two or three decades. Working as a farmer is a 
complex and diverse way of living involving several exposures in 
mingled composition.
Published studies during the last decade or more have 
suggested that exposure to farming environment during the first 
years of life reduces the risk atopy, rhinitis, atopic asthma rather 
than increase the risk as seen when exposed later in life where 
organic dust exposure has been associated with increased risk. 
Presented data suggests that the toll-like receptor 2 gene is 
central in the protective effect in a gene-environmental interaction 
fashion, and findings indicates that other exposure than endotoxin 
and glucans might be involved.
The presentation will try to describe central findings in recent 
and relevant studies in the field of farming exposure and atopy 
and respiratory disease.
O08
Volcanic eruptions and respiratory health – the 
Icelandic experience
Hanne Krage Carlsen
University of Iceland, REYKJAVIK, Iceland
The volcano Eyjafjallajökull erupted spring 2010 for the first time 
in nearly 200 years, producing a very fine-grained ash. As the 
eruption was long-almost 6 weeks, and near populated areas – 
concerns were raised about possible health effects of the ash.
The first study of the health of the residents near the volcano 
was undertaken as the eruption was ending, under the control of 
the Chief Epidemiologist as a public health safety measure. The 
aim of the study was to investigate if the volcanic ash was a 
danger to human health, 200 individuals of all ages were studied 
using spirometry, a physician’s exam and questionnaires.
The second study was planned from the university of Iceland 
and used questionnaires to assess the health of a larger 
proportion of the population in South Iceland. A demographically 
matched reference group was found in North Iceland. The results 
from the two studies will be presented at the conference, as well 
as other research into health effect from volcanic exposures in 
Iceland.
Session 3 – Palliative Care
O09
Palliative care and COPD
Abebaw Yohannes
RIHSC Research Centre, MANCHESTER, United Kingdom
Chronic obstructive pulmonary disease (COPD) is major cause 
morbidity in old age. The majority of COPD patients are most likely 
to develop two or more co-morbidities that may contribute to 
substantial burden of symptoms such as intolerable dyspnoea, 
fatigue, depression, anxiety and poor health status. However, 
evidence from the available literature suggests that advanced 
COPD patients are less likely to receive palliative care and/or 
supportive care compared to cancer patients. Factors that 
contribute to this disparity are multi-factorial including diagnostic 
uncertainty when to provide palliative care, patients’ unwillingness 
to discuss advanced care planning with their general practitioners, 
lack of appropriate guidelines when to refer patients to palliative 
care and lack of adequate resources. A few un-blinded studies of 
palliative care provision that included advanced COPD patients 
with other life threatening diseases showed some benefits in 
reducing healthcare utilization, improving quality of life and 
greater patients and caregivers’ satisfaction with the service. Early 
identification and referral to palliative care of those COPD patients 
with a documented progressive decline in lung function and health 
status should be part of routine clinical practice. A well-integrated, 
comprehensive and collaborative approach to address the complex 
needs of patients (physical, psychological and spiritual) with 
moderate-to-severe COPD are worthy of consideration. Adequate 
resources are needed from the health care providers to improve 
end-of-life care and advance care planning for patients with 
COPD. Better symptom controls for dyspnoea and pain 
management for the end-stage of COPD are paramount to reduce 
caregivers’ burden and improve quality of life patients with COPD.
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O10
Characteristics of people with COPD admitted 
to nursing homes in Iceland
Ingibjörg Hjaltadóttir
Landspitali University Hospital, REYKJAVÍK, Iceland
In Europe, as in the rest of the world, the number of old people is 
rising, especially those who are 80 years and older. They are also 
more likely to be chronically ill, frail and in need of assistance or 
nursing home placement. Furthermore a difference in the health 
status and co-morbidity of those moving into a nursing home may 
vary between generations. Smoking has been a significant factor in 
the lives of the generation needing nursing home placement at 
this time. The care of residents having chronic obstructive 
pulmonary disease (COPD) and other smoking related diseases has 
become an increasing concern in nursing homes. The aim of this 
study is to investigate the characteristics, health and functional 
profile of residents with COPD in Icelandic nursing homes. This 
knowledge is needed for those who organize and provide nursing 
home care to be able to provide appropriate care. All residents in 
Icelandic nursing homes are assessed three times each year with a 
comprehensive and standardised instrument, the Resident 
Assessment Instrument. Data from all Icelandic nursing homes will 
be used and analysed with descriptive and analytical statistics. 
Findings will be presented at the congress.
Session 4 – Pulmonary interventions
O11
State of the art: New frontiers in interventional 
pulmonology
Erik van der Heijden
Radboud University Nijmegen Medical Center, NIJMEGEN, 
Nederland
Interventional pulmonology is a rapidly evolving field within 
pulmonary medicine necessitating further specialization of chest 
physicians in this field. It encompasses both diagnostic and 
therapeutic procedures. In this presentation the current state of 
developments in this field is briefly reviewed. Both (technological) 
developments on the diagnostic side and therapeutic side will be 
discussed. The topics discussed will range from developments in 
image quality of flexible bronchoscopes to new developments in 
airways stents placed by rigid bronchoscopy that has been 
available for many decades and still aims for maintaining or 
regaining airway patency. Newer fields for interventional 
pulmonology that will be discussed encompass techniques and 
tools for bronchoscopic lung volume reduction and bronchial 
thermoplasty, an endobronchial treatment for severe astma . 
Endosonography will be discussed separately in 
Session 7
O12
Biomedical engineering and the use of 
prosthetics in modern pulmonology
Tómas Guðbjartsson
Landspitali University Hospital, REYKJAVÍK, Iceland
There is a great demand for tissues and donor organs due to end-
stage organ failure. At present the number of patients that receive 
transplanted organs is determined by the limited supply of organs. 
The use of stem-cell based therapies, replacing missing or diseased 
cells has been studied extensively in recent years. The clinical 
results have been variable. The donor cells are isolated and 
cultured in vitro and later implanted, for instance in patients with 
severe cardiac or pulmonary failure. More promising is the use of 
tissue engineering in replacing tissues or whole organs. Then a 
scaffold, either natural or synthetic, is covered with the stem-cells 
in a bio-reactor and implanted into the patient. Two years ago a 
patient from Iceland became the first patient in history to undergo 
transplantation of a synthetic trachea scaffold, seeded with his 
own stem-cells. This successful case that was reported in the 
Lancet will be described in detail as an example of how stem cell 
technology was successfully combined with state of the art tissue 
engineering to save a patient´s life. 
Session 5 – Pulmonary 
Rehabilitation
O13
Early pulmonary rehabilitation (PR) in COPD
Thomas Ringbaek
Hvidovre Hospital, HVIDOVRE, Denmark
This talk reviews the literature on Early PR in COPD with focus on 
definition, selection of patients, training modality, compliance/
drop-out, and outcomes. Besides, data on 49 COPD patients 
participation in early PR at Hvidovre Hospital are presented. 
O14
The pros of patient involvement in PR as 
experienced by patients
Anne-Grethe Halding
Sogn og Fjordane University College, FØRDE, Norway
Persons living with COPD (Chronic Obstructive Pulmonary Disease) 
are confronted with extensive demands on coping resources 
during their illness course. PR (pulmonary rehabilitation) is 
recommended as part of COPD management to help people cope 
with these demands. Patient involvement in rehabilitation is 
emphasized; however, the concept is unclear, and we have yet 
limited knowledge about patient involvement and contextual and 
relational aspects of PR.
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The aim of this lecture is to clarify the concept of patient 
involvement and explore patients’ experiences of involvement 
during PR within a theoretical framework of patient involvement, 
rehabilitation and self-management.
Patient involvement is emphasized in literature on 
rehabilitation, health promotion and self-management. Literature 
on patient involvement emphasizes relational and contextual 
aspects. Patients have estimated group-based PR contexts to 
encourage their involvement through opportunities for sharing of 
knowledge and providing of mutual support. Through involvement 
they experienced social integration, role identification and 
development of new competences. Involvement during the PR 
program thus increased their engagement and self-management 
skills, self-efficacy, and hope for future health within illness.
Patient involvement appears as a core concept in PR to 
enhance patients’ engagement in self-management and social 
integration during PR. The PR context should support opportunities 
for involvement in sharing of knowledge and reciprocal support 
among patients. Patient involvement in PR has potentials to 
support transitions towards health within illness. This field should 
be further explored. 
O15
The pros and cons of the different dyspnoea 
instruments as an outcome measure in 
pulmonary rehabilitation
Elfa Dröfn Ingólfsdóttir
Reykjalundur, MOSFELLSBÆR, Iceland
Dyspnoea is a very complex and common symptom among 
pulmonary patients. It is also one of the main reasons for the 
patients to be referred to pulmonary rehabilitation (PR). Since PR is 
known to reduce dyspnoea, it is very important to be able to 
measure it, treat it and then to assess the effect of the given 
treatment.
By using specific tools or questionnaires, it is possible to 
quantify dyspnoea and use the results to describe the level of 
chronic disability and also to assess eventual changes after 
intervention.
Dyspnoea can be assessed both in real time and through recall 
and which approach is used can then lead to different results.
It is important to be explicit about the tools used, since they 
have to be “user friendly”in the setting of pulmonary 
rehabilitation. It is also essential to realize which domain or 
dimension the tools are addressing and have different technical 
issues in mind when choosing which tool to use.
O16
The pros and cons of different walk tests as 
outcome measure in pulmonary rehabilitation
Ragnheiður Harpa Arnardóttir
University of Akureyri and Akureyri Hospital, AKUREYRI, Iceland
One of the main aims of pulmonary rehabilitation (PR) is to 
increase exercise capacity. Exercise capacity must be assessed 
before and after PR to target the intensity of prescribed exercise 
and evaluate the effect of the PR. Laboratory tests are expensive 
and not always available, so the need for simple field tests is great. 
Several different field tests have thus been developed and 
validated for pulmonary patients and are widely used as outcome 
measure in PR. There are two main categories of field tests; timed 
walk tests and externally paced tests. The most frequently used 
test is the 6-minute walk test. Other timed tests are the 12-minute, 
the 3-minute and the 2-minute walk tests. Amongst externally 
paced walk tests the incremental shuttle walking test and the 
endurance shuttle walking test are most widely used. Lately, short 
speed-tests, like the 30 metre test, have been suggested for 
pulmonary patients. Different tests provide different information 
and the sensitivity for change differs also. The primary outcome in 
walk tests is meters walked, walkwork (m x kg), endurance time, 
or speed, depending on the test. Besides that, most test results 
include information about resting and end-exercise heart rate, 
dyspnoea, ratings of perceived exertion, exercise-induced 
hypoxemia, leg or lumbar pain, i.e. factors that can add valuable 
information about the patient's condition and motivation. Tests of 
longer duration or more strenuous tests are considered more 
informative, which probably explains why a timed test of 6 
minutes is more frequently used than a 2-minute test. until lately, 
most patients referred to PR have had moderate to severe COPD 
with seriously decreased exercise capacity. For patients with less 
decreased exercise capacity the ceiling effect of various tests must 
be considered, as ceiling effects could seriously underestimate the 
effect of PR. Endurance tests have been found more sensitive to 
change after PR than other field tests. The well-documented need 
for training tests can be a problem in clinical work, as this 
increases the time needed for testing, but is considered necessary 
for valid results.
Conclusion: All walk tests include some pros and cons in terms of 
surroundings/ equipment needed, time consumption, what 
information they yield, retest effects and sensitivity to change. The 
choice of test must suit the particular testing purpose, the 
patient�s state of health and be performable at the clinic.
O17
The pros and cons of different activity monitors 
and self-rated activity scales
Margareta Emtner
Uppsala University, UPPSALA, Sweden
Accurate assessment is required to assess current and changing 
physical activity levels, and to evaluate the effectiveness of 
interventions designed to increase activity levels. The most 
commonly used measurement used to measure a person’s physical 
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activity or sedentary time is self-report. A well-known drawback 
with self-reports is that they are depending on the reporting 
person’s memory, sincerity and the type of definition that is used 
for physical activity. Other ways to assess a person’s physical 
activity level is to use some kind of activity monitor, e.g. 
pedometers or accelerometers.Correlations between self-report 
and activity monitors are low-to-moderate and ranged in a recent 
review from -0.7 to 0.96, i.e. self-report measures of physical 
activity were both higher and lower than directly measured levels 
of physical activity.Among the accelerometers the Dynaport 
MiniMod, Actigraph GT3X and SenseWear Armband (all trixial 
monitors) are the most valid monitors during standardized physical 
activities in patients with chronic obstructive pulmonary disease 
(COPD). The DynaPort MiniMod and Actigraph GT3X discriminate 
best between different walking speeds in patients with COPD.
Session 6 – RHINE study: New data
O18
Changes in the prevalence of asthma, rhinitis 
and respiratory symptoms over a 20 year 
period
Christer Janson
Uppsala University, UPPSALA, Sverige
Background and aim: The Respiratory Health In Northern 
Europe study (RHINE) is part of the European Community 
Respiratory Health Survey (ECRHS). In the RHINE project we have 
gathered respiratory health data on a cohort that was 20–44 years 
of age at the start of the study in 1990 to 1994 and then followed 
in 1999–2000 and 2010 to 2012. The aim of this investigation is 
to present changes in the prevalence of wheeze, asthma and hay 
fever over a 20 year period in subjects from Iceland, Norway, 
Sweden, Denmark and Estonia.
Methods: The present investigation included approximately 11 
000 participants that answered a postal questionnaire three times 
over a 20 year period. The participants were from three centres in 
Sweden and one centre each from Iceland, Norway, Denmark and 
Estonia. Wheeze was defined as having had wheeze or whistling in 
the chest during the last 12 months. Asthma was defined as 
having had an attack of asthma within the last 12 months or 
current use of medication for asthma. Hay fever was defined as 
answering yes to having hay fever or other kinds of nasal allergy.
Results: The prevalence of wheeze decreased from 20.4 to 
18.6%. This decrease was mainly seen in subjects born between 
1966 to 1973: 22.4 to 17.5, whereas the prevalence was relatively 
unchanged in subjects born between 1945 to 1955 and 1956 to 
1965. The prevalence of asthma increased from 4.5 to 8.3% and 
this increase was relatively similar in all three birth cohorts. The 
prevalence of hay fever increased from 19.7 to 24.7. This increase 
was largest in the subjects born between 1966 and 1973: + 8.3 
% units compared to +5.8 % units in subjects born between 1956 
and 1965 and +2.1 % units in subjects born between 1945 and 
1955.
Conclusion: This longitudinal study shows a decrease in the 
prevalence of wheeze and an increase in the prevalence of asthma 
and hay fever over a 20 year period. The decrease in wheeze and 
increase in hay fever was largest in the youngest birth cohort. The 
change in prevalence may be a combination of ageing and a birth 
cohort effect. Comparisons with cross sectional data in the three 
Swedish centres collected with similar methodology in the 
GA2LEN survey may make it possible to disentangle how much of 
this prevalence changes that is related to a birth cohort effect.
Session 7 – Diagnosis and staging of 
lung cancer
O22
Recent Advances in the Staging of Lung Cancer: 
the 7th edition of TNM
Peter Goldstraw
National Heart and Lung Institute, Imperial College, 
DARTMOUTH, United Kingdom
The 7th Edition of the TNM Classification for Lung Cancer enacted in 
January 20110 was the first revision for 12 years and the most 
radical for 35 years. It has been estimated that for 1 in 6 cases this 
would result in a different stage being assigned compared with the 
6th edition. The 7th edition is the first to incorporate carcinoid 
tumours into the TNM classification, and to emphasise the use of 
TNM in the clinical management and trial design for small-cell lung 
cancer (SCLC). It provided pathologists with the first standardised 
definition of ‘visceral pleural invasion’ and provided clinicians and 
researchers with an internationally agreed nodal map. There are now 
precisely defined anatomical boundaries for each nodal station, 
which alongside the new map, are recognised as the recommended 
means of describing regional lymph node involvement for lung 
cancer. A minimum number of lymph nodes to be removed by the 
surgeon and examined by the pathologist when establishing the pN 
category of any resection case has beenincluded. The 7th edition 
incorporates additional size cut-points, new T sub-categories and a 
re-classification of cases in which there are additional tumour 
nodules in certain locations. Some of the resulting TNM stage 
groupings have been upstaged and some down-staged, more closely 
aligning stage with prognosis. In situations in which cases that have 
been traditionally treated surgically have been upstaged in the 7th 
edition one may wonder if these cases should now be considered for 
adjuvant therapy after complete resection. Where cases previously 
considered to be inoperable have been down-staged one may 
wonder if selected cases in these categories should now be 
considered for surgical treatment, albeit in a multi-modality setting. 
It is important that these suggestions are tested in appropriate 
clinical trials before such changes in the treatment algorithm are 
accepted as a new standard of care.
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Endosonographic staging of lung cancer
Erik van der Heijden
Radboud University Nijmegen Medical Center, NIJMEGEN, 
Nederland
Endosonography has evolved to be the first step staging procedure 
in patients with suspected lung cancer challenging the (former?) 
surgical cervical mediastinoscopy as gold standard. Esophageal 
ultrasound guided fine needle aspiration (EuS-FNA) and 
endobronchial ultrasound guided transbronchial needle aspirations 
(EBuS-TBNA or EBuS) allow for safe, reliable and complete 
mediastinal staging in an outpatient procedure under conscious 
sedation. In this presentation the current literature is reviewed and 
requirements and practical issues for starting a program on are 
discussed.
O24
CT screening of lung cancer – Danish screening 
study
Asger Dirksen
Copenhagen University, COPENHAGEN, Denmark
In the Danish Lung Cancer Screening Trial 4,104 men and women, 
healthy heavy smokers/former smokers were randomized to five 
annual low-dose multi-slice CT scans or no screening. Two 
experienced chest radiologists read all CT scans and registered the 
location, size and morphology of nodules, and nodules between 5 
and 15 mm without benign characteristics were rescanned after 3 
months. Growing nodules (>25% volume increase and/or volume 
doubling time < 365 days) and nodules > 15 mm were referred 
for diagnostic workup. In the control group, lung cancers were 
diagnosed and treated outside the study by the usual clinical 
practice.
Participation rates were high in both groups (screening: 
95.5%; control: 93.0%; p<0.001). Lung cancer detection rate was 
0.83% at baseline, and mean annual detection rate was 0.67% at 
incidence rounds (p=0.535). More lung cancers were diagnosed in 
the screening group (69 vs. 24, p<0.001), and more were low 
stage (48 vs. 21 stage I–IIB non-small cell lung cancer (NSCLC) 
and limited stage small cell lung cancer (SCLC), p=0.002), 
whereas frequencies of high-stage lung cancer were the same (21 
vs. 16 stage IIIA–IV NSCLC and extensive stage SCLC, p=0.509). 
March 2010 at the end of screening, 61 patients had died in the 
screening group and 42 in the control group (p=0.059). 15 and 
11 had died of lung cancer, respectively (p=0.428).
Conclusion CT screening for lung cancer brings forward early 
disease, and at this point no stage shift or reduction in mortality 
was observed. Many more lung cancers were diagnosed in the 
screening group, and further follow-up is needed to decide 
whether the excess cases of cancer in the screening arm are due 
to overdiagnosis or of clinically relevance and would have killed 
the patient if not resected at an early stage.
Session 8 – COPD 1 Aspects on 
disease progression
O25
Can we recognize the rapid decliners in COPD?
Tarja Laitinen
University Hospital of Turku, TURKU, Finland
Objective: Lately several subphenotypes have been recognized in 
COPD. Patients whose FEV1 is declining rapidly are considered to 
have poor prognosis and thus, they should be identified early on. 
Our aim in the present study was to examine the individual 
development of FEV1 in the COPD cohort over the period of five 
years.
Methods: Study subjects (N=607) represented all severity stages 
of the disease (mean FEV1 56% of expected in the beginning of 
the study). They have had an average 8.3 spirometries performed 
during the follow-up period. To determine a five-year FEV1 change 
for each patient we used the mixed-effects modeling for linear 
trend. We used the Bayesian analysis to determine the true 
decliners at the probability level of 95%.
Results: For majority (N=545/607) of the patients the FEV1 trend 
was negative/declining (mean -40ml/year, SD +41ml). The trend 
correlated weakly to the baseline FEV1 level (R= - 0.1, p<0.01). 
Based on the Bayesian model, 24% of the COPD patients were 
true decliners. Their annual loss of FEV1 was 80 ml (SD +30ml), 
while among the rest of the patients the annual loss of FEV1 was 
30 ml (SD +30ml).
Conclusions: COPD patients show significant heterogeneity in 
the progression of disease when measured by FEV1 trend. 
Bayesian analysis which uses simulations to determine the 
probability level for the observed trend (=individual-change-over-
time) may offer novel approaches for personalized medicine.
O26
Why do COPD patients exacerbate?
Per Bakke
University og Bergen and Haukeland University Hospital, 
BERGEN, Norway
An exacerbation of Chronic Obstructive Pulmonary Disease (COPD) 
may be defined as an acute event characterized by worsening of 
the patients respiratory symptoms that is beyond normal day-to-
day variation and leads to a change in medication. Exacerbations 
are associated with increased systemic and airway inflammation 
and may be caused by bacterial and respiratory viral infections. 
They may also be precipitated by environmental factors. Those 
reporting two of more exacerbations of COPD per year are often 
defined as ‘frequent exacerbators’. This is a phenotype that 
appears to be stable over time. 
The most common cause of exacerbations is bacteria. Bacteria 
are isolated from sputum using standard culture techniques in 
40% to 60% of exacerbations. The three most common species 
isolated in COPD exacerbations are Haemophilus influenzae, 
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Moraxella catarrhalis, and Streptococcus pneumoniae. Less 
frequently, exacerbations may be caused by Pseudomonas 
aeruginosa, gram negative Enterobacteriacea, Staphylococcus 
aureus, Haemophilus parainfluenzae, and Haemophilus 
hemolyticus. Bacteria in the lower airways have been hypothesized 
to disrupt host defense mechanisms leading to a vicious cycle of 
epithelial cell injury, defective mucociliary clearance, chronic 
mucous hypersecretion, and inflammatory cell infiltration, further 
damaging host defenses and leading to bacterial adherence and 
growth. 
Rhinovirus is responsible for the common cold and has a role 
in COPD exacerbations. Studies using molecular biology 
polymerase chain reaction techniques have provided evidence of 
the role of rhinovirus in the cause of COPD exacerbations. In 
studies from the London COPD cohort, up to 40% of 
exacerbations were associated with respiratory viral infections. In 
the Northern hemisphere, COPD exacerbations are more common 
in the winter months and may also be more severe. The increase in 
exacerbations may be caused by the increasing prevalence of 
respiratory viruses in low temperature winter months or increased 
susceptibility to upper respiratory tract virus infections in cold 
weather. 
Frequent exacerbators have a higher incidence of lower airway 
bacterial colonization and bacteria may also play a role in 
susceptibility to viral infection in COPD. 
Epidemiologic data supports a role for air pollution in the 
cause of some COPD exacerbations with studies showing an 
increased risk of hospitalization for COPD with increased levels of 
pollutants. Air pollution likely causes COPD exacerbations through 
modulation of airway inflammation and immunity. 
O27
What’s new in COPD treatment?
Christer Janson
Uppsala University, UPPSALA, Sverige
The management of COPD has changes drastically over the last 
decades. Data from a large sample of COPD patients from primary 
health care centres (PHCC) in Sweden, the PATHOS study, shows 
that the incidence of exacerbations has decreased from 3.0/year 
1999 to 1.3/year 2009. Parallel to this the pharmacological 
treatment of COPD has undergone large changes with the 
introduction of long acting muscarinic antagonists (LAMA) and 
fixed combinations of inhaled corticosteroids and long acting beta-
2-agonists (LABA). The PATHOS study also shows that the 
structure for management of COPD has improved with higher 
proportion of PHCC with spirometers, COPD nurses and smoking 
cessation programs.
In the last few years a number of new pharmacological 
treatment options for COPD have become available. These include 
roflumilast a phosphodiesterase 4 inhibitor, indacaterol an 
ultralong LABA and two new LAMA substances: aclidinium and 
glycopyrronium. Bronchoscopic lung volume reduction has also 
emerged as a method that might benefit certain COPD patients 
with emphysema and hyperinflation.
Taken together new treatment options and optimal use of 
established treatment both pharmacological and non-
pharmacological has the potential to further improve the 
prognosis in COPD. Improving the structure of COPD management 
in primary and secondary care and a more aggressive approach in 
preventing exacerbations are also priorities.
Session 9 – Home mechanical 
ventilation
O28
A life at home on a ventilator – reflections 
through the lens of caring science
Berit Lindahl
Borås University College, BORÅS, Sverige
There is a great power in technology, it has a remarkable and 
often invisible impact on everything it touches or comes in contact 
with. In health care practices the mastery of technological 
equipment often means protecting health and life as well as 
possibilities to master critical illness and death. Technologies are 
certainly not value-neutral objects but have a value in itself and 
when a human being is connected to technology his/her body risks 
being objectified. However, technological developments and 
success in technological treatments have made it possible to treat 
people with advanced technological equipment not only in 
hospitals but also in the homes – one such treatment is home 
mechanical ventilation (HMV).
The presentation put forward various aspects of life situation 
and impact on family life from an inside perspective when living a 
life at home on a ventilator. Research findings, both from an adult 
and child perspective, generated through qualitative research 
methods will be critically reflected on as well as the use of theories 
and existential philosophies as means to help health care 
personnel to encounter the ventilator assisted person and perform 
good quality care. Research has shown that there is a lack of 
knowledge about the physical and existential needs of the 
ventilator assisted person. In what way do place and space 
interact in the care process? There may be a risk when professional 
care moves from the hospital to the home. This means that there 
might be a risk that routines, security regimens and design of 
technology that originate from hospital norms and values 
thoughtlessly also move into people’s homes. This situation is often 
connected to that various professionals enters into the home and 
suddenly private life becomes public.
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HMV at South West Hospital District in Finland
ulla Anttalainen
Turku University Hospital, TURKU, Finland
In the beginning of year 2004 the coordination of the treatment of 
neuromuscular respiratory insufficiency patients was started in 
Turku university Hospital. Before that time acute treatment 
decisions were made in emergency room or in intensive care unit 
and many times the patient himself could not express his own will. 
To avoid these kind of situations, the HMV unit, consisting one 
doctor (anesthesiologist) and one nurse (with ICu background), 
started systematically visit neuromuscular patients during their 
control visits in neurology or pulmonary wards. They explain the 
patients how the disease most likely affects their breathing, eating 
and motion etc. and what we can do to help the symptoms. They 
also can do home visits for example to titrate the non-invasive 
ventilation or to evaluate the need for hospital treatment. HMV 
unit coordinates the treatment between special and primary health 
care, and in hospital neuromuscular patients are treated in 
co-operation with HMV unit and pulmonology or neurology wards. 
With active HMV unit, we have significantly reduced the need for 
emergency tracheotomies, ICu treatment days or hospital days 
generally in the neuromuscular patients leading to lower costs also 
in the treatment.
O30
Management of airway secretions in home 
mechanical ventilation
Tiina Andersen
Haukeland University Hospital, BERGEN, Norway
Home mechanical ventilation provides long term mechanical 
ventilation support for persons with chronic respiratory failure, 
who predominantly have a neuromuscular disorder (NMD). 
Ventilatory support aims to achieve adequate ventilation, which 
can only be assured if the airways are clear of secretions. Retained 
airway secretions lead to reduced gas exchange and will form 
favorable conditions for bacteria to grow. This may lead to 
pneumonia, which is the most frequent cause of death in this 
patient group. Therefore, it is important both to prevent and to 
treat effectively accumulation of airway secretions in persons with 
NMD.
The aim of the respiratory physiotherapy in persons with NMD 
is to increase inspiratory volumes and expiratory flow. It involves 
daily deep breaths to prevent atelectasis and stiffness of thorax, 
airway clearance and especially effective assisted cough. In non-
invasive patients, techniques such as glossopharyngeal breathing, 
air stacking, manually assisted cough and mechanical insufflation-
exsufflation (MI-E) are used alone or in combination. In invasive 
patients, MI-E followed by short suction in the cannula and just 
below, may be a more effective and gentle alternative to deep 
tracheal suction.
Tailoring the home based program for airway secretion 
management is based on individual assessment of the patient (i.a. 
measurements as peak cough flow and vital capacity), evaluation 
of the cough quality and the bulbar function, and patients 
resources to master the home treatment. In practice, a therapeutic 
trial is conducted in most NMD patients who present with a 
manifest airway secretion problem, to determine the effect and 
expected feasibility of the actual technique in the home setting.
O31
Choice of ventilator in LTMV (Long term 
mechanical ventilation)
Ove Fondenes
Haukeland University hospital, BERGEN, Norway
The lecture will focus upon how to choose the appropriate device, 
method and settings for LTMV and which factors one needs to 
consider. Noninvasive ventilation is preferable whenever the 
patient has sufficient bulbar function to remove secretions. In life-
supportive treatment ventilators with internal batteries and 
enhanced alarm capabilities are required, however patients with 
only nighttime hypoventilation may be adequately treated with 
simple bilevel positive pressure (BiPAP) devices. Patients with 
additional daytime hypoventilation will usually be better off with a 
more sophisticated ventilator with internal batteries and volume 
controlled ventilation by a mouthpiece if secretion stagnation is a 
problem. A wide range of cross-over / hybrid ventilators have been 
marketed during the last few years. Some ventilators offer the 
choice between passive and active exhalation valve circuits in one 
device and many devices offer different kinds of variable pressure 
support on the basis of a so called volume guarantee or safety 
volume. Some of these automatic algorithms are quite complex 
and in general the pressure response to changes in tidal volume or 
average minute ventilation varies significantly between different 
manufacturers. The theoretical advantages of the hybrid ventilation 
modes remains to be proved in clinical studies although clinical 
practice has rapidly incorporated these machines and modes 
already, it would seem. Choosing the appropriate settings of the 
ventilator in supportive treatment requires appropriate monitoring 
capabilities and experienced clinicians with a keen eye on the 
underlying pathophysiology.
O32
Morbid Obesity and Ventilation
Eva Lindberg
Uppsala University, UPPSALA, Sweden
Overweight is a well-known risk factor for sleep apnea syndrome 
and respiratory failure due to obesity hypoventilation syndrome 
(OHS) is one of the most severe consequences of obesity. Since 
2009 almost 50% of Swedish patients who are prescribed home 
mechanical ventilation get the treatment due to an underlying 
OHS. Definitions, prevalences, symptoms and treatment of OHS will 
be discussed during the Session. 
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Session 10 – Beginning COPD
O33
The challenge of experienced stigmatisation for 
self-infliction among persons living with COPD- 
can health care personnel make a difference?
Anne-Grethe Halding
Sogn og Fjordane University College, FØRDE, Norway
Chronic obstructive pulmonary disease (COPD) results from gene-
environment interaction. Cigarette smoke is the most commonly 
encountered risk factor; however, it is not the only risk factor. 
Tobacco control is considered the most effective preventive 
intervention, and smoking cessation is a key element in health 
personnel’s counseling of patients who smoke.
The aim of this contribution is to explore COPD patients’ 
experienced stigmatization for self-infliction, and to discuss 
challenges of possible ‘victimblaming’ in conversations between 
health care personnel and patients.
Persons’ experiences of health and illness are influenced by 
their history and the culture in which they live, including prevailing 
norms for lifestyle and tobacco control. A strong focus on the 
individual’s responsibility for health and lifestyle may individualize 
the responsibility for diseases associated with unhealthy lifestyles 
as well. Health care personnel are obliged to counsel patients on 
lifestyle, in special smoking cessation. Methods used in tobacco 
control have been under debate because of the danger of 
stigmatizing the smoker. Experienced stigmatization is a moral 
devaluation and a threat towards a person’s ego identity.
During encounters with members of society and health care 
personnel, persons living with COPD have experienced 
stigmatization and blame for having a self-inflicted disease. 
Negative emotions and defensive actions provoked by experienced 
stigma may hamper help-seeking, self-management, and 
rebuilding of a positive identity during long-term illness.
This challenge should be considered in planning and 
conducting of PR. More attention toward the complexity of 
tobacco control and smoking cessation support, as well as the 
threat of stigmatization, may conquer negative effects of 
stigmatization and strengthen partnership in self-management.
O34
The experience of families with beginning 
COPD
Guðrún Hlín Bragadóttir1, Helga Jónsdóttir2, Þorbjörg Sóley 
Ingadóttir2, Bryndís S. Halldórsdóttir2
1Háskóli Íslands, KÓPAVOGUR, Iceland
2University of Iceland, REYKJAVÍK, Iceland
AbstractCOPD often progresses for years with insidious decline in 
lung function with the onset of symptoms out of context with 
airflow limitation. Adjustment to symptoms in daily life is gradual 
and the disease often moderately advanced when healthcare is 
finally sought. Experience of shame because of smoking can hinder 
help seeking.
The purpose of this study is to gain insight into the experience 
of living with COPD at beginning stages; how persons come into 
terms with the disease, how symptoms develop, manifest and 
affect life as a whole. The research question is: What is the 
experience of families with beginning stages of COPD?
The methodological approach was interpretive 
phenomenology. Participants had already finished participation in 
an intervention study on individuals with COPD, stage II and III 
and family members, Partnership to enhance self-management of 
people with COPD and their families. In continuance with the 
intervention study further data was collected through four family-
focus group interviews (n=35) and a subsample of eight families. 
Data from both family interviews and focus groups are the data of 
this study.
Results are analyzed into themes; Preliminary analysis reveal 
self-inflicted concealed disease, fighting in silence and to be 
enclosed in own addiction as some of the major ones.
Further analysis will be presented at the conference. 
O35
Bodily (dis)integration; physical aspects and 
phenomenal experience of smoking
Marianne Klinke, Helga Jónsdóttir
University of Iceland, REYKJAVÍK, Island
Background: The experience of being addicted to smoking is 
multidimensional. Of particular concern is the lack of concepts to 
describe breakdown that occurs in bodily coherence when people 
apparently ignore the physical consequences of smoking tobacco 
in spite of intellectually recognizing their addiction to nicotine. This 
incoherence makes it difficult to sufficiently describe and establish 
efficient strategies to come to terms with the urge of smoking.
Objective: Articulate the concepts “body image”and 
“affordances”to illustrate the phenomenal experience of being 
addicted to nicotine.
Methods: The phenomenal experience will be targeted by a 
description of physical aspects of addiction and the personal 
bound subjective experience. The concepts ‘body image’ and 
‘affordances’ will be introduced as a way to integrate these two 
dimensions. Patient cases are used to illustrate the applicability of 
the concepts in the phenomenological investigation of smoking.
Results: Any imbalance between the physical aspects of smoking 
and personal experience is pathological and may lead to 
suppression of the consequences of smoking. Pathological body 
image disturbances are not a deficiency of own self-knowledge 
per se but should be regarded as a tricky dispensation of self-
referential information related to nicotine addiction. This 
preservation of self-knowledge often leads to a subtle experience 
of shame.
Conclusion: understanding the disintegration of bodily 
experience in tobacco addiction and the ability to communicate 
this experience may provide a launch pad of designing new 
approaches to health care for people addicted to nicotine.
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The relationship between stress management/
relaxation exercises and anxiety, depression, 
health related quality of life and smoking 
Kristín Rósa Ármannsdóttir, Helga Jónsdóttir
University of Iceland, REYKJAVÍK, Iceland
Background: The prevalence of anxiety and depression among 
people with COPD and the lack of health promoting acts, good, 
appropriate and beneficial interventions to decrease anxiety, 
depression and stress among people with COPD are of concern. 
Research on stress, stress management and relaxation is lacking.
Methods: A cross-sectional study design, based on baseline data 
from an interventional study on patients diagnosed with COPD: 
“Partnership to enhance self-management of people diagnosed 
with chronic obstructive pulmonary disease and their families“ 
(N=100). The research question is: Is there a relationship between 
stress management/relaxation exercises and anxiety, depression, 
health related quality of life and smoking?
Results: People who used stress management scored significantly 
higher on anxiety and depression HADS scale compared to those 
who did not do anything to control stress. There was also a 
significant difference on mean score on the St.George’s 
Respiratory Questionnaire on health related quality of life between 
those who used stress management and those who did not. 
People who did stress management and/or relaxation exercises 
scored higher on the scale which suggest significantly more health 
reduction. No relationship was found between smoking behaviour 
and the using of stress management and relaxation exercises.
Conclusion: There seems to be a relationship between actions to 
control stress and undertake relaxation exercises and how people 
with COPD experience and evaluate their health, anxiety and 
depression. This can be due to some benefit that people find from 
controlling stress and doing relaxation exercises, which has been 
described in the literature. Further researches on the stress 
management and relaxation effects on anxiety, depression and 
health related quality of life are warranted.
Session 11 – Lung infections: Broken 
defences-vulnerable lungs
O37
Ventilator Induced Lung Injury – Mechanical 
strain and cellular endurance
Sigurbergur Kárason
Landspítali University Hospital, REYKJAVÍK, Iceland
Ventilator treatment is often life-saving but has the inherent risk of 
causing damage to lung tissue. This has been confirmed both in 
animal and clinical studies where there is an obvious link between 
ventilator settings and outcome which has lead to the creation of 
the term; Ventilator Induced Lung Injury (VILI).
VILI is believed to mainly reflect cellular injury caused by 
overdistension (baro/volutrauma) and repetitive collapsing/
opening of alveoli (atelectrauma) and oxygen toxicity. This may 
cause an increase in capillary/alveolar permeability and initiate a 
cascade of proinflammatory cytokines and increased translocation 
of bacteria from the lung into the bloodstream, producing and 
propagating both a local and a systemic inflammatory response 
(biotrauma) that may lead to multiorgan dysfunction.
Patients with Acute Respiratory Distress Syndrome (ARDS) are 
the most challenging for intensive care physicians to provide with 
adequate ventilator treatment. The only method of mechanical 
ventilation that has been shown in randomised trials to improve 
survival of ARDS patients is the use of low tidal volumes (6 mL/kg 
predicted body weight) and plateau pressures £ 30 cmH2O. 
However, it is still not known how to individualise ventilator 
therapy, e.g. how to set PEEP, which is perhaps reflected in the 
high mortality of patients with ARDS which is still between 
30–60%.
Many methods of monitoring respiratory mechanics to guide 
ventilator treatment have been proposed but none has gained 
popularity during clinical circumstances. Also, the injury to the lung 
is heterogeneous so acquiring one optimal ventilator setting for 
the whole lung may be impossible. High Frequency Oscillatory 
Ventilation (HFOV), keeping the lung quite still during treatment, 
was hoped to diminish lung injury and improve survival but recent 
clinical trials on early use of HFOV in ARDS patients have showed 
either no difference or worse outcome compared with 
conventional ventilator therapy.
It therefore seems that there is still a lack of applicable clinical 
methods to measure respiratory mechanics and estimate the 
mechanical strain of lung tissues to guide conventional ventilator 
treatment in the purpose of attenuating VILI.
It would also be of value if it would be possible to increase the 
tolerance of the lung cells and tissues of the mechanical strain 
they have to endure during ventilator treatment.
These topics and recent studies on them will be addressed in 
the lecture.
O39
Pneumonia due to influenza; is there a genetic 
susceptibility ?
Magnús Gottfreðsson
Landspitali University Hospital, REYKAJVIK, Iceland
Pneumonia due to influenza virus is the most severe manifestation 
of influenza, and most patients who die due to influenza have 
pneumonia. Pre-existing humoral immunity plays an important role 
in determining the severity and outcome of seasonal influenza. 
However, it has been suggested that other host factors, possibly 
genetic, play an important role in the pathogenesis of influenza, 
especially when no pre-existing immunity is present. Introduction 
of novel influenza strains during pandemics can be viewed as a 
natural experiment, enabling researchers to identify these potential 
factors. Familial aggregation analysis of fatal influenza during the 
Spanish flu in Iceland, 1918 did not provide conclusive evidence 
for such factors. However, recent studies suggest that interferon-
inducible trans-membrane (IFITM) protein 3, previously identified 
as a strong, non-selective inhibitor of viral replication in vitro, has 
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a role in intrinsic resistance to influenza A infection in vivo in mice 
and humans. More specifically, one SNP rs12252, which results in 
a truncated IFITM3 protein missing the first 21 amino acids, was 
shown to be three times as common in patients hospitalized 
during the 2009 H1N1 influenza A pandemic, compared to 
ethnically matched Europeans. At the present time, the 
implications of these findings for public health are unclear. More 
research is needed to confirm the role of IFITM3 and other 
potential host factors in other influenza infections, such as the 
emerging H5N1 and H7N9 strains. ultimately, such studies could 
identify pathways for drug development and facilitate optimization 
of health care resources.
O40
Bronchiectasis and Cystic Fibrosis; pathogens 
and the airway epithelium
Ólafur Baldursson
Landspitali University Hospital, REYKJAVIK, Iceland
Bronchiectasis (BE) is a chronic disease characterized by a vicious 
cycle of infection and inflammation, leading to bronchial wall 
destruction, abnormal widening of the airway lumen. Symptoms 
may range from those of intermittent airway infections to a chronic 
systemic inflammatory state advancing to respiratory failure. The 
etiology is diverse, from classic BE associated with TB or pertussis, 
to localized molecular defects in cilia structure or ion channels as 
in cystic fibrosis (CF). In addition, studies indicate that the 
prevalence of BE in COPD may be significant, and relevant for 
therapeutic strategies.
In BE due to all causes, Pseudomonas aeruginosa (Pa) infection 
is particularly difficult to eradicate and generates destructive 
inflammatory response. It is therefore important to attempt to 
better understand the interactions between this pathogen and the 
airway epithelium. The unusual beneficial effect of macrolide 
antibiotics on Pa infection in BE is of particular interest to us, since 
this class of antibiotics is not designed to eradicate Pa.
We used a human airway epithelial model to study these 
effects and found that Pa disrupted the epithelium rapidly in vitro. 
However, pretreatment with azithromycin protected the airway 
epithelium from this effect. In a subsequent study, using airway 
epithelia in vitro, we found that Pa isolates from CF patients were 
significantly less invasive than wild-type Pa, and that this effect 
depended on soluble factors.
The data suggest that careful definition of the 
microenvironment during Pa airway infections may generate novel 
therapeutic strategies.
References:
O'Donnell A, Bronchiectasis in Patients With COPD: A Distinct Phenotype ? 
Chest. 2011; 140(5): 1107-8.
Smith MP. Non-cystic fibrosis bronchiectasis. JR Coll Physicians Edinb 
2011;41:132-9.
Halldorsson S, et al. Azithromycin Maintains Airway Epithelial Integrity during 
Pseudomonas aeruginosa Infection. Am J Respir Cell Mol Biol 2010; 42: 
62-68.
Halldorsson S, et al. CF sputum enhances antibiotic tolerance and reduces 
virulence of Pseudomonas aeruginosa in a bronchial epithelial model 
system. Submitted.
Session 12 – Difficult to treat astma; 
what do we know and where are we 
going?
O41
Introducton with definition, prevalence 
numbers, characteristics and different 
phenotypes. What are the issues we are dealing 
with?
Anneke ten Brinke
Medical Centre Leeuwarden, MOLENEND, Nederland
Asthma is a heterogeneous condition. Most patients with asthma 
can be adequately treated with inhaled corticosteroids and 
bronchodilators. However, a minority of patients has persistent 
symptoms, frequent exacerbations or loss of lung function. 
According to recent international consensus, these patients are 
labelled as “difficult-to-treat asthma”. The causes of “difficult-to-
treat asthma”are multiple, and may vary from poor adherence or 
inadequate inhalation technique to persistent exposure to 
aggravating factors. Only a small proportion of patients with 
“difficult-to-treat asthma”has truly “severe, refractory asthma”and 
is candidate for novel therapeutic approaches. By using a recently 
published algorithm, patients with “severe refractory asthma”can 
be distinguished from patients with “difficult-to-treat asthma”. At 
least three phenoytypes of severe asthma in adults have been 
consistently identified. These phenotypes include: 1) severe, early 
onset (allergic) asthma 2) severe, late onset asthma with persistent 
eosinophilia, and 3) a less well defined type of asthma, dominated 
by highly symptomatic, obese women with late onset asthma. In 
this talk the clinical and pathobiological characteristics of these 3 
subgroups will be discussed and the first steps towards targeted 
phenotype-specific treatment will be explored.
O42
Evaluation of the difficult to treat patient in the 
clinic and treatment adherence
L Bjermer
Skåne University Hospital, LUND, Sweden
Despite modern treatment modalities, still a large number of 
patients are insufficiently controlled. uncontrolled patients can be 
divided in to three categories. A) Easy to control, B) Difficult to 
control and C) Severe refractory asthma.
In the 'easy to control' group, control can be achieved after 
some minor or moderate adjustments. A careful check on 
inhalation technique ruling out technical problems and non-
intentional non adherence is an important step. Other important 
means are to identify environmental trigger factors and to give the 
correct medication to the right patient.
'Difficult to treat patients' represent the daily life challenge 
and constitutes the largest fraction of uncontrolled asthmatics. 
Important factors that need to be considered are 'personality 
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traits', 'complex environmental settings' and interfering 
'co-morbidity'. Anxiety and depression is more prevalent among 
asthmatic patients compared to general population and there is a 
positive association with degree of disease severity. For treatment 
success it is of utmost importance to understand the individual 
need and disease perception and to be sure that the caregiver and 
the patient agree upon the same treatment goals (concordance). 
Interfering co-morbidity is another important factor to consider. 
The majority of asthmatics suffer from concomitant rhinitis, mostly 
rhinosinusitis. It is well known than an uncontrolled or 
undertreated rhinitis increases the risk of getting an asthma 
exacerbation with or without need for hospitalization. Some 
patients with RS also have obstructive sleep apnea increasing the 
biological stress of the lower airways even more. Gastroesophagal 
reflux (GERD) is another possible contributing co-morbid condition 
that should be ruled out.
When adherence is good, environmental factors are controlled 
and comorbid-conditions are treated, severe 'refractory asthma' 
can be stated when the patient do not respond to high dose of 
inhaled corticosteroid treatment. The reason for non-response 
could be either that the dominating inflammation per se is 
corticosteroid resistance or refractory when given in 
pharmacological doses. True steroid resistance does exist although 
rather seldom. The most common reason for steroid resistance is 
either the inflammation predominantly is situated in the peripheral 
small airways difficult to reach by the inhaled route. Another 
reason can be acquired steroid resistance due to external factors 
that are possible to change, at least in theory. Examples are Obese 
or smoking asthmatics or asthma developed in athletes. True 
genetically determined resistance to corticosteroids also exist, 
although in a small fraction of patients. On the other hand, most 
of the patients have some degree of inflammatory components 
non-responsive to corticosteroid therapy. It is well known that 
corticosteroid therapy do not prevent lung function and do not 
influence important parts of the asthmatic inflammation involved 
in airway remodeling. To identify these mechanisms and to define 
ne treatment modalities also for these components is probably 
much more important than to identify a small subset of patients 
with general and genuine corticosteroid resistance.
O43
Allergic and nonallergic factors in difficult to 
treat asthma
Paula Kauppi
Helsinki University Central Hospital, HELSINKI, Finland
Aim: to study factors affecting severe asthma. Asthma is the most 
common long-term disease affecting population from teenagers to 
adults and elderly people. Despite being very common, only a 
small minority suffer from severe disease, and deaths because of 
asthma are rare. Exacerbations, hospitalizations, emergency 
department visits and work- disability in addition to asthmatic 
symptoms are signs of deteriorating asthma control. Recurrent 
episodes of exacerbations are markers of difficult disease.
Methods: In 2010, self-estimated asthma severity, co-morbid 
allergic conditions, use of asthma medication and health care 
services were assessed in the Finnish pharmacy survey. The study 
included 1114 patients purchasing asthma or allergy medication in 
pharmacies all across the country.
Results: Older age, food allergy severe enough to need a self-
management plan and atopic eczema were associated with severe 
asthma.
Previously, in addition to older age, regular long-term smoking 
and diminished lung function have been reported as risk factors 
for severe asthma and excacerbations. In 2008 in Finland, 52% of 
the hospital days in asthma were used by patients 65 years or 
older, and only 15% by patients 15 years or younger.
Both indoor and outdoor air problems may provoke respiratory 
symptoms. Skin prick test positivity against cat or dog and having 
a pet at home is reported to increase risk of hospitalization for 
asthma. Likewise, both increasing concentrations of ozone and 
NO2 have also been found to increase risk of hospitalizations.
Self-estimated disease severity and work-ability predict well 
coping with disease not only in asthma but also in other chronic 
diseases such as low-back pain or depression. In a Finnish public 
sector employee study, asthma increased the risk of long-term 
work disability by 1.8-fold. Risk for permanent work disability in 
asthma was 1.9-fold and in asthma and depression together 6.8-
fold. 
Conclusions: When aiming to better asthma control in difficult to 
treat asthma, it’s important to take a broader perspective to 
patient’s situation and consider the role of life style factors, 
adherence to the treatment, allergies and co-morbidities. 
Session 13 – Tuberculosis in the 
Nordic countries
O45
Our battle against tuberculosis in the mirror of 
time
Gunnar Boman
Uppsala lungmedicin, UPPSALA, Sverige
During the last part of the 19th century the situation was very 
severe for persons suffering from “consumption”(tuberculosis - 
TB). Most of them were poor with long working hours and living in 
overcrowded conditions. Around 1900 people in the Nordic 
countries began to organise the battle against TB. In 1901 
“Danmarks Nationalforening til Tuberkulosens Bekaempelse” 
started, in 1904 “Svenska nationalföreningen mot tuberkulos”, in 
1906 the Icelandic Sanatorium Association, in 1907 “Föreningen 
för Tuberkulosens Bekämpande i Finland”and in 1910 “Den 
norske Nationalforening mot Tuberkulosen”. There were very few 
hospital beds for the “consumptives”until the first public sanatoria 
opened: Hålahult 1900 and Õsteråsen 1901 (SWE), Lyster 1902 
(NO), Nummela and Takaharu 1903 (FIN), Silkeborg 1903 (DK) and 
Vifilstadir in 1910 (IS). The TB mortality decreased slowly 
inDenmark,NorwayandSweden, while it remained high in Finland. 
InIcelandthe mortality increased until 1930 and then dropped 
dramatically. The advent of effective chemotherapy in the form of 
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PAS fromSwedenand streptomycin fromuSAaccelerated the decline 
in the late 1940: ies. The battle against tuberculosis illustrates the 
roots of many aspects of today’s “respiratory medicine”.
O46
Experience of program management of 
tuberculosis in Finland
Rauni Ruohonen
Filha, HELSINKI, Finland
In 1990´s the tuberculosis (TB) problems started to increase in the 
neighbouring areas of Finland. Same time the knowledge on TB 
decreased among our health care workers (HCW´s). In this 
situation development of a written National TB program was seen 
necessary. It was prepared in broad cooperation between different 
stakeholders aiming at national consensus in different measures of 
TB control. The program includes practical guidance for HCW´s as 
well as strategic outlines. The preparation period improved the 
understanding and cooperation between different parties. The 
program was published in 2006. An expansive training program in 
its implementation started on 2007 and continues still today.
Several questionnaires were made to the district health 
services to follow the progress during the implementation, in 
1999, 2004, 2009 and 2012. The answers show that the TB 
control has markedly improved. Responsibilities have been 
clarified, responsible persons for TB nominated in most hospital 
districts in infectious disease, pulmonary disease and pediatric 
disease departments. District guidelines have been developed and 
cooperation between different local parties has improved. Directly 
observed treatment has improved and treatment outcome 
monitoring was taken in use. HCW´s appreciate the national and 
district guidance as well as regional training events organized in 
frame of the program. Infection control has improved. This is partly 
due simultaneous development of national prevention program for 
SARS and bird flu. Establishment of a national expert group for 
treatment of difficult TB cases has farther improved the 
cooperation between the specialists in infectious, pulmonary and 
pediatric diseases and empowered the local HCW´s in treatment of 
challenging patients.
O47
Tuberculosis among resident immigrants in 
Iceland
Thorsteinn Blöndal, L. Gudmundsson, K. Blöndal
REYKJAVÍK, Iceland
During the period 1998–2012, foreign-born persons from 32 
countries accounted for 61.9% (109/176) of the tuberculosis (TB) 
cases in Iceland. Out of those 109 persons 45.4% were diagnosed 
during the first year after entry to the country, 53.6% during the 
first 2 years and 73.7% during the first 5 years. TB was more 
prevalent among the persons of South-East Asian origin: 18.8% 
were from the Philippines, 8.5% from Thailand and 8.0% from 
Vietnam. One third of the resident immigrants in Iceland were 
from Poland. However, among them TB was rare. 
During the period 1998–2012, several micro-epidemics of 
tuberculosis emerged among subpopulations of the resident 
immigrants.
TB is rare among native Icelanders. The main target group for 
active TB screening in Iceland are the immigrants from the South-
East Asia during their first year of stay in the country, even if 
considerable proportion of TB cases emerges up to 5 years after 
the entry. It is important to continue immigrant screening at entry 
among the persons from the high TB prevalence countries in order 
to keep the incidence of TB stable.
Session 14 – Partnership with 
individuals and families facing the 
existence of COPD
O51
Partnership with individuals and families facing 
the existence of COPD
Helga Jónsdóttir1, Alda Gunnarsdóttir2, Bryndís S. Halldórsdóttir2, 
Gunnar Guðmundsson3, Ingibjörg K. Stefánsdóttir2, Jón Steinar 
Jónsson4, Rósa Jonsdottir2, Þorbjörg Sóley Ingadóttir2
1Faculty of Nursing University of Iceland, REYKJAVIK, Iceland
2Landspítali Reykjavík, REYKJAVIK, Iceland
3Lungnadeild Landspítala, Læknadeild Háskóla Íslands, 
REYKJAVIK, Iceland
4Heilsugæsla höfuðborgarsvæðisins, Læknadeild Háskóla Íslands, 
REYKJAVIK, Iceland
Background: Self-management educational programs have been 
crucial in efforts to manage COPD in people with an advanced 
disease, but have achieved less attention in people with a 
beginning disease.
Methods: RCT, participants recruited in healthcare centres and 
lung physicians’ offices. Intervention was provided for 6 months 
with a subsequent follow-up for 6 months. Control group received 
usual care. Intervention: 3–4 individual/family conversations, 
smoking cessation and one group meeting.
Results: Of 291 invited individuals 72 rejected invitation, 100 
were excluded or not reachable, 119 were randomized into 
experimental and control groups. Thirty six family members 
participated. One fourth didn´t know about disease. More than 
50% smoked, mean age was 59 years. There was no difference 
between experimental and control groups on health related quality 
of life on St. Georges Respiratory Questionnaire, anxiety and 
depression on Hospital Anxiety and Depression Scale, self-reported 
physical activity, smoking status and self-reported exacerbations 
the previous six months. Individuals in experimental group were 
significantly less influenced by COPD on the Illness Intrusiveness 
Rating Scale. Satisfaction with participation in research was good 
(experimental group 87–98%, control group 65–80%).
Conclusions: Limited effectiveness is contributed to considerable 
gains of participation in the control group, as well as timing, 
length and relatively low intensity of the partnership intervention, 
which suggests how to develop healthcare for this growing group 
of patients. 
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Session 15 – Biomarkers in asthma – 
diagnosis and management
O52
Clinical significance of different phenotypes in 
asthma
Vibeke Backer
Bispebjerg University Hospital, COPENHAGEN, Denmark
Objective: Asthma is the most frequent chronic illness in 
adolescents and young adults living in western societies. Asthma is 
characterized by respiratory symptoms and signs of reversible 
airway obstruction. The current diagnostic tools include various 
questionnaires, physiological measurements and biomarkers, but 
many of them are inaccurate or require set-ups only possible in 
hospital settings. There is a need for diagnostic tools that are valid, 
standardized and simple to use.
Fractional exhaled nitric oxide (FENO) and inhaled mannitol 
are examples of a biomarker and a physiological measurement 
respectively that are safe, standardized and easy to use. FENO 
correlates to sputum inflammatory phenotype and is regarded as a 
biomarker for eosinophilic bronchial inflammation in asthma. A 
close association between AHR to mannitol and FENO has also 
been found in asthmatic subjects with eosinophilic phenotype, 
whereas neutrophilic phenotypes have low FENO and weak 
response to mannitol.
Conclusion: There seems to be different phenotypes, which might 
respond differently on treatment with inhaled steroid.
O54
Airway hyperresponsiveness in asthma
Maria Juusela
HUS Medical Imaging Center, HELSINKI, Finland
Airway hyperresponsiveness (AHR) in asthma is complex. Airway 
inflammation in asthma originates from a multicausal pathway in 
three different processes: acute inflammation, chronic 
inflammation and airway remodelling.
AHR is defined as a reactive narrowing of the airways, which 
leads to airflow limitation. AHR has been traditionally divided into 
two components, the transient and the persistent.
AHR is measured by different methods, direct or indirect, with 
varying criteria of abnormality. A direct provocative agent, such as 
histamine or methacholine, acts on airway smooth muscle (ASM) 
cells. This approach is in contrast to the indirect methods, which 
trigger the induced ASM contraction and airway flow limitation by 
causing an excess release of inflammatory mediators, which cause 
a cascade that determine in ASM constriction.The use of inhalation 
syncronized dosimetric tidal breathing methods has become more 
popular recently, because of the high reproducibility and 
repeatability of this breath actuated method.Interpreting the 
results of AHR is method dependent. The PD15FEV1 value 
combines the information of bronchial hypersensitivity with the 
reactivity of ?FEV 1–15%.
The GINA Guidelines suggest the use of BHR testing following 
a normal spirometry(http://www.ginaasthma.org) for further exam-
inations of undiagnosed respiratory symptoms. Free run test is fre-
quently used in assessment of exercise-induced bronchoconstric-
tion in children. The ERS Task Force recommends the use of BHR 
testing in titration of anti-inflammatory theraphy. The Finnish 
Guidelines for asthma diagnosis and consider AHR to histamine 
PD15 =0.4oo mg and methacholine PD20 =0.600 mg specific for 
a physician diagnosed asthma. Recently, ?FVC at PC20 was listed 
to have a good reproducibility in assessment of small airway 
obstruction.
Findings of my thesis (http://urn.fi/uRN:ISBN:978-952-10-8176-7) 
suggest that quantitative assessment of BHR by different cut off 
levels provides a tool for characterization of phenotypes of airway 
disorders in epidemiological studies.
1.  Prevalence of BHR was 21% in the general adult population in 
Helsinki. Prevalence of BHRms defined as histamine PD15FEV1 
= 0.4 mg was 6%.
2.  The main risk factor for BHR was decreased FEV1. Impaired 
MEF50 was an independent determinant for BHRms regardless 
of age.
3.  Of the subjects with BHR 69 % were ever smokers, and 32% 
current smokers. BHR was dose dependently associated with 
pack years of smoking.
4.  Atopy combined with obstruction yielded a six-fold risk for 
BHR. Multisensitization yielded a four-fold risk for BHRms.
5.  Obesity (BMI>30 kg/m2) was not significantly associated with 
BHR.
6.  Exhaled nitric oxide (FENO) leveled the BHR severity only 
among the nonsmokers.
Juusela M et al. Int J Circumpolar Health 2008; 67(4): 308-317.
Juusela M et al. Clin Respir J 2012; DOI:10.1111/ j.1752-699X.2011.00279.x.
Juusela M et al. accepted for publication ERJ 2013.
O55
Novel Therapies in Asthma – The Biomarker 
Era?
Andrew Menzies-Gow
Royal Brompton Hospital, LONDON, United Kingdom
The presentation will cover why biomarkers are needed to guide 
novel therapies in severe asthma. The role of blood and sputum 
eosinophils to guide targeted anti-IL-5 therapy will be reviewed. 
The role of atopy and exhaled nitric oxide measurements will be 
discussed. The concept of Th2 high and low asthma and its 
implications for novel targeted therapies will be discussed. The 
paucity of biomarkers both for non-eosinophilic asthma and to use 
as a guide to decide in which patient endotypes to perform 
bronchial thermoplasty will be reviewed.
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Session 16 – Person centered care
O56
Written Self Management Plan: a useful tool 
for asthma and COPD patients experiencing 
exacerbation at home?
Liv Hasund Eid, Helga Groa Sigurdardottir, Lena Kristin Jørgensen, 
Kari Hvinden
Glittreklinikken, HAKADAL, Norway
Background: The purpose of a written Self Management Plan is 
to have a useful tool for patients with asthma and COPD to 
manage exacerbations at home. The Self Management Plan is 
prepared during pulmonary rehabilitation by a nurse, in 
collaboration with the patient and a physician.
Objectives: Is an Self Management Plan a useful tool for asthma 
and COPD patients when experiencing exacerbation at home?
Method: Sixty-six patients (51 asthma, 15 COPD) received during 
a four week in-patient occupational pulmonary rehabilitation an 
Self Management Plan. Sixty-four vs. 57 patients answered a 
follow-up questionnaire 6 vs. 12 months post pulmonary 
rehabilitation. Patients were asked about the usage of inhalation 
medicine and if the Self Management Plan was useful when 
experiencing exacerbation. The questionnaire contained three main 
questions and follow-up questions; closed and open, as well as a 
scaling question.
Main Results: Fifty-five (86%) patients used the Self 
Management Plan after 6 months. 7 and 2 patients (11% and 
3%), respectively reported no effect or that the Self Management 
Plan was not suitable. Fifty (88%) used the Self Management Plan 
12 months after PR; 2 (4%) patients had not used the Self 
Management Plan and 2 (4%) replied the Self Management Plan 
was not suitable. Necessity of the Self Management Plan on a 
scale from 0–10 was after 6 and 12 months 8.5 and 8.3, 
respectively. Inhalation medicines were used as prescribed. Several 
patients replied that the Self Management Plan resulted in a better 
communication with their physician. Some patients showed the 
Self Management Plan to their employer for a better 
understanding of the actual patient’s disease.
Conclusion: Patients with asthma or COPD experience the Self 
Management Plan to be a useful tool when experiencing 
exacerbation
O57
Patient participation during hospitalization: 
Contributions and hindrances
Bente Bjørsland
Hedmark University College, ELVERUM, Norge
Objective: Patients suffering from chronic obstructive pulmonary 
disease (COPD) do often need hospitalization related to their 
breathing difficulties. This study aims to illuminate what 
contributes or not to patient participation during hospitalization.
Methods: A qualitative descriptive approach was used. Two 
women and four men with severe COPD, age 53–74, were 
in-depth interviewed at home after hospital discharge. Data were 
transcribed verbatim and analyzed in inspiration of Malterud’s 
systematic text condensing.
Findings: The analysis resulted in two main themes and nine sub-
themes. The first main theme, Factors by the informer that 
contributes or hinders patient participation, implies that they 
experienced patient participation when they were exact about 
their needs and conscious about their knowledge. Breathing 
difficulties, lack of strength and little faith in their own knowledge 
and experiences was a hindrance for participation. The second 
main theme, Factors by the nurse that contributes or hinders 
patient participation, showed that the nurse contributed to patient 
participation when she was understanding and caring, when she 
was familiar with the patient and had time to offer. Lack of time 
and respect for the patient was experienced as a hindrance for 
participation.
Conclusions: Patient participation was related to factors both by 
the informers and the nurse. The patients could be challenged to 
be more active and have faith in their own knowledge. The nurses 
should listen more carefully to the patients. Both the patient and 
the nurse must change to become more equal partners.
O58
Exercise training – nothing for me. An interview 
study in patients with chronic obstructive 
pulmonary disease.
Karin Wadell, Petronella Nordwall Strömberg, Anncristine 
Fjellman-Wiklund
Umeå University, UMEÅ, Sweden
The major symptoms in patients with chronic obstructive 
pulmonary disease (COPD) are dyspnea, decreased physical 
capacity and level of physical activity. Exercise training has been 
proven to decrease dyspnea, improve physical capacity and health 
related quality of life and is a recommended strategy in treatment 
guidelines. However, many patients decline participation in 
exercise training programs offered to them. There is scarce 
information in the literature about how patients with COPD 
experience the discussion about physical exercise as treatment 
method. The objective of this study was to explore thoughts and 
feelings when talking about exercise training as treatment in 
patients with COPD.
Six women and four men with moderate to severe COPD, naïve 
to exercise training as treatment, were interviewed. The data was 
analyzed using grounded theory. 
The analysis resulted in one core category and four categories. 
For most of these participants exercise training was something 
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unknown. Exercise training was important but not for them. They 
had a perception that they could not perform exercise training or 
did not have the knowledge of what or how to perform it.
The patients express that physical exercise is important but an 
unknown territory for them. The results from these interviews are 
of great importance for health care professionals to take into 
account when informing patients with COPD about exercise 
training at treatment strategy. If the information about meaning 
and content of exercise training is changed there might be an 
increased amount of patients who understand that this effective 
treatment is valid also to them.
O59
The need of support to patients with lung 
cancer and their relatives
Maria Olin1, Cecilia Arving2
1Karolinska Institutet, Dept Medicine Solna, STOCKHOLM, 
Sweden
2Uppsala University, Department of Public Health and Caring 
Sciences, UPPSALA, Sverige
The incidence of lung cancer in Sweden is approximately 3500 
individuals each year and 15 percent of these are under the age of 
60. The majority of these patients are both active on the job 
market and have families with children living at home. The purpose 
of this study was to find out what kind of support these patients 
and their partners need.
A qualitative research design with semi-structured questions 
was used. Interviews were conducted with five patients and their 
partners, all of them having children aged 5–18 living in their 
households. The results were categorized into four groups: 
emotional, instrumental, informative and appraisal support.
Both the patients and their partners were satisfied with the 
medical information they had received. Practical assistance 
through advanced medical care at home (ASIH) was also seen as a 
great benefit. However, they expressed a need for more 
opportunities to talk with someone. In contrast to the patients, 
their partners felt that they had not been seen or confirmed by the 
hospital staff. There was also a concern about the needs of the 
children and a lack of knowledge as to how to address these 
needs. They requested personnel that had experience of working 
with children and their need of support.
In conclusion, the study shows that the partners are happy 
with the medical care that the patients receive, but they 
themselves experience a lack of support from the health care 
service. A lack of knowledge regarding the needs of the children is 
evident, and therefore an action plan regarding how to better 
handle these needs is necessary.
Session 17 – Pulmonary Arterial 
Hypertension
O60
Pulmonary Hypertension – Causes and 
Diagnosis
Göran Rådegran
Skånes Universitetssjukhus, LUND, Sweden
Pulmonary hypertension (PH) may according to the Dana Point 
Classification be due to; Group 1.) pulmonary arterial hypertension 
(PAH), Group 2.) left heart disease, Group 3.) lung diseases and/or 
hypoxia, Group 4.) chronic thrombo-embolic disease (CTEPH), or 
Group 5.) be due to unclear and/or multi-factorial mechanisms. PH 
is diagnosed by right heart catheterisation, and defined by 
exhibiting a mean pulmonary artery pressure ≥ 25 mmHg at rest. 
PH is further divided into pre-capillary or post-capillary PH. Pre-
capillary PH exhibit a pulmonary capillary wedge pressure (PCWP) 
≤ 15 mmHg at a normal or reduced cardiac output. Post-capillary 
PH exhibit a PCWP > 15 mmHg at a normal or reducedCO.Post-
capillary PH is further sub-divided into passive or reactive (out of 
proportion) PH, depending on whether the trans-pulmonary 
gradient (TPG) is ≤ 12 mmHg or > 12 mmHg, respectively. Pre-
capillary PH may be related to Group 1, 3, 4 or 5, whereas post-
capillary PH is related to Group 2. Moreover, in specific, survival in 
untreated PAH patients has been found to be only ~2,8 years from 
diagnosis, and if related to systemic sclerosis as low as ~1 year. 
Thus, in order to improve survival and optimize future treatments 
in PAH, as well as in PH of other aetiology, an increased 
knowledge of the causes of the various types of PH, is urged for. 
This will be addressed in the present talk.
O62
Treatment of CTEPH. Is surgery the solution?
Søren Mellemkjær
Aarhus University Hospital, AARHUS, Denmark
Chronic thromboembolic pulmonary hypertension (CTEPH) 
develops in up to 4% of patients after acute pulmonary embolism 
(PE). However, many patients that are diagnosed with CTEPH have 
not previously been hospitalized with clinical episodes of PE. For 
that reason, CTEPH should be considered in any patient with 
unexplained dyspnea with or without a history of PE. A diagnostic 
algorithm will be proposed. The value of lung ventilation-perfusion 
scan and lung CT-angiogram will be discussed. The disease can 
potentially be cured with pulmonary endarterectomy (PEA). The 
results of nearly 20 years of experience with PEA from Aarhus 
university Hospital, Denmark, will be presented. But which 
patients should be referred? And are there any alternatives to 
surgery?
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Session 18 – Treatment guidelines 
on COPD
O63
Updated GOLD guidelines – Pro
Jørgen Vestbo
Odense University Hospital, ODENSE, Denmark
The current GOLD document is not a guideline as it is impossible 
to write a ‘global guideline’ – rather, it is a strategy document 
meant to inspire. And hopefully form the basis for, national and 
regional COPD guidelines.
The 2011 revision of the GOLD document and the 2013 
update mainly contain changes in assessment and approach to 
management as well as 2 new chapters, one on exacerbations and 
one on comorbidities. The definition of the disease is only slightly 
modified and now mentions exacerbations. The diagnosis is still a 
clinical diagnosis (GOLD does not endorse screening) and the fixed 
ratio of FEV1/FVC < 0.7 is maintained as criterion of airway 
obstruction for simplicity. The new document requires a spirometry 
for diagnosis instead of just recommending it.
Assessment of the COPD patient is split in assessment of 
symptoms, assessment of airflow limitation based on spirometry, 
assessment of risk of exacerbations, and assessment of 
comorbidities. The assessment of symptoms, airflow limitation and 
exacerbation history enable the clinician to classify the patient in 1 
of 4 groups, groups A–D. This is neither a staging process, nor a 
prognostic classification; the grouping is meant as an aid to 
guiding subsequent management.
Smoking cessation is still seen as the most important objective 
of COPD management although other exposures should be 
reduced as well. Non-pharmacological parts of COPD management 
include physical activity and pulmonary rehabilitation. 
Pharmacological therapy should be guided by a combined 
assessment of symptoms and risk and is split in suggestions for 
initial therapy, other therapies, and alternative treatments. The 
document strongly encourages assessment of comorbidities and 
comments on treatments for comorbidities in the COPD patient.
O64
A case against GOLD
Peter Lange
University of Copenhagen and Respiratory Section, Hvidovre 
Hospital, COPENHAGEN, Denmark
The recent update of the GOLD document was launched in the end 
of 2011. The update follows the tradition of earlier versions and is 
a comprehensive document consisting of several chapters 
describing the diagnosis, initial assessment, treatment of stable 
disease and exacerbations. The document also focuses on the 
treatment of the most important COPD comorbidities.
The committee behind this document states that it should not 
be regarded as a guideline, but rather as an inspiration for creating 
local guidelines. Most of the statements in the document are 
evidence-based. The new version abandoned the ‘escalator 
approach’, which implied addition of more medication with 
decreasing FEV1. Instead, the new version introduced a ‘quadrant 
based’ approach where the patients are grouped into four groups 
A–D. These groups are defined on the basis of three dimensions: 
spirometry, exacerbations and symptoms. Although all these 
dimensions are most relevant while assessing patients with COPD, 
the new A–D categorizing approach has been subject to much 
criticism. Firstly, the defining cut- of values: FEV1 value of 50% of 
predicted, two or more exacerbations in the previous year and CAT 
sore of 10 (or mMRC of 2) are not evidence based. Secondly, the 
correct placing of an individual patient into A–D groups is 
complicated as the most severe score of the lung function 
dimension and the exacerbation dimension overrules the less 
severe one, when deciding if the patient belongs to the high risk 
groups C / D or to the low risk groups A / B. Thirdly, the fact that 
different scenarios could be responsible for a patient belonging 
into high risk groups C/D call for a more differentiated medical 
treatment than the options suggested by GOLD. Additionally, the 
document does not provide suggestions on how to continue 
medical treatment once the exacerbations and symptoms have 
been controlled by either reduction of harmful exposures like 
smoking or by medical treatment.
In conclusion, although the GOLD document includes 
important information on how to assess and treat patients with 
COPD, the quadrant based approach creates confusion and should 
be modified in the future updates.
Session 19 – Interstitial lung 
diseases
O65
State of the art 30–40 min
Gisli Jenkins
University of Nottingham, NOTTINGHAM, United Kingdom
Idiopathic Pulmonary fibrosis (IPF) is a chronic progressive lung 
disease, with a prognosis worse than most cancers and without 
known cure. The incidence of IPF is increasing, although the causes 
of this increase are not known. However, some environmental and 
genetic associations have been determined and these will be 
discussed.
Although the aetiology of IPF remains unknown, the 
pathogenesis of the disease is rapidly emerging. IPF is thought to 
result from recurrent epithelial injury inducing the production and 
activation of growth factors that leads to the activation of 
fibroblasts and matrix synthesis which, in susceptible individuals, 
fails to stimulate repair but amplifies positive feedback loops and 
promotes the development of fibrosis. A key growth factor in this 
pathway in the pathogenesis of IPF is Transforming Growth 
Factor-b (TGFb), and molecules which interact with this pathway 
are likely to be crucial in developing novel strategies to inhibit the 
development of fibrosis. The key steps in this pathway and 
potential strategies to inhibit it will be described.
The last 10 years has seen a paradigm shift in IPF research 
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with an explosion of clinical trials, and trial data that has emerged 
in association with these trials. This has improved our 
understanding of the natural history of disease as well as 
identifying potentially useful therapies, and confirming that 
immunosuppressive therapies targeting inflammation are 
unhelpful, and possibly harmful. Key recent clinical trial data will 
be described, including the Capacity and Panther trials.
O66
Human bronchial basal epithelial cells as 
candidate EMT precursors in idiopathic 
pulmonary fibrosis
Þórarinn Guðjónsson
University of Iceland, REYKJAVIK, Iceland
Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease 
with high morbidity and mortality. The cellular source of IPF is 
unknown but one suggested source is epithelial-to-mesenchymal 
transition (EMT). In this work we show that epithelium overlying 
fibrotic foci in IPF contains p63 positive basal cells but no ciliated 
or goblet cells. This basal epithelium has acquired increased 
expression of mesenchymal markers (N-cadherin, Vimentin) and 
increased CK14 while retaining E-cadherin expression. The 
underlying fibrotic foci showed both E- and N-cadherin positive 
cells. This pattern of expression led us to hypothesize that p63 
positive basal cells could act as EMT precursors in IPF. In support 
of this we also demonstrate that VA10, a p63 positive basal 
epithelial cell line, acquires marked up-regulation of EMT markers 
when cultured in medium containing ultroser G (uG, serum 
supplement). Isolation of mesenchymal-like cells from the 
uG-treated VA10, based on depletion of EpCAM+ cells and 
positive selection of Thy-1+ cells shows that these cells have 
acquired major hallmarks of EMT with loss of epithelial markers 
(E-Cad, EpCAM, miR200c) and gain of mesenchymal markers 
(N-Cad, Vimentin, Thy1). Furthermore, they show increased 
migration and anchorage independent growth and resistance to 
apoptosis, all phenotypes associated with EMT. This study suggests 
that p63-positive basal cells could act as EMT progenitors in IPF.
O67
The Danish Registry for Interstitial Lung 
Diseases, purpose and perspectives
Charlotte Hyldgaard
Aarhus University Hospital, AARHUS C, Danmark
A national Danish Registry for interstitial lung diseases has been 
developed and will soon be ready to start inclusion.
All respiratory departments across the country are invited to 
participate. The registry is web-based and includes demographic 
and clinical characteristics as well as facilities for storage of HRCT 
scans.
The main ambitions for the registry are:
- To create a unique platform for epidemiological and clinical 
research in interstitial lung diseases.
- To facilitate the collaboration between respiratory departments 
involved in diagnosis and treatment of interstitial lung diseases 
in Denmark.
- To improve the awareness of interstitial lung diseases.
- To provide a platform for Danish contribution to Nordic and 
international co-operation.
O68
A national collaborative effort for the 
registration of idiopathic pulmonary fibrosis 
patient data in Finland
Marjukka Myllärniemi
University of Helsinki, HELSINKI, Finland
Background: Idiopathic pulmonary fibrosis (IPF) is the most 
common idiopathic lung parenchymal disorder, with median 
survival of 3–5 years (ATS/ERS statement 2011). The exact 
incidence and prevalence of IPF in Finland is unknown. This study 
was designed as a pilot study to collect epidemiological data on 
IPF in Finland.
Materials and methods: A collaborative network, the FinnishIPF 
consortium was formed from representatives (pulmonary 
physicians) from each university hospital (Helsinki, Turku, Tampere, 
Kuopio and Oulu). Ethical permission to obtain informed consent 
was received from the Helsinki university Central Hospital, and 
was approved by all other four university Hospitals. All university 
hospital databases were screened for the Dg number(s) J84.1, 
J84.9 during year 2012. Patient data was re-evaluated by a 
pulmonary physician and uploaded to an electronic web-browser-
accessible registry database by a pulmonary physician or a trained 
research nurse.
Results: After the initial screening of patients from the search 
(J84.1, J84.9), approximately 40–50 patients from each hospital 
were identified as IPF patients. Informed consent has been 
obtained from 200 patients, out of which 125 patients data have 
been re-evaluated by a pulmonary physician and uploaded to the 
registry database. Analysis from the first 125 patients in the 
registry showed, that the mean age of diagnosis in the Finnish 
university hospitals was 68.5 years. The male-to-female ratio was 
0,6. 25% of patients had undergone diagnostic thoracotomy in 
order to obtain the diagnosis of IPF. Mean FVC at diagnosis was 
2,84 (78%), mean DLCO was 55 (volume-adjusted 78). Only five 
patients had diffusing capacity below 35.
Discussion: Our initial data obtained from five Finnish university 
hospitals suggest, that national collaborative efforts can yield 
high-quality epidemiological data on IPF. Our results suggest, that 
most IPF are diagnosed at mild-moderate stage in the Finnish 
university hospitals. Our future goal is to expand our research to 
local district hospitals, compare data from different geographical 
areas in Finland, and collect data on disease survival and the 
effects of treatment.
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Session 20 – Nursing care for people 
with advanced lung diseases and 
their families
O69
Caring burden of home-dwellers with partners 
suffering from COPD or dementia in relation to 
aspects of social support
Bente Nordtug
Høgskolen i Nord-Trøndelag, LEVANGER, Norge
Methods: Cross-sectional study, (n= 206). Summary: The Relative 
Stress Scale measured caring burden and was found to be lower 
and change less with severity in the COPD group. In multiple 
regression analyses, characteristics of the ill partner such as 
aggressive behavior, degree of self-reliance, hours they could 
adequately be alone, in addition to public services, social support 
or withdrawal from family and friends, and gender of the caregiver, 
were overriding the type of illness. Different factors added to the 
caring burden of females and males, explaining 58 % of the caring 
burden for females, and 77 % for males. 
Conclusions: In future management of health services it seems 
beneficial to emphasize these findings, and consider gender 
differences in the efforts to improve the caregivers’ capacity for 
extensive caring in the homes
O70
The effects of real-time telemedicine 
consultations between hospital-based nurses 
and severe COPD patients discharged after 
exacerbation admissions
Anne Dichmann Sorknæs1, Jest Peder1, Mickael Bech2, Lise 
Hounsgaard2, Finn Olesen3, Birte Østergaard2
1OUH-Odense University Hopsital & Svendborg Hospital, V. 
SKERNINGE, Danmark
2University of Southern Denmark, ODENSE, Denmark
3Aarhus University, AARHUS, Denmark
Introduction: Hospitalisation with acute exacerbation of chronic 
obstructive pulmonary disease (AECOPD) causes a major burden for 
the COPD patients and is a common cause for admissions and 
readmissions to medical wards.
Objectives: To investigate the effect of one week of daily real-time 
telemedicine video consultations (teleconsultation) between 
hospital-based nurses specialised in respiratory diseases (telenurses) 
and patients with severe COPD discharged after AECOPD in addition 
to conventional treatment compared to the effect of conventional 
treatment.
Methods: Patients admitted with AECOPD at two different 
locations were recruited at hospital discharge and randomly 
assigned (1:1) to either daily teleconsultation for one week in 
addition to conventional treatment, the TVC group or to 
conventional treatment, the CT group. The telemedicine equipment 
consisted of a briefcase with built-in computer including a web 
camera, microphone and measurement equipment.
Primary outcome: consisted of the total number of readmissions 
within 26 weeks after discharge.
Results: A total of 266 patients (mean age 71.5 years, SD 9.5 
years) were allocated to either TVC (n=132) or CT (n=134). No 
significant difference was noted between the groups (p = 0.62).
Conclusion: In conclusion, addition of one week of 
teleconsultations between hospital-based telenurses and patients 
with severe COPD discharged after hospitalisation with AECOPD 
was as safe and effective as conventional treatment, but it did not 
significantly reduce readmissions or affect mortality.
O71
Chronic Obstructive Pulmonary Disease – test 
of physical activity level in a home setting
Lisbeth Marie Oestergaard, Christina Nielsen, Nina Skavlan 
Godtfredsen
Bispebjerg University Hospital, COPENHAGEN, Denmark
Background: 
In connection with the “Online Chronic Obstructive Pulmonary 
Disease (COPD) Rehabilitation – a pilot study”the patients were 
tested in their own home before and after the study. In extension 
of the pilot study and with reference to the online study this year, 
test of physical activity level in a home setting are in focus.
In a hospital setting different kinds of tests using space and 
special equipment can be performed. This kind of tests is not 
possible or strictly comparable with test in a home setting. 
Furthermore, patients with severe or very severe COPD may have 
challenges performing the same standardized test battery as in the 
hospital due to fatigue and shortness of breath.
Objective:
To evaluate and gain experience in testing the physical activity 
level of patients with severe or very severe COPD in a home 
setting
Methods:
In connection with “Online COPD rehabilitation 2012”the goal is 
to include 48 patients diagnosed with severe or very severe COPD 
through 2013. The patients are tested in their own home setting. 
In hospitalized rehabilitation patients are usually tested with 
Shuttle-walk-test (Incremental and Endurance) or 6-minute-walk, 
however this is not feasible in a home setting. Therefore other 
physical tests are performed; Timed-up-and go 2,45m performed 
twice, Sit-to-stand performed once and 2-minute knee-lift-test 
performed once.
Results:
Results from the patients who have completed study until now will 
be presented.
Conclusions:
The pilot study showed promising results. Conclusions based on 
results from the extended study period will be shown.
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O72
Family nursing practice for patients with lung 
diseases
Helga Jónsdóttir, Bryndís S. Halldórsdóttir, Þorbjörg Sóley 
Ingadóttir
University of Iceland, REYKJAVÍK, Iceland
Reorienting the focus of health systems to incorporate a 
multifaceted approach that allows for comprehensive and humane 
health care is pending. using the participatory paradigm approach, 
we describe a study of a partnership-based family nursing practice 
for people with lung diseases. The results are presented with 
narrrative analysis that reveal the meaning and experience of the 
family nursing practice in the following interlacing descriptive 
statements: (a) surfacing and contextualizing health problems, (b) 
responsiveness of services, (c) security-stability-self-direction, and 
(d) unified family efforts- transformation. We conclude that the 
conceptual framework of partnership is a useful approach to 
nursing practice within a nurse clinic for people with advanced 
breathing difficulties and their families. The results will be 
discussed from different angels in three consequent presentations: 
The theoretical framework, diversity of patient problems and 
working with families.
Session 21 – Sleep 2
O73
New technological approaches to a major 
public health problem
Samuel Kuna
University of Pennsylvania, PHILADELPHIA, USA
Sleep medicine is strategically positioned to capitalize on the use 
of emerging telehealth technologies that are transforming 
healthcare to home-based delivery. Application of video 
teleconferencing, wireless transmission of data, and patient access 
to personal medical information promise to increase patient access 
to care, promote self-management, and be more cost effective 
than current in-person models of care delivery. Innovative 
telehealth programs at the Philadelphia Veterans Affairs Medical 
Center, Philadelphia, PA, uSA have been developed to treat 
patients with chronic insomnia using cognitive behavioral 
treatment for insomnia delivered by video teleconferencing. An 
interactive website has also been developed that allows patients 
with obstructive sleep apnea to complete clinical outcome 
questionnaires, view the daily results of their positive airway 
pressure treatment, access educational videos and documents, and 
e-mail their sleep specialist. use of these technologies allows 
patients to receive care of their sleep disorder without coming to 
the sleep center. Research studies are urgently needed to 
determine the most cost effective way to use these new telehealth 
technologies to diagnose and manage patients with sleep 
disorders.
O74
Telemonitoring of CPAP therapy
Tarja Saaresranta
Turku University Hospital, TURKU, Finland
Telemonitoring has been successfully used to improve adherence for 
nasal CPAP therapy. However, the effect of telemonitoring on nursing 
time has not been reported. We compared telemonitoring with 
regular nursing procedure in terms of patient satisfaction, CPAP 
adherence and nursing time during the habituation phase of the 
CPAP therapy in OSAS. After CPAP titration at home, patients were 
randomized to the telemonitoring (TM) or the control group (CTRL). 
TM used S9 Elite® (ResMed, Australia) fixed pressure CPAP device 
with wireless, remote monitoring system (ResTraxx Online System®, 
ResMed, Sydney, Australia), and CTRL similar CPAP devices without 
telemonitoring. Both groups were encouraged to call the sleep nurse 
during the habituation phase, if running into problems with 
treatment. Both groups were satisfied with patient education and 
support. CPAP adherence was similar in both groups. After the 
habituation phase, TM considered less frequently control visit at 
doctor’s office necessary than CTRL. Nursing time per patient was 
shorter in the telemonitored group than in the control group. 
According to our preliminary results, patients are satisfied with 
telemonitoring. Moreover, telemonitoring seems to save nursing 
resources during the habituation phase of the CPAP therapy.
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Home mechanical  ventilation
P01
Evaluation of the laryngeal response patterns 
during mechanical insufflation-exsufflation
Tiina Andersen, Astrid Sandnes, Magnus Hilland, Thomas 
Halvorsen, Ove Fondenes, John-Helge Heimdal, Ole-Bjørn Tysnes, 
Tom Karlsen, Thor-Andre Ellingsen, Marit Arnevik Renså, Gunvor 
Mo Norstein, Ola Drange Røksund
Haukeland University Hospital, BERGEN, Norway
Objective: Mechanical insufflation-exsufflation (MI-E) is used to 
assist cough in patients with neuromuscular diseases. Clinically, 
MI-E may be challenging in patients with bulbar Amyotrophic 
Lateral Sclerosis (ALS), possibly related to laryngeal dysfunction. 
Laryngeal response patterns to MI-E have not been established. 
We aimed to investigate laryngeal response patterns to MI-E in 
healthy individuals and in patients with ALS.
Methods: Continuous videorecorded transnasal fiberoptic 
laryngoscopy was obtained in twenty healthy individuals and in 
eight patients with ALS (two non-bulbar and six bulbar) while 
performing MI-E using Cough Assist® (Respironics, uSA) 
according to a standardized protocol applying pressures of ±20 to 
±50 cmH2O.
Results: Both the healthy and non-bulbar ALS subjects managed 
to coordinate their cough well with MI-E. However, some 
heterogeneity was observed in healthy subjects in relation to both 
laryngeal anatomy at rest and during the application of MI-E. In 
bulbar ALS, the heterogeneity was more pronounced, and the 
vocal fold response could not be observed in four of six patients 
during parts of the MI-E sequence, due to hypopharyngeal 
obstruction during exsufflation or/and severe adduction of 
aryepiglottic folds during insufflation. In one of the six bulbar ALS 
patients, pronounced hypopharyngeal obstruction and high 
standing epiglottis concealed the response of structures below.
Conclusion: The laryngeal response to MI-E in patients with 
bulbar ALS differed from that observed in healthy subjects and in 
patients with non-bulbar ALS, in that laryngeal structures adducted 
during insufflation as well as during exsufflation. This adduction 
severely compromised the size of the laryngeal inlet, potentially 
compromising airflow and the effect of MI-E.
P02
The characteristics of patients on home volume 
control ventilation in Iceland
Björg Eysteinsdóttir1, Edda Gunnarsdóttir2, Oddný Fjóla Lárusdóttir1, 
Bryndís Halldórsdóttir2, Þóra Guðmunda Gísladóttir1, Kristbjörg 
Leósdóttir1
1Landspítali, REYKJAVÍK, Island
2Landspitali, REYKJAVÍK, Island
Introduction: In Mars 2013, out of population of 360.000 in 
Iceland, there were altogether 3427 people using a home 
ventilation, 3205 on continuous positive airway pressure (CPAP), 
149 on bilevel PAP (BiPAP), 62 on adaptive servoventilation and 
11 on home volume control ventilation (Elisée). The use of volume 
ventilation has increased substantially since 2006 when the first 
Elisée device arrived. Elisée device are used for various diseases 
that patients have to use in home care 24hours/day. Our aim is to 
describe this treatment in the well defined population of Iceland.
Methods:  All the patients who started treatment on Elisée device 
from 2006 are included. The subjects were altogether 26 patients 
(19 males and 7 females). The data was taken from their medical 
records.
Results: This group of patients had various diseases: chronic 
obstructive pulmonary diseases (COPD), motor neuron disease 
(MND), Duchenne muscular distrophy, spinal muscular atrophy 
(SMA), muscular dystrophy and chronic respiratory failure due to 
accidents. The group included children and adults. The youngest 
patient in the group was 13 months and the oldest was 80 years. 
Ten of them died, three went on BiPAP device after a period on 
Elisée, two went into palliative care and eleven continued to use 
the Elisée device.The patients were all living at home except for 
two of them that were planning to go home again.
Conclusions: This group included patients of all ages, from 
infants up to elderly people. The patients that did not use it 24 
hours/day have stopped the treatment or gone back to simpler 
ventilator control.
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Is it possible to prevent tracheostomy related 
infections in patients with long-term 
mechanical ventilation (LTMV)?
Sølvi Margrethe Flaten1, Heidi, Øksnes Markussen2, Solfrid 
Indrekvam2, Sissel Frostad Oftedal1, Gunvor, Mo Norstein1, Ove 
Fondenes1
1National Centre of Excellence in Home Mechanical Ventilation - 
NCH, BERGEN, Norge
2Haukeland University Hospital, BERGEN, Norway
Background: This project was a result of a specialization program 
in respiratory nursing at Bergen university College, Norway.
NCH receives frequent enquiries from health personnel and 
caregivers regarding hygiene concerning tracheostomy patient, 
cleaning of tracheostomy cannulas, inner cannula, tracheostoma 
and replacement interval.
Aims: To search and identify evidence-based practice procedures/
protocol for cleaning of cannulas in patients outside the hospital.
Method: Literature study of existing research and literature 
related to cleaning procedures.
Search: Best Practice/Pub Med/Medline OvidSP/Ovid Nursing/
Cochrane Library/NKH/Swedevox and Google.
Results: The majority of research papers found were related to 
surgical techniques/entering the cannula and procedures in 
relation to hospitalized patients.
Results:
Guidelines 9
Rewievs 10
RCT/Crossover study 1
In-vitro microbiologic study 1
Systematic review 1
Experimental study 1
Review articles 6
Procedures from medical company 3
Two studies showed different outcome regarding bacteriology. 
One study concluded that cleaning the tracheostomy inner cannula 
with detergent and water was sufficient to achieve decontamina-
tion. Another studied showed that P. aeruginosa and S. aureus bio-
films in pediatric tracheostomy tubes were not eradicated by stan-
dard cleaning methods.
There was no evidence on how long the patient can use the 
same cannula before replacement.
Conclusion: Little research is published on hygiene in tracheosto-
my patient with LTMV outside hospital. Only two studies with high 
evidence from controlled studies, however with conflicting results.
There is a general lack of information regarding the prevalence 
of tracheostomy related infections in LTMV.
Practical procedures and guidelines recommendations are 
mainly consensus based.
Obstructive lung disease
P04
Measurement of activities of daily living in 
COPD: a systematic review
Tania Janaudis-Ferreira, Beauchamp Marla, Robles Priscila, 
Goldstein Roger, Brooks Dina
West Park Healthcare Centre, TORONTO, Canada
Objectives: The objectives of this systematic review were to 
synthesize the literature on measures of activities of daily living 
(ADL) that have been used in individuals with chronic obstructive 
pulmonary disease (COPD) and provide an overview of the 
psychometric properties of the identified measures.
Methods: Studies that included a measure of ADL in individuals 
with COPD were identified using electronic and hand searches. 
Two investigators performed the literature search. One investigator 
reviewed the study title, abstract and full-text of the articles to 
determine study eligibility and performed the data extraction and 
tabulation. In case of uncertainty, a second reviewer was 
consulted.
Results: A total of 679 articles were identified. Of those, 116 met 
the inclusion criteria. Twenty-seven ADL instruments were 
identified, of which 11 instruments were respiratory disease-
specific while 16 were generic. Most instruments combined 
Instrumental ADL (IADL) with Basic ADL (BADL). The majority of 
the instruments were self-reported; only 3 instruments were 
performance-based. Twenty-one studies assessed psychometric 
properties of 16 ADL instruments in patients with COPD.
Conclusions: Although several ADL instruments were identified, 
psychometric properties have only been reported in a few. 
Selection of the most appropriate measure should focus on the 
target construct (BADL or IADL or both), type of test (disease-
specific vs. generic and self-reported vs. performance-based), 
depth of information obtained and psychometric properties of the 
instruments. Given the relevance of ADL to the lives of patients 
with COPD its assessment should be more frequently incorporated 
as a clinical outcome in their management. 
P05
Prevalence and profile of patients with a 
diagnosis of COPD participating in non-
pulmonary rehabilitation programs
Tania Janaudis-Ferreira1, D’Souza Lorna2, Goldstein Roger1, Brooks 
Dina1
1West Park Healthcare Centre, TORONTO, Canada
2St John’s Rehab Program, Sunnybrook Health Sciences Centre, 
TORONTO, Canada
Objectives: to determine the prevalence of patients with a 
primary or secondary diagnosis of COPD among individuals who 
completed a non-pulmonary rehabilitation program and to 
describe the clinico-epidemiological profile of these patients. 
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Methods: Retrospective electronic data review of 4694 patients 
who completed a non-pulmonary inpatient rehabilitation program 
at the St John’s Rehab program of Sunnybrook Health Sciences 
Centre, Toronto, Canada between July 1st 2010 and July 1st, 2012. 
Sex, age, primary or secondary diagnosis of COPD, reason for 
admission, type of program completed, length of stay and 
functional independence measure (FIM) on admission and 
discharge were collected. 
Results: Three hundred fifty-one patients (50.1% male and 
49.9% female) were identified with a primary (6.3%) or secondary 
(93.7%) diagnosis of COPD. Mean (SD) age was 76 (10). The 
majority of the patients participated in the Musculoskeletal 
inpatient program (n= 143; 41%). Other types of programs were: 
Cardiac (n = 88; 25%); Complex Care (n = 49; 14%); Neurology 
(n = 26; 7%); Amputees (n = 21; 6%); Transplants (n = 9; 3%), 
Oncology (n = 8; 2%), Trauma (n = 3; 2%) and Burns (n = 1; 
0.3%). The primary reason for admission for most of these patients 
was Cardiac (n= 69) followed by “Status Post unilateral Hip 
Replacement”(n=40). The mean (SD) length of stay was 20 (13) 
days. The Mean (SD) of the FIM on admission and discharge was 
91 (11) and 108 (9) respectively. 
Conclusions: The prevalence of patients with COPD was 7.5%. 
COPD is a common comorbidity among patients admitted for 
musculoskeletal and cardiac rehabilitation. In order to optimize the 
management of patients with COPD enrolled in other 
rehabilitation programs, it may be worthwhile introducing COPD-
specific interventions.
P06
Multiple symptoms and quality of life in people 
with Chronic Obstructive Pulmonary Disease 
(COPD)
Christine Råheim Borge1, Astrid K. Wahl2, Torbjørn Moum3
1University of Oslo/ Health and Society and Lovisenberg Diaconal 
Hospital, OSLO, Norway
2Universtiy of Oslo/ Institute of Health and Society, OSLO, Norge
3University of Oslo/Institute of Basic Medical Sciences, OSLO, 
Norge
Background: There is a lack of investigation on how 
breathlessness in COPD may be associated with other symptoms 
such as depression, anxiety, fatigue, sleeping difficulties, and pain. 
Furthermore, pain is a symptom that may be under recognized in 
COPD in particular as it might be associated with low quality of 
life (QOL).
Aims: To investigate how multiple symptoms are associated with 
breathlessness and to explore the prevalence, intensity, and 
location of pain in COPD and how pain is associated with QOL.
Method: 154 patients with COPD participated in a cross-sectional 
study. They performed a pulmonary function test and responded to 
the Respiratory Quality of life scale, Brief Pain Inventory, The 
Hospital Anxiety and Depression Scale, Lee Fatigue Scale, General 
Sleep Disturbance Scale and Quality of Life Scale. Multiple 
regression analyses were performed controlling for socio-
demographic and clinical variables.
Results: Two papers[1;2] have been published from this study 
showing that breathlessness is significantly associated (p<0.01) 
with symptoms of depression, anxiety, fatigue, as well as with 
sleeping difficulties and pain. 72% of the patients indicated the 
location of pain on a body diagram. Pain interference and pain 
intensity showed a significant association with disease specific 
QOL (p<0.001).
Conclusion: There is a need to recognize the role and function of 
multiple symptoms associated with breathlessness in COPD. Such 
a focus might help patients with COPD gain a better QOL.
1  Borge CR, Wahl AK, Moum T: Association of breathlessness with 
multiple symptoms in chronic obstructive pulmonary disease. J 
Adv Nurs 2010;66:2688-2700.
2  Borge CR, Wahl AK, Moum T: Pain and quality of life with chronic 
obstructive pulmonary disease. Heart Lung 2011;40:e90-101.
P07
Hospital-based pulmonary rehabilitation in 
patients with COPD in Sweden – a national 
survey
Karin Wadell1, Tania Janaudis-Ferreira2, Mats Arne3, Karin Lisspers4, 
Björn Ställberg4, Margareta Emtner5
1Umeå University, UMEÅ, Sweden
2Sunnybrook Research Institute, St John’s Rehab Hospital, 
TORONTO, Canada
3Department of Neuroscience, Uppsala University, UPPSALA, 
Sverige
4Dept. Public Health and Caring Sciences, Family Med and Prev 
Med Uppsala Univers, UPPSALA, Sverige
5Department of Neuroscience and Medical Sciences, Uppsala 
University, UPPSALA, Sverige
Pulmonary rehabilitation (PR) is an evidence-based multidisciplinary 
intervention that leads to decreased dyspnea, improved physical 
capacity and quality of life in patients with chronic obstructive pul-
monary disease, COPD. PR is cost effective and is recommended in 
treatment guidelines for these patients. However, the availability of 
PR programs varies between and within different countries. The aim 
of this study was to investigate the availability and content of hos-
pital-based PR programs in patients with COPD in Sweden.
A cross-sectional descriptive design was applied using a web-
based questionnaire which was sent out to all hospitals in 
Sweden. The questionnaire consisted of 32 questions that 
concerned availability and content of PR in patients with COPD 
during 2011.
Seventy-one out of 72 hospitals responded the electronic sur-
vey. Forty-seven (66%) hospitals offered PR for patients with 
COPD. Around 75% of the hospitals in southern and middle parts 
of Sweden and 33% of the hospitals in the northern part offered 
PR. Forty percent of the patients declined participation. A total 
number of 1355 patients participated in PR which represents 0.3% 
of the COPD population in Sweden. All hospitals had exercise train-
ing as major component and 25% offered an educational program.
Not even half a percent of the patients with COPD in Sweden 
took part in a hospital based PR program during 2011. There was 
a considerable geographic discrepancy in availability over the 
country. To enable a greater part of the increasing number of 
patients with COPD to take part in this evidence-based treatment, 
there is a need of evaluating other settings of PR programs; in 
primary care, at home and/or over the internet.
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P08
Genetic variant of the nicotinic receptor gene 
and the long term prognosis of smokers
Henna Kupiainen1, Mikko Kuokkanen2, Jukka Kontto2, Jarmo 
Virtamo2, Veikko Salomaa2, Ingeleif Jonsdottir3, Tarja Laitinen1
1University of Turku, TURKU, Finland
2National Institute for Health and Welfare, HELSINKI, Finland
3DeCode Genetics, REYKJAVIK, Iceland
Study objective Polymorphisms in the nicotinic acetylcholine 
receptor gene (CHRNA3/A5 locus) has been associated with 
several smoking related traits such as nicotine dependence, 
cigarette consumption, smoking cessation, lung cancer and the 
development of COPD. Our aim was to study one of the 
polymorphisms (rs1051730) in long term prognosis among 
smokers.
Subjects and methods: Genotyping was done in two 
longitudinal cohorts: Finnish COPD patients (N=575, 74% men) 
among which several clinical variables are available and among 
smoking men (N=1911) to whom only basic demographic 
information was available. The analyses were done using 
multivariate logistic regression model and Cox proportional 
hazards model. Additive model was used in all analyses and OR 
and HR values are given for minor homozygote. Finnish 
Health2000 population cohort (N=1728) was used for control.
Results: The genetic variant increased the risk of COPD when 
compared to the Finnish population at large (OR=1.4, p=3.2 x 
10-5). Among COPD patients the minor allele was associated with 
cancer (adjusted OR 2.39 CI 1.00-5.67), in smoking men with 
pack years (adjusted OR 1.43 CI 1.09-1.96) and in both cohorts 
with all-cause mortality. Adjusted hazards ratios in COPD patients 
and in smoking men were HR 2.24, CI 1.22-3.82 and HR 1.23, CI 
1.09-1.50, respectively.
Conclusions: Genetic variance found in the chromosome 15q25 
locus may have clinical value in predicting high risk patients.
P09
Impaired carbon monoxide diffusion capacity is 
the strongest predictor of the decline in 
exercise capacity in chronic obstructive 
pulmonary disease
Amir Farkhooy1, Christer Janson2, Harpa Arnardottir3, Margareta 
Emtner2, Andrei Malinovschi2, Hans Hedenström2
1Uppsala University, UPPSALA, Sweden
2Dept. Medical Sciences, Uppsala University, UPPSALA, Sverige
3Dept. of Rehabilitation, Akureyri Hospital, AKUREYRI, Island
Objective: To evaluate the relationship between exercise capacity, 
assessed by standardized 12 minute walking test (12MWT), and 
various lung function parameters obtained by spirometry, body 
plethysmography and diffusion capacity (DLCO) measurements in 
patients with chronic obstructive pulmonary disease (COPD).
Methods: A total of 34 patients (22 women) with moderate to 
very severe COPD, aged 63 ± 8 years (mean ± SD) were 
investigated regarding lung function (spirometry, lung volumes 
and DLCO) and exercise capacity (12MWT) at baseline and follow-
up, 5 years later. The subjects were part of a cohort of 86 patients 
consecutively recruited when being referred for physical training to 
the Dept. of Respiratory medicine at uppsala university hospital.
Results: Patients were characterized at baseline by FEV1 of 1.2 ± 
0.4L (41 ± 13% predicted), RV of 3.4 ± 1.0L (187 ± 58% 
predicted) and DLCO of 3.8 ± 1.2 mmol/min/kPa (51 ± 16% 
predicted). A decrease of 12MWD was found between baseline 
and follow-up (927 ± 193m vs. 789 ± 273m, p<0.001). DLCO 
and 12MWD at baseline were the only independent predictors of 
12MWD at follow-up in a multiple logistic regression model that 
also included all other lung function parameters, gender, age and 
BMI. Furthermore DLCO value at baseline showed to be the 
highest predictor of loss in 12MWD after 5 years (R2=0.18, 
p=0.009). These results were also consistent in a multiple logistic 
regression model that included all other lung function parameters, 
gender, age and BMI.
Conclusions: In a 5 year longitudinal study, DLCO measurements 
at baseline were the most important predictors of declining 
exercise capacity in COPD patients. These results suggest that 
integration of DLCO in the clinical work up provides a more 
comprehensive assessment in patients with COPD.
P10
Systemic inflammation and cardiovascular 
disease in chronic obstructive pulmonary 
disease (COPD)
Ólöf Birna Margrétardóttir1, Thor Aspelund2, Vilmundur Guðnason3, 
Gunnar Guðmundsson4
1Faculty of Medicine, University of Iceland, REYKJAVÍK, Iceland
2Icelandic Heart Association, KÓPAVOGUR, Iceland
3Faculty of Medicine, University og Iceland, Icelandic Heart 
Association, KÓPAVOGUR, Iceland
4Department of Respiratory Medicine and Sleep, Landspitali 
University Hospital, REYKJAVÍK, Iceland
Background: Chronic obstructive pulmonary disease (COPD) has 
significant morbidity and mortality. Cardiovascular diseases are a 
common cause of mortality and systemic inflammation has been 
found in COPD.
Objective: To evaluate systemic inflammation and to measure 
signs of cardiovascular disease with non-invasive laboratory 
studies in the study population.
Methods: Subjects with COPD were identified among subjects in 
the Age Gene/Environment Susceptibility (AGES) study. Study 
population was divided into four groups; non-smokers with normal 
spirometry (NS-NS, control group), smokers with normal spirometry 
(S-NS), non-smokers with abnormal spirometry (NS-AS) and 
smokers with abnormal spirometry (S-AS). Inflammatory markers 
(C-reactive protein (CRP), interleukin-6 (IL-6), white blood cells 
(WBC)) were measured. Arterial macrovascular and microvascular 
disease was evaluated.
Results: S-AS group had the highest values of CRP and WBC. This 
finding was significant after adjustment for age, gender and body 
mass index (BMI). S-AS group had the most calcium in the 
coronary arteries and aorta. This was significant after adjustment 
for age, gender and history of cardiac event. Measurements of 
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carotid intima-media thickness and plaque showed similar results 
that were significant after adjustment for age, gender and statin 
use. There was a significant difference in periventricular white 
matter lesions (PVscore). Other measurements of brain vasculature 
(signs of microbleeds and infarcts) were non-significant.
Conclusion: Smokers with COPD had more inflammation. 
Vascular changes were seen in thorax but not in the brain, 
suggesting that COPD has the most effect on the vascular system 
in vicinity of the lungs.
P11
How to improve the care of COPD- and 
Asthmapatients in Sweden
Alf Tunsater1, Birgitta Jagorstrand1, Kerstin Romberg1, Leif Bjermer1, 
Ann Ekberg-Jansson2
1Allergy Competence Center, LUND, Sweden
2Angereds Narsjukhus, GOTEBORG, Sweden
Background: A tool for quality monitoring is the use of 
indicators. So far there have been no quality tools that provide 
opportunities to develop the quality of care in terms of respiratory 
diseases in Sweden. 
Aims: To build a National Quality Registry for COPD and Asthma 
in order to improve the quality of asthma and COPD care and to 
ensure equal treatment in all parts of Sweden. 
Methods:  A steering committee was appointed to select 
important indicators of quality. The committee was composed of 
specialists in general medical practice, allergologists, 
pulmonologists, paediatricians, asthma nurses and representatives 
of patient organizations. 
Results: The registry was designed to fit the Health Care Centres 
in primary care, although the COPD part of the registry also has a 
hospital version. It contains personal information about diagnosis, 
treatment, and outcomes. When entering the registry you can 
choose between Asthma and COPD. You will only see and answer 
questions relevant for the certain disease. Many questions relates 
to both diagnosis such as spirometry data and smoking habits. 
Examples of registrations are: Time of diagnosis, smoking habits, 
lung function, basic allergy screening, health care consumption 
such as emergency visits and hospital treatments, patient reported 
outcomes and treatment. 
Conclusions: The Swedish Association of Local Authorities and 
Regions (SALAR) now supports the results of the steering 
committee’s work - “The Airway Registry”. The feedback from the 
registry to the health care units will be of utterly importance and 
enable development of the quality of care of patients with asthma 
and/or COPD in Sweden. It will also provide unique opportunities 
for research. An official report of registry summaries will be 
presented every year.
P12
Bronchial hyperresponsiveness to methacholine 
in relation to asthma control in children and 
adults – results from the MIDAS study
Andrei Malinovschi, Christer Janson, Lennart Nordvall, Hans 
Hedenström, Kjell Alving
Uppsala University, UPPSALA, Sverige
Bronchial hyperresponsiveness (BHR) is a hallmark of asthma. BHR 
to methacholine is used for diagnosis, but the role in monitoring 
treated asthma is not established. In the present study we 
assessed the relation between BHR to methacholine, airways 
inflammation, asthma control and symptoms.
Methacholine challenge and exhaled nitric oxide (FeNO) 
measurements were done in 371 asthmatics (aged 10-35 years) 
with inhaled corticosteroids prescribed. PD20 <0.3 mg defined 
moderate-severe BHR, 0.3 to 1.0 mg borderline-mild BHR, and 
>1.0 mg normal response (Schulze et al. Resp Med 2009). Well-
controlled asthma (≥20 in Asthma Control Test) was found in 68% 
of children (<18 years) and 75% of adults (≥18 years). All subjects 
answered questions on asthma symptoms.
Moderate-severe BHR was found in 61% of children and 44% 
of adults. FeNO increased with more severe BHR in both children 
and adults, with a higher explanatory value in children (R2=0.15 vs 
0.06). Well-controlled asthma was less prevalent in the moderate-
severe BHR group than the other two BHR groups in adults (66% 
vs 83% and 82%, p<0.05), whereas no significant difference was 
found in children (68% vs 76% vs 63%). Higher prevalence of 
wheezing and asthma attack last year was found with higher BHR 
in both children and adults (p<0.05 both). Dyspnea at rest related 
to BHR in children (p=0.007), while exercise-induced dyspnea was 
associated with BHR in adults (p=0.007).
In conclusion, bronchial hyperresponsiveness to methacholine 
was common in this treated asthma population and related both 
to airways inflammation and clinical aspects of asthma. BHR 
appears to be stronger related to poorer asthma control and 
exercise-induced dyspnea in adults than children.
P13
Altered fibroblast repair function in COPD
Oskar Hallgren1, Sara Rolandsson1, Annika Andersson-Sjöland1, 
Elisabet Wieslander2, Magnus Dahlbäck2, Leif Eriksson2, Jonas 
Erjefält1, Claes-Göran Löfdahl1, Leif Bjermer1, Gunilla Westergren-
Thorsson1
1Lund University, LUND, Sweden
2AstraZeneca, LUND, Sweden
During wound healing processes fibroblasts accounts for wound 
closure by adopting a contractile phenotype and produce 
extracellular matrix (ECM) molecules. During normal wound 
healing the process is terminated when the wound has healed and 
the initial trigger disappears. However when the trigger persists, as 
is the case in COPD with the repeated exposure of cigarette 
smoke, the wound healing process becomes pathological and the 
fibroblast phenotype is likely to be altered. Our aim was to 
investigate the repair capability, defined as ECM production and 
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contractility, in centrally (bronchial) and distally (alveolar) derived 
fibroblasts from severe COPD patients and control subjects. 
The repair functions were different in centrally and distally 
derived fibroblasts from COPD patients compared to the 
corresponding cells from control subjects. Distally derived 
fibroblasts from COPD patients were more contractile and this was 
dependent on increased ROCK1 activity. In addition, these cells 
had enhanced production of the proteoglycan versican. Versican 
have been suggested to interfere with de novo synthesis of elastin 
and may thus be important in formation of emphysema. Centrally 
derived fibroblasts from COPD patients had a lower basal 
production of the basement membrane-stabilizing proteoglycan 
perlecan which may indicate alterations of the bronchial basement 
membrane in COPD. To summarize, our results suggest that 
fibroblasts from COPD patients have altered repair functions. 
Importantly, there was a difference in function between bronchial 
and alveolar fibroblasts which may reflect the different 
pathological processes in these sites.
P14
Bronchial hyperresponsiveness with histamine 
associates with incidence of asthma in a 
general adult population sample
Maria Juusela1, Paula Pallasaho2
1HUS Medical Imaging Center, HELSINKI, Finland
2Control of Hypersensitivity diseases, Finnish Institute of 
Occupational Health, HELSINKI, Finland
Bronchial hyperresponsiveness (BHR) was assessed as a risk factor 
for incidence of asthma.
In Helsinki, 6062 subjects took part in a postal survey of 
respiratory and allergic symptoms and diseases in 1996, of whom 
292 participated in the bronchial challenge studies in 2001-2003. 
Later, 4302 subjects of those original 6062 subjects were 
participating in a follow-up postal survey in 2007.
In 1996 and 2007, a self-administered postal questionnaire 
was used. The same survey has been used in the FinEsS studies in 
Sweden in Norrbotten, Õrebro, Stockholm and recently in 
Gothenburg, in Estonia in Tallinn, Narva and Saarenmaa, and in 
Finland in Lapland and Helsinki.
The histamine test was performed for 292 randomly selected 
subjects according to the dosimetric, tidal breathing method by 
Sovijärvi et al. (1993). Histamine PD15FEV1 was defined.
Multiple logistic regression analysis was used to assess the risk 
factors for incidence of asthma.
Results: In 1996-2007, a 4.0% cumulative incidence of asthma 
was found during the 11 years’ follow up. After the time of the 
clinical examinations and the BHR testing, 10 incident cases of 
physician diagnosed asthma occurred. Eight subjects were women, 
and eight were ever smokers (range of pack years 7-43, mean 15).
The number of symptomatic individuals with severe or moderate 
BHR was 8 (3.4%), which yielded an 18.34 folded risk for incident 
asthma (CI95%3.64-92.43).
In a multivariate model, symptomatic BHR independently 
increased the risk for incidence of asthma (OR 6.16 for PD15FEV1 ≤ 
1.6 mg and OR 13.85 for PD15FEV1 ≤ 0.4 mg), as did family 
history of asthma (OR 15.99; OR 30.36), pack years ≥10 (OR 9.60; 
OR 16.07), use of allergy medication (OR 11.93; OR 17.49).
Conclusions: Symptomatic BHR independently increases the risk 
for incidence of asthma already during a 4-6 year’s follow up in 
the general adult population in Helsinki, Finland.
P15
Respiratory function and chemical exposures 
among female hairdressers in Palestine
Maysaa Nemer1, Petter Kristensen1, Khaldoun Nijem2, Mayes 
Kasem3, Liv IB Sikkeland4, Johny Kogerud4, Espen Bjertness1, Marit 
Skogstad3
1University of Oslo, OSLO, Norge
2Hebron University, HEBRON, -------
3National Institute of Occupational Health, OSLO, Norge
4Oslo University Hospital, OSLO, Norge
Aims: To characterize respiratory symptoms, lung function, asthma 
and knowledge of exposure to hazards among female Palestinian 
hairdressers. The study is a longitudinal study including a subset 
study of induced sputum among 30 hairdressers and 30 control 
subjects. A group of university students and staff serve as a control 
group.
Methods: The cross-sectional study included 170 female 
hairdressers in 56 salons, and 170 control subjects. A sub group of 
the participants was selected with a total of 60. This group 
performed several examinations related to respiratory function, 
symptoms and asthma, including eNO, induced sputum, lung 
function and blood examination. Exposure to ammonia was 
measured in the salons where the participating hairdressers were 
working. The entire group will be subjected to follow-up after 5 
years.
Results: Nineteen per cent of the hairdressers reported wheezing 
versus 11% in the control group. Adjusting for age and height, 
there was a forced expiratory volume in 1 second reduction of 
0.093 (95% confidence interval = 0.06-0.15) comparing 
hairdressers with controls. A small number of hairdressers used 
respiratory protective equipment, and satisfactory ventilation in 
salons were lacking (1).
Selected results from the subset study will be presented at the 
conference.
Conclusions: Female hairdressers had higher prevalence of 
reported asthma and respiratory symptoms than the controls. They 
had lower lung function measurements than the control group. 
Increasing the awareness of occupational health hazards and 
improving the work conditions for the hairdressers inPalestine is 
needed. 
1) Nemer M, Kristensen P, Nijem K, Bjertness E, Skogstad M. Respiratory 
function and chemical exposures among female hairdressers in Palestine. 
Occup Med (Lond) (2013) 63 (1): 73-76.
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P16
Managing Asthma in the Outpatient Clinic – 
Athletes with exercise-induced asthma
Asger Sverrild, C Porsbjerg, L Steensen, B Nybo, V Backer
University Hospital Bispebjerg, University of Copenhagen, 2400, 
Danmark
Background: In most cases of exercise-induced asthma in 
athletes an objective measurement of disease is often required as 
part of a Therapeutic use Exemption application. An objective 
diagnosis often demands multiple testing with bronchial 
provocations and lung function measurements. Currently no 
guidelines exist on a diagnostic strategy in this group of subjects.
Aim: To evaluate the use of diagnostic tests in newly referred 
athletes with possible exercise-induced asthma in a specialized 
outpatient clinic.
Methods: Medical records on all patients with a suspected 
diagnosis of asthma referred to the outpatient clinic at Bispebjerg 
Hospital, Copenhagen, Denmark in 2010 where reviewed, and 
data on reversibility to beta2-agonist and airway 
hyperresponsiveness (AHR) to inhaled mannitol, methacholine and 
eucapnic hyperventilation was collected. Subjects with exercise-
induced symptoms that reported to spend at least 10 hours a 
week on their sports were defined as athletes and were included 
in the analysis.
Results: Of 361 subjects referred with possible asthma to the 
outpatient clinic, 102 (22%) were categorized as athletes with 
possible exercise-induced asthma. Seventy-two subjects were 
diagnosed with asthma of whom 96% had at least one diagnostic 
test performed, and 78% ended up with an objectively confirmed 
diagnosis of asthma. A total of 57 subjects (79.2%) had more 
than one test as part of the diagnostic process.
Conclusion: Of athletes with exercise-induced asthma referred to 
an outpatient clinic, eight out of ten had their diagnosis objectively 
confirmed. In 79% of the subjects, two or more test for AHR or 
reversibility was necessary as part of the diagnostic process.
P17
Genetic factors account for most of the 
variation in serum tryptase in humans – a twin 
study
Asger Sverrild1, S Van der Sluis2, K.O. Kyvik3, L.H. Garvey4, C 
Porsbjerg1, V Backer1, S.F. Thomsen5
1University Hospital Bispebjerg, University of Copenhagen, 2400, 
Danmark
2Vrije Universiteit, Dep. of Functional Genomics & Dept of 
Clinical Genetics, AMSTERDAM, Netherlands
3University of Southern Denmark, Institute of Regional Health 
Services Research, ODENSE, Danmark
4Copenhagen University Hospital, Gentofte, Danish Anaesthesia 
Allergy Centre, COPENHAGEN, Danmark
5Copenhagen University Hospital, Gentofte, Dep. of Dermato-
Allergology, COPENHAGEN, Danmark
Background: Mast cells are involved in a variety of diseases 
including inflammatory diseases like asthma. Tryptase is a known 
marker of both mast cell burden and activity. However, little is 
known about the genetic influence on serum tryptase variation. 
Also, only few and conflicting data exist on serum tryptase in 
asthma. We aimed to estimate the overall contribution of genetic 
and environmental factors to the variation in serum tryptase, and 
to examine the correlation between serum tryptase and asthma, 
rhinitis, markers of allergy, airway inflammation and airway 
hyperresponsiveness (AHR) in a sample of Danish twins.
Methods: A total of 575 twins underwent lung function tests and 
had AHR to methacholine, exhaled nitric oxide, skin prick tests and 
serum tryptase performed. Multiple regression and a variance 
components model, using the statistical package SOLAR, was 
computed.
Results: Serum tryptase values were available in 569 subjects. The 
intra-class correlation in serum tryptase in monozygotic and 
dizygotic twin pairs was 0.84 and 0.42, p<0.001. Variance 
decomposition showed that genetic factors accounted for 82% 
(CI95%: 74-90; p<0.001) of the variation in serum tryptase. Body 
Mass Index and sex, but not asthma, rhinitis or AHR were 
correlated to serum tryptase.
Conclusions: As much as 82% of the variation in serum tryptase 
is due to genetic factors. Body mass index and sex, but not asthma 
or AHR to methacholine, correlate to serum tryptase. A genetic 
overlap may exist between serum tryptase and body mass index.
P18
Asthma severity and diagnostic assessment in 
older asthma in a 12-months cohort of patients 
referred for specialist asthma assessment.
Celeste Porsbjerg, Asger Sverrild, Vibeke Backer
Bispebjerg Hospital, COPENHAGEN, Danmark
Background: Patients with late onset asthma represent a greater 
challenge to the respiratory specialist. However, limited evidence is 
available on how patients with late onset asthma are generally 
diagnosed and managed in tertiary care.
Aim: To compare the level of diagnostic assessment in older versus 
younger adults with suspected asthma in a representative cohort 
of asthma patients.
Methods: A retrospective study of all patients referred for tertiary 
specialist assessment on suspicion of asthma over a 12-month. 
Data on symptoms, history of asthma, lung function, NO and 
allergic sensitisation were assessed.
Results: Over the 12 months period, 283 patients with either a 
suspicion of, or known asthma, were referred. The mean age was 
37.6 years (SD 16.7 years), of whom 157 (56%) were aged < 40 
years, and 126 (44%) > 40 years. 
Compared to young adults aged under 40, subjects aged > 40 
years reported more frequent exacerbations (25% vs 13%, p< 
0.003), more courses of prednisolone (11% vs 6 % , p=0.02), as 
well as courses of antibiotics (31% vs 24%, p = 0.007) over the 
past 12 months.
Furthermore, the level of lung function was significantly lower 
among subjects > 40years (FEV1 % of predicted : 81.3% 
(SD:22.4) vs 94.4% (SD:17.3%), although the level of eNO was 
similar ( 26 ppb vs 28 ppb).
In spite of the severity of asthma in the older group, the level 
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of diagnostic assessment was lower in older subjects: Symptom 
frequency was assessed in 16% vs 27%, (p= 0.02), reversibility 
testing was performed in 44% vs 58% (p=0.01), NO 
measurement in 49% vs 77% (p< 0.001) and bronchial 
provocation (mannitol and/or metacholine) in 36% vs 60% 
(p<0.001).
Conclusion: Among adults referred for specialist assessment on 
suspicion of asthma, the severity of asthma increased with age, 
but the level of diagnostic assessment decreased, indicating that 
lack of asthma control in older adults may partially relate to 
insufficient diagnostic assessment.
P19
The effect of smoking cessation on airway 
inflammation in young asthma patients
Christian Grabow Westergaard, Celeste Porsbjerg, Vibeke Backer
Bispebjerg Hospital, Respiratory Rersearch Unit, COPENHAGEN 
NV, Danmark
Objective: Asthma patients who smoke experience more 
pronounced symptoms as well as steroid treatment resistance. This 
may relate to smoking-induced changes in airway inflammation in 
terms of increased neutrophilia and reduced eosinophilia. Whether 
these inflammatory changes are reversible is unknown. In the 
present study, we hypothesized that in young asthma patients, 
airway neutrophilia would be reduced and eosinophilia would 
increase after five weeks of smoking cessation. Thus, the aim of 
the present study was to evaluate the short-term effect of smoking 
cessation on airway inflammation in young asthma patients.
Methods: 45 steroid-free asthmatic smokers (age 19-40) were 
examined with induced sputum and exhaled nitric oxide (eNO) one 
week before and five weeks after smoking cessation. Mean 
number of packyears was 15.6 (range 10-25).
Results: 25 patients quit smoking successfully. A difference in 
change in sputum neutrophil-% was observed between quitters 
and non-quitters (-7%versus+5%,respectively,p=0.063). The 
median D-eosinophil-% was similar between both groups at 0.0% 
and -0.5%, respectively (p=0.493). The median D-eNO were +4.0 
ppb and +2.0 ppb, respectively (p=0.263).
Conclusion: The data of the present study suggests that smoking-
induced neutrophilia in the asthmatic airways are of reversible 
character even over a short-term period of smoking cessation. This 
beneficial effect of smoking cessation may contribute to increasing 
the motivation of asthma patients to quit smoking.. However, 
future studies including higher sample sizes and a longer smoking 
cessation period are required.
P20
Comorbidity between chronic obstructive 
pulmonary disease and type 2 diabetes in adult 
twins
Howraman Meteran1, Vibeke Backer1, Kirsten Ohm Kyvik2, Axel 
Skytthe3, Simon Francis Thomsen1
1Respiratory Research Unit, Bispebjerg Hospital, COPENHAGEN 
NV, Danmark
2Institute of Regional Health Services Research & Odense Patient 
data Explorative, ODENSE, Danmark
3The Danish Twin Registry, ODENSE, Denmark
Aim: To examine the relationship between chronic bronchitis and 
chronic obstructive pulmonary disease (COPD), and type 2 
diabetes in adult twins.
Methods: Questionnaire data on chronic bronchitis and hospital 
data on diagnosed COPD on 13,649 twins, 50-71 years of age, 
from the Danish Twin Registry, were cross-linked with hospital 
discharge diagnosis data on type 2 diabetes from the Danish 
National Patient Registry.
Results: The risk of type 2 diabetes was higher in subjects with 
symptoms of chronic bronchitis compared with subjects without 
symptoms of chronic bronchitis (3.5 vs. 2.3%), OR=1.46 (1.03-
2.07), p=0.035; and in subjects with diagnosed COPD compared 
with subjects without diagnosed COPD (6.6 vs. 2.3%), OR=2.50 
(1.58-3.97), p=0.000. The results were significant after adjusting 
for age, sex, smoking and Body Mass Index (BMI). Correlations 
between genetic effects on chronic bronchitis and type 2 diabetes; 
and between genetic effects on diagnosed COPD and type 2 
diabetes, respectively, were 0.25 (0.00-0.59), p=0.130 and 0.35 
(0.00-0.72), p=0.134.
Conclusions: Patients with chronic bronchitis and COPD have an 
increased risk of type 2 diabetes independently of sex, age, 
smoking and BMI. Furthermore, comorbidity between these 
diseases seemed not to be explained by shared genetic factors. The 
increased risk of type 2 diabetes must be accommodated in the 
management of patients with chronic bronchitis and COPD.
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Respiratory movements among patients with 
severe COPD and emphysema in the supine 
and standing forward leaning position with 
support of the forarms
Asdis Kristjansdottir1, Magdalena Asgeirsdottir1, Hans Beck1, Petur 
Hannesson2, Maria Ragnarsdottir2
1Reykjalundur, MOSFELLSBAER, Iceland
2Landspitali National and University Hospital Reykjavik, 
REYKJAVIK, Iceland
Background: Forward leaning position is freequently used to 
reduce dyspnea but thoracic respiratory movements in this position 
are not known. 
Objective: To study respiratory movements in supine and 
standing leaning forward position with support of the forarms 
among patients with emphysema and severe COPD. Furthermore 
to study respiratory movements in the forward leaning position 
during dyspnea. 
Method: Nineteen patients with emphysema and severe COPD 
GOLD 3 and 4 underwent spirometric measurement and position 
of their diaphragm was assessed. Respiratory movements during 
quiet and deep breathing were measured in supine and standing 
forward leaning position using the RMMI (MTT, Keldnaholt, 112 
Reykjavik, ICELAND). Patients then bicycled with the work rate tar-
get set as fixed fractions of the peak work rate tolerated in a pre-
program incremental exercise test. When dismounting the bicycle, 
respiratory movements were measured in the forward leaning 
position. Patients rated their level of dyspnoea at rest and after 
bicycling. 
Results: Participants were 8 men and 11 women mean age 61±7 
years and mean BMI 23.59±4.63. Respiratory movements during 
quiet breathing in supine position were significantly (abdominal 
p=.025, lower- and upper thoracic p=.020) greater than in the 
forward leaning position. In forward leaning during dyspnea, 
lower- and upper thoracic movements were significantly (p=.001; 
p=.005, respectively) less than abdominal movements. Mean 
dyspnea on 0-10 scale was 0,95±1.13 at rest and 5.5± 0.96 at 
the end of bicycling. 
Conclusion: Respiratory movements in the forward leaning 
position are less than in supine. Indicating that patients with 
emphysema and severe COPD use this position to reduce 
respiratory effort. 
Pulmonary care
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Online Chronic Obstructive Pulmonary Disease 
Rehabilitation – a pilot study
Lisbeth Marie Oestergaard, Christina Nielsen, Nina Skavlan 
Godtfredsen
Bispebjerg University Hospital, COPENHAGEN, Denmark
Background: Widespread evidence exists in favor of exercise 
training for patients with severe or very severe chronic obstructive 
pulmonary disease (COPD). Some of these patients decline the 
offer to attend the hospitalized rehabilitation program due to 
fatigue, severe shortness of breath, transportation time and so 
forth. Due to developments in video conference technology it is 
possible for these patients to receive online rehabilitation in their 
home.
Objective: To improve COPD patients’ quality of life and increase 
their physical activity level.
Methods: 11 patients diagnosed with COPD - 7 of these with 
very severe COPD - participated in a pilot study in 2012. They 
received online rehabilitation using video conference technology 
allowing the patients to see and communicate with the instructor 
and with each other. 4 patients were online at the same time, 
twice a week for 1 hour, during a period of 7 weeks. They received 
exercise training and education. Patient evaluation included 
health-related quality of life (CAT, 15D), physical tests (timed-up-
and go 2,45m (2,45m) and sit-to-stand (STS)) performed in the 
patient’s home.
Results: All 11 patients completed the course. Overall attendance 
rate was 95 % and any absence was due to sickness or holiday. 7 
patients experienced improvement in quality of life (CAT), 9 
patients improved their time on the 2,45m test, 6 patients 
increased number of STS.
Conclusions: Online rehabilitation can be useful for patients, 
with severe or very severe COPD, who are unable to attend 
hospitalized rehabilitation. However, further research is needed to 
evaluate the clinical outcomes and cost-effectiveness of this 
program, which will be continuing with new patients in 2013.
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Effects of high-repetitive single limb exercises 
on isokinetic local muscle endurance capacity 
and maximal strength during shoulder flexion 
and knee extension in patients with COPD
Andre Nyberg, Britta Lindström, Karin Wadell
Umeå University, UMEÅ, Sweden
Forty-four patients with chronic obstructive pulmonary disease 
(COPD) [21 male; mean (SD) age; 68.7 (5.6) years, FEV% predict-
ed; 44.6 (9.7) BMI; 25.6 (4.4)] were recruited and randomized to 
either high-repetitive single limb exercises (HRSLE) in combination 
with patient education (PE) or PE alone. Blinded measurements of 
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muscle function were performed at baseline and after 8 weeks on 
a stationary dynamometer. Isokinetic peak torque (Nm) and the 
total work (joules) of 30 consecutive repetitions at an angular 
velocity of 60° per s was used for maximal strength and local mus-
cle endurance respectively. HRSLE is a strength training regimen 
performed with one leg /arm at a time alternating the left/right 
side using elastic bands and body weight as resistance.
The magnitude of change was greater in the HRSLE group on 
all isokinetic outcome measures. Local muscle endurance during 
shoulder flexion (mean difference 70 joules, 95% CI 29 to 112 
joules, p=.002) and during knee extension (mean difference 235 
joules, 95% CI 77 to 386 joules,p=.002). Maximal strength during 
shoulder flexion (mean difference 3,7Nm, 95% CI -0,4 to 7,8 Nm, 
p=.029) and during knee extension (mean difference 7,7Nm, 95% 
CI 0,3 to 15,1 Nm, p=.042) Log transformed p-values are 
presented for variables not normally distributed.
The present study shows that 8 weeks of HRSLE improves 
isokinetic maximal strength and local muscle endurance capacity 
in patients with moderate to severe COPD.
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Excellence of preventive chest care: an 
evidence-based ?Medicine challenge?
Ahmed Eltobgy, Abdullah Dr Al-Temani, Mohamed Abd Elhafiz 
Prof Abd Elhaleem
College of Medicine, Tabuk University, TABUK, Saudi Arabia
Background: Recently, there has been increased interest in the 
gap between research findings and their implementation in 
Preventive Chest Services (PCS). The simplest practical strategy to 
overcome this problem is to implement the Evidence-Based 
Medicine (EBM) principles. Therefore, Excellence Health Care (EHC) 
environment can be developed within a culture characterized by 
increased patient satisfaction through continuous quality 
improvements.
General Objective: The study aimed to introduce and clarify the 
concepts of EBM and HCE as related to PCS to decision makers, 
researchers, and services’ providers in order to improve the 
performance, efficiency, and quality of the current practice.
Material and Methods: The study has been developed through 
four consequential phases. The 1st phase involved a Systematic 
Literature Review (SLR) based on a well-structured process. The 2nd 
phase requisite a consultation process with preventive health 
experts (14) utilizing Delphi technique. The 3rd phase required a 
cross-sectional analytic research design and a representative 
sample of physicians (118) at the PHS delivery level. The last phase 
concerned with data management, interpretation and utilization of 
findings.
Results: The search and retrieval process yielded 184 related 
programs and models in which 21 programs and 7 models have 
met the inclusion criteria. The general characteristics of the studied 
sample of physicians have been described. Low degree of 
awareness of EBM and HCE has been detected and varied among 
the different levels of service delivery points. Important qualitative 
problems (24) and misconceptions (16) have been evaluated.
Conclusion: Addressing key policy concerns in the study arena 
could substantially enhance preventive chest care quality.
Pulmonary malignancies
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Quality from the patients perspective –  
a questionnaire study
Lisa Jelf Eneqvist1, Mirjam Forsgren1, Malin Lövgren2, Carol 
Tishelman3, Åsa Wetterdahl1, Karl Kölbeck1
1Karolinska university hospital Lung allergy clinic, STOCKHOLM, 
Sweden
2LIME,MMC, Karolinska intitute, STOCKHOLM, Sweden
3MMC, Karolinska institute, STOCKHOLM, Sweden
Every year approximately 600 patients are diagnosed with lung 
cancer at Karolinska university hospital; these patients are facing 
a tough period of investigation and treatment.
Over the years we have tried to measure what the patients 
think of the care they receive by handing out questionnaires, but 
the problem is that medical staff has interpreted the results 
according to there reality and context. In doing so we can´t be sure 
that improvements are carried out from the patients perspective. 
The purpose of this study was to study how patients, under 
evaluation for lung malignancy, experience the quality of care 
given to them.
The study is based on the form QPP (Quality from the patient’s 
perspective). The patients have been asked to describe how they 
have experienced their care situations and how important each 
situation has been. 252 surveys were handed out with a response 
rate of 65%.
The result demonstrated care areas where patients wanted 
improvements. This information facilitates the work of ongoing 
improvements carried out at Lung Allergyclinic. We are able to 
intensify our work in shortening the waiting time when it is 
experienced most stressful and also to find actions in order to 
relieve the stress during waiting time itself. A lot of care areas 
were experienced as well-functioning. This is important to keep in 
mind at times of changing routines or reorganization. The response 
rate was high given the severely ill patient group. However, we 
have to suppose that this study might describe the experiences of 
the less ill patients.
Result and the questionnaire will be shown at the congress.
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Incidental detection on CT is an independant 
prognostic factor of survival in patients 
operated for non-small cell lung carcinoma
Andri Wilberg Orrason, Steinn Jonsson, Martin Ingi Sigurdsson, 
Kristjan Baldvinsson, Hunbogi Thorsteinsson, Tomas Gudbjartsson
University of Iceland, REYKJAVIK, Iceland
Objective: Non-small cell lung carcinomas (NSCLCs) are 
sometimes detected incidentally due to imaging for unrelated 
disease. We studied the rate of incidental detection and its impact 
on long term survival in a nation-wide cohort of patients operated 
for NSCLC.
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Methods and materials: All patients that underwent pulmonary 
resection for NSCLC in Iceland 1991-2010. Incidentally and 
symptomatically detected patients were compared retrospectively 
in 5 year periods.
Results: Out of 512 patients, 174 (34%) were diagnosed 
incidentally. The incidentally detected tumors were smaller and 
diagnosed at earlier TNM-stages. 5-year disease specific survival 
(DSS) for patients with symptoms, incidentally detected on CXR, 
and CT, was 40%, 57% and 80% respectively. In multivariate 
analysis patients detected incidentally on CT had significantly 
improved DSS compared to those diagnosed on CXR or 
symptomatically (HR 0.38, 95% CI 0.16-0.88, p=0.02), after 
correcting for several differing factors including tumor stage.
Conclusions: One third of NSCLC patients are detected 
incidentally, and this ratio has not changed for two decades. Still, 
the proportion of CT-detected NSCLCs is increasing and these 
patients seem to have more favorable survival than patients 
detected incidentally on CXR or with symptoms.
 
P27
Medical thoracoscopy: outdated or still going 
strong?
uffe Bodtger, Asbjørn Høegholm, Fatin Willendrup
Naestved Hospital, NAESTVED, Danmark
Background: thoracoscopy is the golden standard in diagnosing 
recurrent pleural effusions. Medical thoracoscopy (MT) with patient 
in light sedation and with local analgesia is a safe and cost-
effective procedure. Two Nordic studies published since 1998. Only 
two departements in DK is active.
Method: retrospective analysis of MT performed in our 
department 01/01/2009 - 01/06/2012.
Results: we performed 19 MT (ECOG scores 0 or 1; female: n=4; 
median age 69 (range 46-84 years)) with no complications. Four 
patients proceeded to surgical VATS for diagnosis and three to 
surgical resection. Malignant mesothelioma was identified in five 
(25%) patients by MT; VATS identified additionally two (10%) and 
later surgery/VATS confirmed three cases. MT identified 4 patients 
with metastatic adenocarcinoma (lung: n=3, unknown: n=1), with 
VATS confirming the latter. Eight patients had reactive pleuritis 
(one confirmed by VATS) or other benign lesion. Three patients had 
an earlier malignant diagnosis, none had metastases herefrom. 
Five (26%) resp seven patients (36%) were dead 6 resp 12 
months after MT.
Conclusion: MT is a safe procedure, sparring surgical procedures, 
identifying 9/11 malignant cases (82%).
Sleep and non invasive ventilation
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Audit on use of noninvasive ventilation (NIV) 
for patients (pt.) with exacerbation in Chronic 
Obstructive Pulmonary Disease (COPD) at a 
University Hospital in Denmark
I. Titlestad, H. Fretheim, M. Pourbazargan
Odense University Hospital, ODENSE C, Danmark
Introduction: Pt. with clinical presentation of COPD in 
exacerbation and acute hypercapnic respiratory failure are 
routinely treated with NIV based on randomized trials showing 
benefit on less need of intubation and lower mortality. These trials 
included selected COPD pt. fulfilling predefined inclusion and 
exclusion criteria, and only limited data on unselected COPD pt. 
exist.
Method: Data from medical records and arterial gas analyses 
were retrieved from all pt. receiving NIV admitted acutely to an 
acute medical ward with transfer to a respiratory ward in the 
period 1st January to 31st December 2010. Demographic data 
collected included age, gender, diagnoses at discharge 
(comorbidities), and when present FEV1. Criteria for ordination of 
NIV was judged by arterial gas analysis (pH lower than 7.35 and 
pCO2 > 6 kPa) after initiated standard treatment and diagnosis of 
COPD. Primary measures were referral to ICu, 7- and 30-day 
mortality rate.
Results: In total 124 cases were studied (105 pt.: 91 pt. once and 
in 17 pt. > 1). COPD was present in 91 pt. but not in 14 pt. who 
all received NIV only once. In 98 COPD pt. cases (89%) pH was < 
7.35 (mean 7.244 SD 0.24) and pCO2 > 6.0 kPa (mean 10.85 and 
SD 3.70). When grouping the COPD pt. according to pH ≥ 7.25 
(60 pt.) or pH < 7.25 (40 pt.) at initiation, higher 7- and 30-day 
mortality rates were seen for the lower pH group (17 and 23.3% 
vs. 30 and 32.5%) and transfer to the ICu was more frequent 
(5.0% vs. 20%).
Conclusion: NIV use in unselected pt. with COPD in a medical 
setting was initiated in pts. in more critical conditions compared to 
the randomized trials. Mortality rates were not surprisingly higher 
at lower pH levels at initiation of NIV. If NIV is offered to all 
eligible patients is planned.
P29
Prevalence of sleep bruxism in the general 
population: measurements and symptoms
Sigrun Sigmundsdottir, Erna S Arnardottir, Thorarinn Gislason
Landspitali - The National University Hospital of Iceland, 
REYKJAVIK, Iceland
Objectives: Sleep bruxism (SB) is a stereotyped movement 
disorder characterized by grinding or clenching of teeth during 
sleep. This study aimed to estimate SB in the general population.
Methods: Data were obtained from 426 adults aged 41-66 years. 
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All subjects answered questionnaires and were invited for an 
ambulatory type 3 sleep study with audio and electromyography of 
masseter muscles (T3, Nox Medical, Reykjavik, Iceland). 
Identification of SB and sleep apnea was based manual scoring 
and AASM diagnostic criteria (2007). When audio revealed 
movement or orofacial activity such as coughing and swallowing, 
these events were not included as SB events. SB identification was 
based on bruxism episode index (BEI), per hour of sleep (phasic, 
tonic and mixed). Low frequency SB was characterized by BEI ≥2 
and high frequency SB by BEI ≥4.
Results: Preliminary results for the first 189 subjects show a 
16.4% prevalence of SB in the general population (3.7% with 
high frequency and 12.7% with low frequency). The 7 subjects 
with high frequency SB had on average ± SD 7.5 ± 2.1 BEI while 
the 24 subjects with low frequency had on average ± SD 2.8 ± 
0.6. Grinding or clenching teeth occurring at least weekly was 
reported by 10% of subjects. However only 2 out of 7 subjects 
with high frequency SB reported teeth grinding or clenching and 
none of those with low frequency SB. The majority of subjects 
reporting teeth grinding or clenching did not have measurable SB 
during the sleep study.
Conclusion: The low number of subjects with measurable SB, that 
reported teeth grinding or clenching, suggests that either the 
subjects are unaware of their condition or that the diagnosis 
criteria needs improvement. Also, more than one night of SB 
assessment may be needed as it may not occur every night.
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Daytime sleepiness, respiratory symptoms and 
quality of life. – An epidemiological study on 
general populations in Iceland and Sweden
Bryndís Benediktsdóttir1, Christer Janson2, Eva Lindberg2, Erna Sif 
Arnardóttir1, Thorarinn Gíslason1
1University of Iceland, REYKJAVÍK, Iceland
2Uppsala University, Respiratory Medicine and Allergology, 
UPPSALA, Sweden
Objective: This prevalence of excessive daytime sleepiness (EDS) 
and the association of EDS with respiratory symptoms and large 
variety of health variables was investigated in two well 
characterized random samples from the general population.
Methods: Adults aged >40 and living in Reykjavík, Iceland 
(n=939) and uppsala, Sweden (n=998), were invited (www.
boldstudy.org). Response rates 81, 1% and 62, 2%. In addition, 
the participants were asked to answer: The Epworth Sleepiness 
Scale (ESS), Short Form-12 and standardised questions about sleep 
and health, diabetes and hypertension. 
Results: In Reykjavik mean (+/- SD) ESS was 6.0 +/- 3.9, 
compared to 6.1+/- 3.9 in uppsala. The prevalence of EDS, defined 
as ESS scores >10, were 18.5% in uppsala and 18.4% in 
Reykjavík. EDS was more common among men than women and 
was more prevalent in age groups <60years (p<0.0001) but not 
related to body max index (BMI) or smoking status. Those 
reporting habitual snoring and apneas scored higher on ESS 
(p<0.0001) and so did also those with respiratory symptoms; 
wheeze and breathlessness (p<0.05), cough (p<0.0001), asthma 
(P<0.01) and nasal allergy (p<0.02), There were no difference in 
EDS depending on insomnia, diabetes or hypertension. Mental 
health scores on SF-12 were significantly lower among those with 
EDS (p<0.05). There was no difference regarding physical health 
scores.
Conclusion: Excessive daytime sleepiness is a common complaint 
in the general population both in Iceland and Sweden. It’s more 
common among men than women, among those who snore and 
have apneas. EDS is also related to respiratory symptoms, allergy 
and decreased mental quality of live.
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The Icelandic Sleep Apnea Cohort (ISAC)-
Prevalence of Restless Legs Syndrome among 
patients with Obstructive Sleep Apnea before 
and after CPAP treatment, compared to the 
general population
Bryndís Benediktsdóttir1, Christer Janson2, Allan Pack3, Sigurður 
Júlíusson4, Erna Sif Arnardóttir1, Thorarinn Gíslason1
1University of Iceland, REYKJAVÍK, Iceland
2Uppsala University, Respiratory Medicine and Allergology, 
UPPSALA, Sweden
3Center for Sleep and Circadian Neurobiology, University of 
Pennsylvania,, PHILADELPHIA, United States of America
4Landspítalinn University Hospital, REYKJAVÍK, Iceland
Objectives: To compare the prevalence of reported restless legs 
syndrome (RLS) between subjects with obstructive sleep apnea 
(OSA) and the general population. Also possible changes with 
CPAP treatment.
Materials and Methods: The OSA subjects (n=822) were newly 
diagnosed with moderate or severe OSA (665 males,157 females). 
The control subjects (n=742) were randomly chosen Icelanders 
(394 males, 348 females) who participated in another 
epidemiological study (www.boldcopd.org). Measurements 
included a standardized RLS rating scale, questions about sleep 
and the Epworth Sleepiness scale. The change with CPAP 
treatment was assessed after 2 years (n=538).
Results: Among OSA males 23.3% reported RLS but 12.9% of 
control males (p<0.001). 35.8% of OSA females reported RLS but 
24.4% of control females (p=0.03). Both among OSA patients and 
controls those with RLS more commonly reported insomnia, 
daytime sleepiness, nocturnal sweating, snoring and gastro 
esophageal reflux (p<0.05). No relationship was found between 
RLS and age, BMI, hypertension or respiratory disease in a logistic 
regression adjusting for the presence of OSA and the other factors 
mentioned. No relationship was found between RLS and sleep 
apnea severity. Subjects using CPAP had a decreased prevalence of 
RLS from 25.7% to 13.8% while no change was observed in those 
subjects not using CPAP (p=0.04 for difference between groups).
Conclusions: RLS is more prevalent among OSA patients than 
controls. CPAP treatment decreases RLS symptoms significantly.
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Interstitial and occupational lung 
disease
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Vitamin D Supplement – Is It Safe To Use In 
Well-Treated Sarcoidosis Patients
Andrea Browatzki, Ida Steffensen
Hilleroed Hospital, HILLERØD, Danmark
Rationale: Hypercalcemia occurs in about 2-10 % of patients 
with sarcoidosis. A VitD hypersensitivity syndrome can occur if 
extrarenal tissues produce 1,25(OH)2D in an unregulated manner 
causing hypercalcaemia. Recently the withholding of VitD in VitD 
deficient potentially hypercalcaemic patients has been questioned. 
The aim of this study was to investigate if VitD and calcium 
treatment had influence on the calcium levels measured in blood, 
urine or bones and if there was an effect on the inflammatory 
activity in well-treated patients suffering from sarcoidosis.
Method: Retrospective, descriptive study performed on 99 
consecutive, randomized sarcoidosis patients.
Patients underwent pulmonary function tests, X-ray and/or 
high-resolution CT (HRCT) of the lungs, dual energy X-ray 
absorptiometry, (DXA) and Ca2+ levels (urine, ionized, serum),
angiotensin-converting enzyme (ACE), creatinine and 25(OH)D 
(VitD).
All patients who underwent treatment with 
immunosuppressive agents received Prednisolone and/ or 
Azathioprine or Methotrexate according to international 
guidelines.
About half of the patients with sarcoidosis in full remission 
received VitD supplement (10 to 38 μg daily) until desired level of 
80mmol/l.
Results: VitD treatment was given to 41 (41,4 %) patients. Before 
any treatment 11 patients (11,1) % had hypercalcemia, 9 (9,1%) 
had hypercalcinuri and DXA scanning was performed in 36 
patients (36,3%); 10 (10,1%) had osteoporosis.
During VitD-treatment none of the sarcoidosis patients showed 
progression of the disease in either chest-X-ray, DLCO, reduction in 
FVC, elevation of Ca2+ (serum, ionized, urine), creatinine or ACE.
Conclusion: Supplement of VitD among well-treated sarcoidosis 
patients induced no progression of the disease.
P33
Comorbidity and survival in Danish patients 
with idiopathic pulmonary fibrosis
Charlotte Hyldgaard, Ole Hilberg, Elisabeth Bendstrup
Aarhus University Hospital, AARHUS C, Danmark
Introduction: Idiopathic pulmonary fibrosis (IPF) is the most 
common of the idiopathic interstitial pneumonias. It is a serious 
and progressive lung disease with a median survival of 3 years. In 
most cases, the disease is not diagnosed until pulmonary function 
is severely impaired.
Objectives: The aim of this study is to characterize comorbidity 
and co-medication in a cohort of Danish IPF patients, and to 
assess the impact of comorbidity on survival.MethodsThe study 
population consists of 121 patients diagnosed with IPF at Aarhus 
university Hospital between April 2003 and April 2009. Patients 
were followed until November 2009. Details on referral, diagnostic 
examinations, pulmonary function tests, concomitant diseases and 
medication have been recorded in the West Danish ILD Registry.
Results: Arterial hypertension (15%), ischaemic heart disease 
(13%), diabetes mellitus (11%) and depression (8%) were the 
most common comorbidities among IPF patients at the time of 
referral. During follow up, additional ten patients were diagnosed 
with diabetes and ten patients with osteoporosis. Twenty-two 
patients (18%) received antidepressant treatment during the 
follow up.
Cardio-vascular disease, defined as coronary heart disease, 
cerebrovascular disease or peripheral arterial disease had been 
diagnosed in 21% (26/121) of the patients prior to the IPF 
diagnosis. No survival difference was found between patients who 
had this comorbidity and those who did not (p=0.17) (crude) and 
p=0.073 (adjusted for gender and age).
Conclusion: Comorbid conditions occur frequently in IPF. In this 
cohort, the presence of a serious comorbidity like cardio-vascular 
disease did not impact on survival, underlining the severity of the 
pulmonary disease itself.
Survival in IPF patients with and without cardiovascular disease.  
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IL-17 and Antigen-Specific IL-17-Responses in 
Distinct Subsets of Patients with Pulmonary 
Sarcoidosis
Mahyar Ostadkarampour1, Anders Eklund1, David Moller2, Pernilla 
Glader3, Anders Lindén4, Johan Grunewald1, Jan Wahlström1
1Karolinska Institutet, STOCKHOLM, Sweden
2Department of Medicine, Johns Hopkins University School of 
Medicine, BALTIMORE, MD, USA
3Department of Internal Medicine & Clinical Nutrition, 
Sahlgrenska Academy, GOTHENBURG, Sweden
4Institute of Environmental Medicine, Karolinska Institutet, 
STOCKHOLM, Sweden
Sarcoidosis is an inflammatory disorder characterized by 
granulomas most commonly affecting the lungs. Sarcoidosis 
patients with Löfgren´s syndrome have a good prognosis, 
particularly if they are HLA-DR3+. The presence of mycobacterial 
antigens, and recently a specific protein, M. tuberculosis catalase-
peroxidase (mKatG), in sarcoidosis tissue has been reported. Th1 
cell responses against mKatG have previously been observed in 
sarcoidosis. In the present study our aim was to investigate the 
presence of interleukin (IL)-17 (synonymous to IL-17A) and IL-17-
producing cells responding to mKatG in sarcoidosis.
Peripheral blood and bronchoalveolar lavage (BAL) cells were 
obtained from sarcoidosis patients. The production of IL-17 and 
IFNγ was evaluated by ELISPOT after stimulation of BAL and blood 
cells with mKatG. The concentration of IL-17 in the BAL fluid of 
sarcoidosis patients and healthy controls was measured by 
quantitative immuno-PCR (qIPCR).
The HLA-DR3+ sarcoidosis patients with Löfgren´s syndrome 
had a significantly higher concentration of IL-17 in BAL fluid 
compared to healthy controls (p<0.05). Patients with Löfgren´s 
syndrome also had a significantly higher frequency of IL-17-
producing cells in BAL fluid samples responding to mKatG, 
compared to patients without Löfgren´s syndrome (p<0.05). No 
such difference between patient groups was observed with regard 
to IFN-γ and not with regard to either cytokine in peripheral blood.
In conclusion, sarcoidosis patients with Löfgren´s syndrome 
had higher levels of IL-17 and more IL-17-producing cells 
responding to mKatG locally at the site of inflammation. This is 
compatible with IL-17-producing cells playing a role in antigen 
elimination and the spontaneous recovery typical of patients with 
Löfgren´s syndrome.
P35
The Finnish IPF-registry
Eva Sutinen1, Jaana Kaunisto2, Eija-Riitta Salomaa2, ulla Hodgson3, 
Seppo Saarelainen4, Hannu Kankaanranta5, Minna Purokivi6, Riitta 
Kaarteenaho6, Marjukka Myllärniemi7
1Lung factor, HELSINKI, Finland
2Turku University Hospital, TURKU, Finland
3Helsinki University Central Hospital, HELSINKI, Finland
4Tampere University Hospital, TAMPERE, Finland
5University of Tampere, TAMPERE, Finland
6Kuopio University Hospital, KUOPIO, Finland
7University of Helsinki, HELSINKI, Finland
Background: Idiopathic pulmonary fibrosis (IPF) is the most 
common idiopathic lung parenchymal disorder, with median 
survival of 3-5 years. The exact incidence and prevalence in Finland 
is unknown, although according to a previous study, the estimated 
prevalence of IPF in Finland is 1000 patients. This study was 
designed to gather epidemiological data on IPF in Finland. <i/> 
Study aims: The aims of the study are 1) to gather clinical 
epidemiologic data on Finnish IPF and to unify criteria for 
diagnostics, treatment and referral to transplantation.
2) to collect biological material for research (genetics, biomarkers 
etc) and to obtain a database for patient recruitment for clinical 
trials.
Materials and methods: A search for Diagnosis numbers J84.1, 
J84.9 from all university Hospitals was made, and yielded 100-200 
patients/hospital. The members of the Finnish IPF-consortium 
re-evaluated all patients. Informed consent to participate to the 
study was asked from all patients that met the criteria for IPF. 
Ethical board statement and permission to perform registry 
research has been obtained from all university hospitals and a 
permission to use hospital databases from all 21 hospital districts 
has been received from the National institute of health and 
welfare. 
Results: Altogether 200 patients have been enrolled and 125 
entered to the database. Initial data; male/female 0,6, mean age 
68,5 years, 25% have been diagnosed using biopsy. Analysis on 
medication used is ongoing
Discussion: A national quality registry, and comparison of 
epidemiological data across different geographical locations, may 
lead to a better understanding of IPF etiology. A national quality 
registry hopefully leads to the centralized and uniform diagnostic 
and treatment protocol across the nation. 
po
st
er
s
NLC 2013 55
P36
Gremlin overexpression in the mouse lung  
– a model for idiopathic pulmonary fibrosis
Katri Koli1, Eva Sutinen1, Pia Rantakari2, Petra Sipilä2, Marjukka 
Myllärniemi1
1university of Helsinki, HELSINKI, Finland
2University of Turku, TURKU, Finland
Introduction: Bone morphogenetic protein gremlin is 
overexpressed in the human idiopathic pulmonary fibrosis (IPF) 
lung. Previous studies have shown, that gremlin overexpression is 
related to fibrosis progression and epithelial-mesenchymal 
transition.
Methods: To induce tissue-specific, conditional expression of 
gremlin in the lung, we generated a mouse strain (SPC-lox-
gremlin) where a loxP-NEO-Stop-loxP-gremlin cassette was cloned 
under the SPC-promoter. These mice were crossbread with the 
R26CreERT strain. Gremlin expression was analyzed using 
immunofluorescence. A subset of mice were exposed to silicon 
dioxide for two months to induce pulmonary fibrosis. At 6 months 
mice were analyzed for alterations in gene expression patterns, 
fibrosis or inflammation scores.
Results: High levels of gremlin protein was detected from 1/3 
SPC-lox-gremlin strains crossed with the R26CreERT strain 
(tamoxifen inducible Cre). Gremlin expression was observed 
throughout the lung parenchyma, in cells that had alveolar type II 
appearance. Surprisingly, we found that gremlin expression was 
not inducible, but was observed constantly in all double-positive 
animals, which were healthy and fertile. At 6 months double-
positive animals showed a very subtle phenotype including larger 
alveolar airspaces and thickening of the pleura. Exposure to silicon 
dioxide induced more severe alveolar injury; however, fibrosis and 
inflammation scores were not different from wild type mice.
Conclusions: Our results show, that lung-specific overexpression 
of gremlin in mice does not yield in acute respiratory problems, but 
may affect the pulmonary microenvironment over time. Further 
studies will elucidate the effect of local gremlin overexpression to 
pulmonary homeostasis and response to environmental stimuli.
P37
Pulmonary disease caused by non-tuberculosis 
mycobacterium (NTM)
Viacheslav Zhuravlev, Tatiyana Otten, Raisa Shegoleva, Ludmila 
Archakova, Nataliya Solovieva, Pavel Gavrilov, Marina Shulgina
Research Institute of Phthisiopulmonology, ST.PETERSBURG, 
Russian Federation
Objective: The frequency of NTM identified as a course of human 
disease increase in Russia as new sophisticated laboratory 
methods are introduced into the clinical practices.
Methods: use of BACTEC MGIT 960 and molecular-genetic 
techniques in the bacteriological laboratory. 245 NTM cultures 
from 181 TB suspects patients were isolated using solid media 
and/or BACTEC MGIT960 (2011-12 years). Primary identification 
of isolated cultures as TB/NTM was done by colony morphology, 
time growth, acid fastness and bacterial cells’ morphology. 
Additionally all cultures were tested by real-time PCR of IS6110. 
Thus identified NTM strains were identified using GenoType CM/
AS (HAIN Lifescience).
Results: Following NTM strains were detected: M.avium (146 
strains 59.6%), M.intracellulare (29 strains 11.8%), M.fortuitum 
(25 strains 10.2%), M.abscessus (13 strains 5.3%), M.peregrinum 
(9 strain 3.6%), M.chelonae (7 strains 2.8%), M.gordonae (4 
strains 1.6%), M.lentiflavum (4 strains 1.6%), M.xenopi (3 strains 
1.2%), M.kansasii (3 strains 1.2%) and M.malmoense (2 - 0.8%). 
The clinical symptoms of NTM pulmonary disease were variable 
and nonspecific. The clinical presentation frequently included fever, 
cough, weight loss, night sweats, hemoptysis, and dyspnea have 
been revealed only at 46(25.4%) patients. 12 patients(6.6%) had 
HIV co infection. Pulmonary infiltrates were the most common 
(57.4%). The location was unilateral in 53.5% and affection in 
upper lobes was observed in 79.5% cases.
Conclusions: The most common NTM specie in the North-West 
region of Russia is M.avium. Pulmonary disease by NTM has 
clinical and radiological symptoms similar to TB. use of accurate 
and rapid molecular-genetic method - GenoTypeCM/AS helps to 
identify of NTM and to ensure adequate diagnosis and treatment.
P38
Activated CD8+ T and NKT cells in BAL fluid 
improves diagnostic accuracy in sarcoidosis
Anders Tøndell, Anne Rø, Arne Åsberg, Magne Børset, Torolf 
Moen, Malcolm Sue-Chu
St.Olavs Hospital, TRONDHEIM, Norge
Background: The clinical diagnosis of pulmonary sarcoidosis is 
based on the presence of noncaseating granulomas in an 
appropriate clinical setting with either bilateral hilar adenopathy 
and/or parenchymal infiltrates. Lymphocytosis with an increased 
CD4/CD8 T cell ratio in bronchoalveolar lavage fluid (BALF) is 
supportive. We investigated the diagnostic accuracy of a predictive 
logistic regression model in sarcoidosis, including BALF cell profile 
and the assessment of HLA-DR+ CD8+ T cells and Natural Killer T 
(NKT) cells.
Methods: Among 180 patients undergoing diagnostic 
bronchoscopy with bronchoalveolar lavage (BAL) and assessment 
of BALF lymphocyte phenotype by flow cytometry, a diagnosis of 
sarcoidosis was made in 48 patients. A binary logistic regression 
model with age, sex, BALF lymphocyte fraction, eosinophils and 
CD4/CD8 ratio (basic model) was compared to a final model also 
including fractions of HLA-DR+ CD8+ T cells and NKT cells. 
Diagnostic accuracy of the two models was assessed by analysis of 
Receiver Operating Characteristic (ROC) curves.
Results: The area under the ROC curve was 0.888 (95% CI: 
0.838-0.938) and 0.934 (95% CI 0.895-0.973) for the basic and 
final model, respectively.
Conclusion: Assessment of HLA-DR+ CD8+ T cell and NKT cell 
fractions improves diagnostic accuracy and further strengthens the 
importance of BAL in the diagnostic work-up of sarcoidosis.
56 NLC 2013
po
sters
P39
Respiratory health in cleaners: Results from the 
Respiratory Health in Northern Europe study
Øistein Svanes1, Trude Duelien Skorge2, Bertil Forsberg3, Thorarinn 
Gislason4, Mathias Holm5, Christer Janson6, Ane Johannessen2, Rain 
Jögi7, Stein Håkon Lygre2, Ferenc Macsali2, Dan Norbäck6, Ernst 
Omenaas2, Francisco Gomez Real1, Vivi Schlünssen8, Torben Ingvart 
Sigsgaard8, Kjell Toren9, Gunilla Wieslander6, Tor Aasen2, Cecilie 
Svanes1
1University of Bergen/Haukeland University Hospital, BERGEN, 
Norway
2Haukeland University Hospital, BERGEN, Norway
3Umeaa University, UMEAA, Sweden
4Landspitali University Hospital, REYKJAVIK, Iceland
5Sahlgrenska University Hospital, GOTHENBURG, Sweden
6Uppsala University, UPPSALA, Sweden
7Tartu University Hospital, TARTU, Estonia
8Aarshus University, AARHUS, Denmark
9University of Gothenburg, GOTHENBURG, Sweden
Introduction: There are few studies on asthma in cleaners from 
Northern Europe, and very limited knowledge of COPD-risk in 
cleaners.
Aims and Objectives: To assess airway symptoms and 
obstructive lung disease in relation to years having worked as a 
cleaner in Northern Europe.
Methods: Respiratory Health In Northern Europe (RHINE) is a 
postal questionnaire follow-up study of the ECRHS I stage I cohort 
established in 1990-94. At the follow-up RHINE III (in 2010-12), 
13405 subjects responded to the questions “have you ever 
worked as a cleaner”(“Yes”n=2114) and numbers of years in such 
work. Associations with self-reported asthma, respiratory 
symptoms and doctor´s diagnosed COPD were analysed with 
multiple logistic regression, adjusting for sex, smoking, age, 
education and centre.
Results: Ever having worked as a cleaner was significantly 
associated with respiratory symptoms, asthma and COPD. This was 
only found for those who had worked with cleaning more than 
one year, while there was no clear difference between having 
worked with cleaning >1 to 4 years vs ≥4 years with cleaning.
*Yes to 3 or more of questions 1-6 in the RHINE III questionnaire.
Conclusion: Working as a cleaner for more than one year was 
associated with an increased occurrence of respiratory symptoms 
and obstructive lung disease. 
P40
Idiopathic Interstitial Pneumonias. A 
nationwide epidemiological study in Iceland
Sigurdur James Thorleifsson1, Gunnar Gudmundsson1, Jonas Geir 
Einarsson2, Helgi Johannes Isaksson3
1Department of Respiratory Medicine, Landspitali University 
Hospital, REYKJAVIK, Iceland
2Department of Pulmonary Medicine, University Hospital in Lund, 
LUND, Sweden
3Department of Pathology, Landspitali University Hospital, 
REYKJAVIK, Iceland
Background: Idiopathic interstitital pneumonias are a group of 
diseases characterized by fibrosis in the lung interstitium and they 
can lead to respiratory failure. There is limited information 
available on epidemiology in the Nordic countries.
Methods: We studied subgroups of idiopathic interstitial fibrosis 
in Iceland during the period from 2002-2012. Cases were found 
by searching the Department of Pathology database. Included 
were those that had surgical biopsy for diagnosis. The following 
diseases were studied: usual interstitial pneumonia (uIP), non 
specific pulmonary fibrosis (NSIP), respiratory bronchiolitis-
associated interstitial lung disease (RBILD) and desquamative 
interstitial pneumonia (DIP) . We studied epidemiology including 
incidence.
Results: During this period there were a total of 40 confirmed 
cases: uIP 15 cases, 11 (73%) males and four (27%) females with 
median age at diagnosis 65.7 years (range 44-67 yrs), incidence 
0.4/ 100.000 per year. NSIP 21 cases, 11 (52%) males and 10 
(48%) women with median age at diagnosis 57.1 years (range 
36-76 yrs), incidence 0.6/100.000 per year. RBILD two cases, 2 
(100%) females with incidence 0.06/100.000 per year. DIP: two 
cases, one (50%) male and one (50%) female with incidence 
0.06/100.000 per year. Mortality was high in assocation with uIP 
but not NSIP.
Conclusion: Idiopathic interstitial pneumonias confirmed by 
surgical biopsy were rare in Iceland and idiopathic pulmonary 
fibrosis was the most common form.
po
st
er
s
NLC 2013 57
Other
P41
Limited evidence for early mobilisation of 
patients hospitalised with community-acquired 
pneumonia. A systematic review
Dorte Melgaard1, Morten Tange-Kristensen2
1North Denmark Hospital, HJØRRING, Denmark
2Copenhagen University Hospital Hvidovre, HVIDOVRE, Denmark
Method: The Embase, PubMed, CINAHL, Cochrane Database of 
Systematic Reviews and PEDro were searched up to June 2012. 
Two independent reviewers identified 355 studies, but only two 
studies (1,2) already included in a 2010 systematic review (3) 
fulfilled inclusion criteria.
Results: An open label study (1) that compared three 
interventions in 145 patients, showed that a patient group 
undergoing intensive bottle blowing treatment (that probably also 
to some extent were mobilised - not described), were hospitalised 
fewer days, mean of 3.9 versus 5.3 in a group of patients early 
mobilised but not bottle-blowing (P = 0.01). No significant 
difference was seen in relation to the third group who were 
instructed to sit up and take 20 deep breaths 10 times a day. The 
other, a group randomisation (different wards) study (2) that 
compared usual care (n=231) with early mobilisation (n=227), 
defined as at least 20 minutes sitting out of bed or ambulating 
within 24 hours of hospitalisation, showed reduced length of stay 
in the intervention group (5.8 versus 6.9 days).
Conclusion: There is limited evidence for the positive effect of 
early mobilisation to length of stay for patients hospitalised with 
community-acquired pneumonia. Further studies evaluating the 
effect of early mobilisation are needed for this patient group. 
References
(1)  Bjorkqvist M, Wiberg B, Bodin L, Barany M, Holmberg H. Bottle-blowing in 
hospital-treated patients with community-acquired pneumonia. Scand J 
Infect Dis 1997;29:77-82.
(2)  Mundy Linda M. Early mobilization of patients hospitalized with community-
acquired pneumonia. Chest 2003;124:883-9.
(3) Loeb M. Community-acquired pneumonia. review. Clin Evid (Online) 2010. 
P42
Cause-specific mortality of TB-patients from 
Estonia: do they die from TB?
Piret Viiklepp, Kaja Rahu, Mati Rahu
National Institute for Health Development, TALLINN, Estonia
Objective: To assess the risk of death in the cohort of patients 
diagnosed with respiratory tuberculosis (TB).
Methods: Data on TB-patients diagnosed alive with respiratory TB 
at working age 25-64 years in 1997-2009, were obtained from 
the Estonian TB registry. The cohort of 3496 males and 1266 
females was traced for mortality through population and cause of 
death registries from the date of diagnosis up to the end of 2011. 
The risk of death in the cohort compared to the general population 
of Estonia was measured by the standardized mortality ratio (SMR) 
with 95% confidence interval (CI).
Results: During the period 1997-2011, 1360 deaths were 
observed vs. 306.32 expected (SMR=4.44; 95% CI 4.20-4.68) 
among males, and 269 deaths vs. 37.38 expected (SMR=7.20; 
95% CI 6.34-8.06) among females. One fourth of deaths occurred 
due to TB. Statistically significant excess mortality was found for 
cancer, diseases of the circulatory, respiratory or digestive system. 
Elevated risk was found for external causes of death, especially for 
exposure to excessive cold (SMR=8.41; 95% CI 6.24-11.08 in 
males, and SMR=15.13; 95% CI 6.08-31.16 in females). High risk 
was observed for selected alcohol-related causes (SMR=4.90; 
95% CI 4.04-5.77 in males and SMR=11.15; 95% CI 7.68-15.66 
in females).
Conclusions: Our study demonstrated extremely high mortality 
risk in the cohort of TB-patients compared to the general 
population, which was caused not only by TB but was clearly 
related to alcohol abuse in the cohort.
P43
Trends in tuberculosis incidence among 
healthcare workers in Estonia, 1999–2012
Kai Kliiman1, Piret Viiklepp2, Manfred Danilovitš1, Kaja Hurt1, 
Anastasia Pärnsalu3
1Tartu University Hospital, TARTU, Estonia
2National Institute for Health Development, TALLINN, Estonia
3The North Estonia Medical Centre, TALLINN, Estonia
Objective: In 1998, the tuberculosis (TB) incidence in Estonia was 
47.5 new cases per 100.000 population and the same year 
National Tuberculosis Program (NTP) was established. The main 
aim of NTP was the reorganization of the TB treatment strategy 
including implementation of infection control measures, regular 
trainings for healthcare workers (HCWs) and renovation of all TB 
wards. We compared the incidence of TB among HCWs during the 
periods 1999-2002 and 2009-2012 to evaluate the influence of 
NTP activities to the HCWs TB incidence.
Methods: Cross-sectional descriptive analysis of TB Registry 
surveillance data.
Results: In period 1999-2002 were diagnosed 46 new cases of 
TB among HCWs and 37 of them (80.4%) had pulmonary TB. The 
average age of the cases was 41.0 years (range 22-66) and 
89.1% of patients were female (n=41). At the time of diagnosis 
17 (37.0%) HCWs were asymptomatic, 8 (17.4%) were smear 
positive and 8 (17.4%) had multidrug-resistant (MDR) TB.
In period 2009-2012 were identified 9 new TB cases among HCWs 
and 88.9% (n=8) of them had pulmonary TB. The average age of 
the HCWs was 41.2 years (range 25-60) and 66.7% of cases were 
female (n=6). At the time of diagnosis 33.3% (n=3) HCWs were 
asymptomatic and 3 (33.3%) were smear positive. Of all HCWs 
22.2% had MDR-TB (n=2).
The incidence rate of HCWs in 1999-2002 was 234.3 cases 
per 100.000 employees and for period 2009-2011 45.4, 
respectively. In general population the incidence rates in the same 
periods were 42.4 and 21.0 cases per 100.000 population, 
respectively.
Conclusion: Since 1999, TB incidence among HCWs decreased 
5.2 times, but it is still 2.2 times higher than the rate for the 
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general population. It is urgent to strengthen the implementation 
of infection control measures to reduce this occupational hazard.
P44
Non-invasiv ventilation support during 
endurance training in COPD
Brit Hov1, Kari Kvisselien2, Trude Støver3, Tiina Andersen4
1Oslo University Hospital, OSLO, Norway
2Innlandet Hospital Trust, LILLEHAMMER, Norway
3Akershus University Hospital, LØRENSKOG, Norway
4Haukeland University Hospital, BERGEN, Norway
Objective: Physical activity is an important part of rehabilitation 
for people with COPD. Exercise intensity is essential to obtain the 
desired physiological changes. Dyspnoea may make it difficult to 
acheive the reqiured intensity. If non-invasive ventilation support 
(NIV) can relieve and assist overloaded respiratory muscles, this 
may help people with COPD to improve exercise tolerance.
Methods: We conducted a literature study with systematic search 
based on methodology from evidence based practice to determine 
if NIV can improve training tolerance during endurance training in 
COPD.
Results: A total of 26 articles were included. 12 physiological 
(one work out), 9 clinical (training intervention > 6 weeks) and 5 
reviews. Physiological studies suggest that using NIV during 
endurance training relieves stress on some components of the 
respiratory muscle pump and reduces respiratory work load. 
Increased exercise intensity and duration, work load, walking 
distance, O2-uptake and levels of dyspnoea was measured during 
training. All the clinival studies showed a positive effect of NIV, 
with the exception of one. Increased work capacity or activity 
tolerance was shown by increased VO2max or tolerated intensity, 
time, work load or walking distance, along with a reduction in 
measured blood lactate, higher anaerobic threshold and an 
improvement in speed:lactate-ratio was shown in some studies. 
The effect appears to be greatest in the patients with severe 
COPD. The most used NIV was Bi-level PAP.
Conclusions: People with COPD may benefit from NIV during 
endurance training. unanswered questions remains regarding the 
selection of patients, the best settings and mode of ventilatory 
support.
P45
Exploration and development of practice with 
non-invasive ventilation (NIV) to patients with 
chronic obstructive pulmonary disease (COPD) 
based on the patients perspectives on the 
treatment
Helle Marie Christensen1, Lotte Huniche2, Ingrid Titlestad3
1Institute of Clinical Research, University of Southern Denmark, 
ODENSE C, Danmark
2University of Southern Denmark, Institute of Public Health, 
ODENSE, Danmark
3Department of Respiratory Medicine J , Odense University 
Hospital, ODENSE, Denmark
Background: Communication during treatment with NIV is 
difficult because of the mask itself, the noise from the machine 
and patients distress. Assessment of life expectancy and end stage 
COPD is difficult and often discussed in the clinical setting, 
especially with regards to continuation of respiratory assistance / 
NIV as life-sustaining treatment.
There is little knowledge of how the patients experience NIV. 
Health professionals express a need for developing new clinical 
strategies which draws on patients perspectives.
Method: This study is based on critical psycological practice 
research where a co-researchers’ group was set up to describe and 
analyze practice of NIV treatment in collaboration with the 
researcher. Health professionals contributed with experience-based 
issues, and the researcher contributed with issues based on a 
combination of fieldwork and semi-structured interviews with 16 
patients and 4 relatives.
Results: Patient interviews revealed that 15 patients expected 
and wanted to be treated with NIV even though 10 of the 
interviewed described fear during treatment and 14 experienced 
more or less discomfort.
Conclusion: The practice research approach facilitated ongoing 
development of clinical practice related to NIV treatment. In partic-
ular, the investigation of patient perspectives generated results 
that were highly productive in qualifying the multidisciplinary 
cooperation and in developing and implementing new manage-
ment strategies.
The research project runs from 2011 to 2014 where further 
results will be available.
P46
Survival among defaulters and treatment 
failures from treatment of pulmonary 
tuberculosis in Estonia
Lea Pehme1, Manfred Danilovits1, Piret Viiklepp2, Alan Altraja3
1Tartu University Hospital, TARTU, Estonia
2Estonian Tuberculosis Registry, National Institute for Health 
Development, TALLINN, Estonia
3Department of Pulmonary Medicine, University of Tartu, TARTU, 
Estonia
Defaulters and failures from treatment of pulmonary tuberculosis 
(PTB) have unfavorable treatment outcome and impart significant 
transmission risk due to infectiousness. This risk is particularly 
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dangerous when coinciding with difficult-to-treat PTB/HIV 
co-infection.
Objective and Methods: We estimated survival of all PTB  
patients after treatment default or failure registered by Estonian 
Tuberculosis Registry during 2004-2006 (n=160). The patients 
were followed until 12.12.2011 and Kaplan-Mayer analysis was 
used for survival analysis.
Results: Median follow-up time was 5.94 (IQR 3.21-6.68) years. 
Fifty defaulters (31.3%) and 17 patients with treatment failure 
(60.7%) died during the observation period. Twenty-four deaths 
(48.0%) occurred among defaulters and 11 deaths (64.7%) 
among failures due to TB and 26 (52.0%) and 6 (35.3%) due to 
other reasons, respectively (p=0.23).
Among the 50 patients (31.3%), who died, median survival 
time was 1.86 (IQR 0.88-3.04) years. Median survival after the TB 
diagnosis was 2,086 (range 370.0-2,920.4) days among 
defaulters and 1,440 (235.0-3,153) days among failures (p=0.26). 
However, median survival after default (2168.5, range 269.7-
2824.1 days) was significantly longer than after failure (933.0, 
range 59.7-2,863.8 days) (p=0.016). Distinctly, median duration 
of treatment was significantly shorter (111.0, range 1.1-415.8 
days) among defaulters than among failures (360.5, range 26.3-
903.7 days) (p<0.001). None of the subjects, who returned to 
treatment, died during the observation period.
Conclusions: Despite the more durable treatment among failures, 
the survival was shorter after failure than after default suggesting 
a better prognosis after default. Return to treatment should also 
be strongly encouraged.
P47
Miliary tuberculosis with pericardial effusion in 
a patient treated with a TNF-alpha inhibitor
Kirsten Braendholt Rasmussen, Casper Lund-Andersen, Mette 
Charlotte Grove
Roskilde University Hospital, ROSKILDE, Denmark
TNF-alpha inhibitors are used in the treatment of rheumatic 
diseases. TNF-alpha plays a role in the function of macrophages 
which is crucial to the ability to control TB infection. Guidelines 
recommend screening for TB before starting treatment with TNF-
alpha inhibitors.
Objectives: A 45-years old man was admitted to hospital due to 
two months of exhaustion and two weeks with cough and fever. 
He suffered from Bechterew´s disease which for two years had 
been treated with Adalimumab (Abbott,uSA). Before starting this 
TB was ruled out by X-ray and Quantiferon-test.
Methods: CRP, ECG and vital parameters were monitored and 
x-ray was done. Sputum was examined including microscopy, 
culture and PCR for mycobacteria. The x-ray showed extensive 
interstitial infiltrates and cardiomegaly why echocardiography was 
done. TB was suspected and treatment initiated.
Results: Initially oxygen saturation was 94%, respiratory 
frequency 30. The stethoscopy was normal, CRP 65mg/l. ECG 
showed atrial fibrillation, echocardiography a pericardial effusion 
of 3cm. Pericardiocentesis was done. The TB diagnosis was 
confirmed by a positive smear and PCR of the sputum. The patient 
recovered on antituberculous and Prednisolone treatment. Contact 
investigations localized the infection to a pub visited weekly by our 
patient. Three other visitors were diagnosed with TB and the same 
strain was found.
Conclusion: The increasing prescription of TNF-alpha inhibitors 
imply increase in the risk of TB, most commonly due to reactivation 
of latent disease. A case describing a person recently infected with 
TB while treated with Adalimumab is presented. It should be noted 
that patients treated with TNF-alpha inhibitors presenting new 
general or pulmonary symptoms might have TB, even if earlier 
screening was negative.
P48
How can we assess driving abilities among 
patients with COPD and respiratory failure?
Laila Vatn
Sykehuset Innlandet HF, FOLLEBU, Norge
Introduction: Litterature and studies have shown that respiratory 
failure can effect physical and cognitive function. This is seldom 
assessed when it comes to patients with COPD and the effect on 
driving abilities.
Aim: I will give an introduction to how to assess driving abilities 
among patients with COPD and respiratoy failure. To drive is an 
important activity to most people and many patients depend on 
driving to be able to function in every day life.
Methods: I will present some of the methods I use, as well as a 
description of potential actions. In addition I will use patient 
examples to illustrate how important mapping of function is in 
assessing drinving abilities.
Results: A multidisciplinary approach to assessing the ability of 
driving is important as COPD with respiratoy failure affects quality 
of life and daily activities. We have the knowledge and methods to 
assess daily activities and can contribute to a hollistic assessment 
for these patients.
P49
Analysis of P2Y12 purinergic receptor 
expression on human bronchial epithelial cells
Siiri Altraja, Alan Altraja
University of Tartu, TARTU, Estonia
We have recently confirmed the presence of the P2Y12 purinergic 
receptor on human bronchial epithelial cells (HBEC). We have also 
shown an up-regulation of cysteinyl leukotrienes’ (CysLT’s) 
receptors by CysLT themselves. Apart from interactions between 
CysLT receptors, alternative pathways of CysLT’s action provoke 
interest, e.g. an action of leukotriene E4 (LTE4) on P2Y12. However, 
this possibility has not confirmed on HBEC, neither there are data 
on the effect of CysLT on the expression of the P2Y12 receptor.
To evaluate the effect of CysLT on the expression P2Y12 mRNA, 
cultured HBEC were exposed to 0-250 nM LTE4 for 1-24 h. The 
potential LTE4-mediated actions were blocked with montelukast as 
a CysLT1-specific antagonist and BAY u9773 as a dual antagonist, 
both at 10-6 M. Changes in the expression of P2Y12 mRNA were 
analyzed with RT-qPCR.
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LTE4 significantly increased the expression of P2Y12 mRNA in 
the HBEC already at 50 nM concentration with the significant 
increase occurring at 12 h onward (1.5-fold, p<0.05). In parallel, 
the mRNA expression of the CysLT1 and CysLT2 receptors was also 
up-regulated (1.8- and 1.5-fold with 50 nM LTE4, respectively, 
p<0.05). Both montelukast and BAY u9773 significantly blocked 
the effect of LTE4 on the P2Y12 expression with restituting its 
expression to the baseline level.
The results show the ability of up-regulation of the P2Y12 
receptor by LTE4, and suggest that this up-regulation may be either 
mediated by the ordinary CysLT receptors or can be at least 
inhibited by the CysLT antagonists.
Supported by the Estonian Science Foundation grants No. 
9103 and 9043.
P50
Extremely drug-resistant tuberculosis (XXDR-
TB) in Estonia: survival and risk factors for 
mortality
Manfred Danilovits1, Piret Viiklepp2, Lea Pehme1, Alan Altraja3
1Tartu University Hospital, Lung Clinic, TARTU, Estonia
2Estonian Tuberculosis Registry, National Institute for Health 
Development, TALLINN, Estonia
3Department of Pulmonary Medicine, University of Tartu, 
TARTU, Estonia
Background: The emergence of extremely drug-resistant 
tuberculosis (XXDR-TB) worldwide has led to a fear of 
untreatability. The terms XXDR-TB and “totally drug-resistant 
tuberculosis (TB)”are not officially defined, but designate in 
practice isolates resistant to all first-line and most second-line 
drugs, including all injectables, all fluoroquinolones and 
ethionamide/prothionamide.
Aims: We observed all patients with pulmonary XXDR-TB 
registered in the Estonian Tuberculosis Registry until 25.01.2013 
and used Kaplan-Meyer method for survival analysis and 
multivariate Cox regression analysis to identify the risk factors for 
mortality.
Results: Of the 20 patients, 15 (75%) were male. Median age 
was 42.0 years (IQR 35.0-55.0). Fifteen patients (75%) were 
previously treated for TB. The patients had resistance to on average 
10.5 drugs.
The follow-up lasted up to 155 months. In most cases, XXDR-
TB developed during prolonged treatment and was related to 
serious adherence problems, particularly alcohol abuse. Six 
patients cured, 11 died and 3 patients were on treatment at 
database closure. The median survival time was 29.44 months 
(IQR 118.54-10.91).
One-year, 5-year and 10-year survivals were 75%, 47% and 
25%, respectively. Living alone was protective against mortality 
but disability status contributed to mortality (p=0.010 and 
p=0.002, respectively). After adjustment for age, only disability 
status before TB diagnosis significantly contributed to mortality 
[hazard ratio (HR) 9.88, 95% confidence interval (CI) 1.90-51.52, 
p=0.007).
Conclusions: Despite the extremely restricted management 
options, satisfactory treatment outcomes are possible in XXDR-TB. 
However, a prolonged risk of transmission of XXDR-TB infection 
exists in the society due to patients’ protracted infectiousness.
P51
A Patient with Angelman Syndrome and 
disseminated infection with M. bovis caprae
Jan Heyckendorf, Christoph Prof. Dr. med. Lange
Research Center Borstel, BORSTEL, Germany
The 22 year-old patient with Angelman Syndrome was presented 
for evaluation of a chronic pericardial effusion (8 years) and new 
epileptic seizures. Due to a post-traumatic paraplegia the patient is 
immobilized permanently. Moreover, there was a positive 
tuberculin skin test with subsequent prophylactic therapy with 
isoniazid for 9 months. The first occurrence of a grand mal seizure 
was reported. A thorax computer tomography (CT) showed 
extensive bilateral infiltrates compatible to pulmonary tuberculosis 
and a pericardial effusion. A left frontal tuberculoma with 
surrounding edema was depicted in a cranial CT. The 
echocardiography presented a pericardial effusion with a swinging 
heart impression with no obvious hemodynamic effect. The culture 
of a broncho-alveolar lavage showed the presence of M. bovis 
caprae with susceptibility against all first-line drugs. Because of 
the inability of indicating loss of vision, therapy with ethambutol 
was not initiated. Instead the regime with isoniazid, rifampin and 
pyrazinamide was extended by adding moxifloxacin. 
Dexamethasone was added to the regime as detumescent agent. 
Because of mental retardation with compliance issues, a port-
system was installed for intravenous anti-tuberculosis drug 
application. Autoimmune-antibodies were negative. After 10 
weeks of treatment, regressive pulmonary infiltrations could be 
registered in CT-imaging. Gastric aspirate specimen were now 
microscopically negative for acid fast bacilli. The reduction of 
dexamethasone lead to recurrent seizures. The initiation of anti-
epileptic treatment was no option (interaction of cytochrome P450 
enzymes). The pericardial effusion was not sufficiently regressive in 
controls by regular echocardiography and drained successfully.
P52
Key elements factors of implementing 
advanced nursing care services for individuals 
with chronic illnesses – Systematic literature 
review
Rut Gunnarsdóttir
Heilbrigdisstofnun Suðurlands, REYKJAVÍK, Iceland
The aim of this thesis is the process of implementation of an 
innovation within the healthcare services. The number of 
individuals who suffer from chronic illnesses is growing fast, and 
advanced nursing care is at utmost importance. The purpose of this 
thesis is to put forth evidence-based checklists for implementation 
of advanced nursing care for individuals with chronic illnesses. 
Light is shed on issues that characterize advanced nursing care for 
patients with chronic illnesses and what needs to be considered 
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when implementing such care. This project is based on 
Donabedian´s ideology on quality of service in the healthcare 
system, which focuses on quality, safety and practicality. Thirty-one 
studies met the inclusion criteria and were used in the review. 
Theories and models for the introduction of innovation, point to a 
process that may be set forth in variable steps. What they have in 
common is a focus on goalsetting, to enable participants, to 
prepare the innovation properly, to show persistence and evaluate 
performance. Most of the services were provided in hospitals or in 
clinics. For successful implementation and operation of specialized 
nursing it is important to base it on knowledge and evidence-
based practice.
It is important to prepare well for the innovation of advanced 
nursing care for the chronically ill. For the innovation of advanced 
nursing care, it is recommended to use evidence based data for 
directions or checklists.
P53
Rehabilitation in healthcare: a concept analysis
Jonina Sigurgeirsdottir
Reykjalundur rehabilitation, MOSFELLSBAER, Iceland
Background: Rehabilitation is a complex concept and in some 
areas its boundaries are unclear. The concept has been used in 
healthcare for almost a century and its meaning has evolved over 
that time.
Aims: To clarify the concept of rehabilitation in healthcare and 
examine the connection between the concepts of ‘rehabilitation’ 
and ‘disability.’
Design: A concept analysis as developed by Walker and Avant.
Method: A literature search in PubMed, CINAHL and Scopus 
yielded a number of peer-reviewed articles that were arranged 
using the Matrix method.
Discussion: Impairment, disability and handicap are captured by 
the World Health Organisation (WHO) as central topics stating that 
‘Rehabilitation provides disabled people with the tools they need 
to attain independence and self-determination’. Critics maintain 
that the word ‘disabilities’ gives this definition a negative focus, 
undermining patients’ abilities. As it is difficult to maintain that a 
person who needs the resource of rehabilitation is not disabled it 
is promising that the ICF definition gives ‘disability’ proper 
consideration, by making it clear that in the context of ‘function’ 
and ‘participation’ a health decrement can occur to anyone, and 
hence that anyone can experience ‘disability’ for a time.
Results: The concept of ‘rehabilitation’ has developed from a 
strong physical orientation into a holistic focus involving patient’s 
being (needs), body functions, structure, activity, participation, and 
contextual factors.
Conclusion: The ICF model provides a comprehensive definition 
of the concept of rehabilitation and successfully connects the 
concept of ‘disability’ with the concept of ‘rehabilitation’.
P54
Exercise induced dyspnea among 12–13 year 
old children
Henrik Johansson
Uppsala University, UPPSALA, Sverige
Introduction: Many children are limited in their physical activity 
because of exercise induced dyspnea (EID).
Aim: The aim was to investigate the prevalence of EID, asthma 
and physical activity level among a population of 12-13 year old 
children in uppsala, Sweden.
Method: A questionnaire was sent to 3815 parents asking them 
to answer the questionnaire together with their child.
Results: The response rate was 61 % (n=2312). EID during the 
last 12 months was reported by 14.3 % (n=330) (girls 16.9 vs. 
boys 11.8 %, p<0.001). Physician-diagnosed asthma was reported 
by 14.6%. Of the participants reporting EID 61% (n=202) did not 
report having a physician-diagnosed asthma. The participants with 
EID, but without physician-diagnosed asthma reported significantly 
more problems such as rhinitis, current wheeze, daytime dyspnea, 
disturbed sleep absence from school, and use of asthma 
medication compared to the group without EID. Children with EID 
and asthma used bronchodilators and inhaled corticosteroids to a 
larger extent than children with EID but no diagnosis of asthma 
(27.3 vs. 11.3%) and (31.2 vs. 4.4%) respectively (p<0,001). Only 
12.4 % of the total population (n=2312) reached the international 
physical activity recommendations (≥1 hour/day 7 days/week on a 
moderate to vigorous level). The proportion of children that was 
physically active ≥ 1 hour/day 7 days/week was 13% among 
children with EID and 12.3% in children without EID (p=0.72). 
Conclusion: Self reported exercise induced dyspnea is common in 
children and the majority of those children do not have an asthma 
diagnosis or asthma treatment. Only a minority of Swedish 
children have a self reported physical activity level that is in line 
with international recommendations.
P55
Long term changes in lung function parameters 
in relation to exercise capacity in healthy 
middle-age men
Amir Farkhooy1, Johan Bodegård2, Hans Hedenström3, Christer 
Janson3, Sverre Kjeldsen2, Knut Liestøl4, Per Torger Skretteberg2, 
Knut Stavem5, Andrei Malinovschi3
1Uppsala University, UPPSALA, Sweden
2Dept. of Cardiology, Oslo University Hospital, Ullevaal, OSLO, 
Norge
3Dept. Medical Sciences, Uppsala University, UPPSALA, Sverige
4Dept. of Informatics, University of Oslo, OSLO, Norge
5Dept. of Medicine, Akerhus University Hospital, OSLO, Norge
Background: Exercise capacity decline occurs in adulthood 
simultaneously with age-related deterioration in cardiac-, lung- 
and peripheral muscle function. Two of the most used lung 
function parameters, forced expiratory volume in 1s (FEV1) and 
forced vital capacity (FVC), also decreases across the adult age-
span.
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Aim: To investigate the relationship between these standard lung 
function parameters and exercise capacity (EC) in healthy subjects.
Methods: From 1972 to 1975, 2014 apparently healthy men 
aged 50 years (range 38 - 62 yrs) were included in a prospective 
study. The subjects performed spirometry (FEV1, FVC) and 
symptom-limited exercise ECG test on an ergometer bicycle (ramp 
protocol 100W/50W increase every 6 min). Spirometry and 
exercise test was performed 7 years later (1979 to 1982) in 1425 
subjects. EC was calculated as the sum of all the work during each 
of the workload levels.
Results: Significant correlations between EC and FEV1 (R2=0.17, 
p<0.001) and FVC (R2=0.13, p<0.001) were found in univariate 
analyses. However, the additive explanatory value of lung function 
parameters for EC was limited in a multiple linear regression 
model including age, height, weight, exercise habits and smoking 
status (R2=0.37 vs. R2=0.32 for a model without FEV1 and FVC). A 
significant decline between baseline and follow-up was found for 
EC (-32.2%±0.6%, p<0.001), as well as for FEV1 (-4.8%±0.5%, 
p<0.001) and FVC (-9.1%±0.3%, p<0.001). Longitudinal 
changes in FEV1 and FVC did not relate to changes in EC (p=0.97 
and p=0.50).
Conclusion: In healthy adult males, lung function parameters had 
a limited explanatory value for exercise capacity at baseline. 
Temporal decline in exercise capacity at seven years follow-up was 
not related to the decline in lung function capacity.
P56
Long term effects of environmental tobacco 
smoke in the European Community Respiratory 
Health Survey II
Inga Sif Ólafsdóttir, Christer Janson
Respiratory Medicine & Allergology, UPPSALA, Sverige
Objective: Passive smoking is associated with harmful effects on 
respiratory health. Most studies on this topic are cross-sectional 
and longitudinal studies are warranted in order to provide more 
evidence of a causal association. The aim of this study is to 
evaluate the association between respiratory health and passive 
smoking exposure.
Methods: The analysis includes data from 29 centres in the 
European Community Respiratory Health Survey I and II (ECRHS). 
The target population includes 15,468 subjects with smoking data 
in stage 2 of ECRHS I, of these 9053 (58.6%) supplied data on 
smoking in the ECRHS II. The follow up time was 8.8+1.2 years 
(mean+SD). The present analyses included 5429 subjects who 
were non-smokers in both surveys.
Results: The 5429 (55% women) subjects had a mean age (±SD) 
of 34.3(±7.2) years in ECRHS I and 43.3(±7.2) years in ECRHS II. 
The passive smoking exposure was 6.8% only in ECRHS II; 23.4% 
only in ECRHS I and 17.1% in both surveys.
Subjects exposed to passive smoking had increased risk (OR 
(95% CI)) of onset of wheeze with breathlessness (1.90 (1.17-
3.09)), nocturnal chest tightness (1.49 (1.07-2.06)), attacks of 
breathlessness following activity (1.74 (1.33-2.28)) and long-term 
cough (2.34 (1.70-3.22)). No significant association was found 
between passive smoking and change in bronchial responsiveness 
or lung function.
Conclusions: Passive smoking is related to an increased risk of 
developing asthma related symptoms and cough during a long-
term follow-up.
P57
Hypoxia activates inflammasome leading to 
activation of IL-18 in the lungs
Fadila Telarevic Cero1, Karl Otto Larsen2, Geir Christensen3, Ole 
Henning Skjønsberg2
1Department of Pulmonary Medicine,Oslo University Hospital 
Ullevål, OSLO, Norge
2Department of Pulmonary Medicine, Oslo University Hospital 
Ullevål, OSLO, Norge
3Institute for Experimental Medical Research, Oslo University 
Hospital Ullevål, OSLO, Norge
Introduction: Inflammasomes are molecular platforms which are 
part of the innate immunity and activate IL-18 and IL-1β thorugh 
caspase-1. They can be activated upon cellular infection and stress. 
(K. Schroder & J.Tschopp, Cell, 2010). Several sterile inflammatory 
responses are mediated by the inflammasome. (u. Ikeda et al. 
Circulation, 2011). Increased levels of interleukin (IL)-18 have 
been found during experimental alveolar hypoxia (K.O. Larsen et 
al. Cardiovasc Res, 2008 ), but it is not known whether hypoxia 
activates inflammasome leading to increased IL-18 levels. We 
wished to investigate if hypoxia activates the inflammasome, 
leading to activation of caspase-1, IL-18 and IL-1β.
Objective: To study activation of caspase-1, IL-18 and IL-1β 
during hypoxia exposure in mice.
Methods: Measuring active caspase-1, IL-18 and IL-1β by 
Western blot analysis in the lungs of C57Bl/6j mice exposed to 
hypoxic conditions at 1, 3, 7 days and 4 weeks.
Results: Active caspase-1 and IL-18 were significantly increased 
at day 3, 7 and 4 weeks. IL-1β showed upregulation, but it did not 
reach statistical significance.
Conclusions: Active Caspase-1 was induced during hypoxia 
indicating activation of the inflammasome. Both IL-18 and IL-1β 
were upregulated, but IL-1β did not reach significance. IL-18 is 
previously been implicated in lung inflammation and cell death 
(F.T.Cero et al. Exp.Lung.Res. 2012). Activation of the 
inflammasome may play a role in the cytokine mediated 
progression of lung disease under hypoxic condition.
Acknowledgements: We are grateful to Almira Hasic and 
Ingeborg Goverud for technical assistance.
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P58
Resection rate and operability of elderly 
patients with non-small cell lung cancer in 
Iceland
Kristjan Baldvinsson, Andri Wilberg Orrason, Hunbogi 
Thorsteinsson, Martin Ingi Sigurdsson, Steinn Jonsson, Tomas 
Gudbjartsson
University of Iceland, REYKJAVIK, Iceland
Objective: An increasing number of elderly patients with non-
small cell lung carcinoma (NSCLC) are evaluated for surgical 
resection. We compared resection rate (RR), operability and 
survival in this group (≥75 years) to younger patients using 
databases in Iceland.
Methods: Information on all patients diagnosed with NSCLC in 
Iceland from 1991 to 2010 was retrieved from medical records 
and the Icelandic Cancer Registry. Tumors were staged clinically 
(TNMc) and the reasons for exclusion from resection were 
registered for patients diagnosed with cTNM stages IA - IIIA.
Results: Of 2263 confirmed cases of NSCLC, 735 (32.5%) 
patients were classified as elderly. Surgical RR for the elderly group 
was 14.7% compared to 26.3% for younger patients (p<0.001). 
The rate of major complications was 12% in the elderly group, not 
different than for younger patients (15%, p=0.45). The same was 
true for 30 day mortality (0.9 vs 0.7%). Five year overall survival 
(39% vs 42%, p=0.28), and cancer specific survival (55% vs. 
47%, p=0.64), were similar. Preliminary results showed that 
56.7% of the elderly patients with localized/regional disease were 
excluded from surgery. The most common reasons were pulmonary 
function (37.4%), multiple co-morbidities (21.6%), central tumor 
location (16.5%), poor ECOG performance status (12.1%), heart 
disease and dementia. Elderly patients with incidentally detected 
tumors were more often operated on than those presenting with 
symptoms (38% vs. 22%, p=0.02).
Conclusion:s Elderly patients with potentially resectable NSCLC 
are frequently excluded from surgery due to co-morbid conditions. 
The favourable 30 day and long term survival for this age group 
compared to younger patients may reflect a selection bias.
P59
Incidence of tuberculosis in children from the 
family contact
Anna Starshinova, Irina Dovgaliuk, Natalia Korneva, Viacheslav 
Zhuravlov
St.Petersburg Institute of Phthisiopulmonology, St. Petersburg, 
Russian Federati, ST.-PETRSBURG, Russian Federation
Children from the family contact of tuberculosis are the most 
threatened group to develop tuberculosis disease. 
Objectives: detection of tuberculosis in the children with the 
family contact
Materials and Methods: at children department of 
phthisiopulmonology we examined 160 patients aged from 1 to 
14 years old who have a family TB contact, in the years 2009-
2011. Diagnostic complex included: QuantiFERON-TB Gold (QFT-
Gs), multislice computer tomography (MCT). Bronchoalveolar 
lavage was simultaneously examined by RT-PCR (IS6110 DNA 
fragment based) and culturing on Lowenstein-Jensen medium and 
BACTEC MGIT960. TB diagnosed basing on clinical, positive QFT-
Gs and Rx symptoms.
Results: after examination only 40 children (25.0%) have not 
tuberculosis disease (I group), 120 patients (85.0%)- II group, 
have tuberculosis: in 76.7% (92) of intrathoracic lymphatic nodes 
and in 23.3%(28) generalized forms. Among them 10.8% cases 
(13) gave positive result in RT-PCR In the second group children 
have significantly higher (64.3% av. 30.0%, χ2=7.01, p<0.01) 
contact with a sick relative with tuberculosis disease with positive 
microbiological tests. 21 children out of the group had contact 
with intentioned father, 35 with mothers. The most hard forms of 
disease were noticed at the contact with intentioned mothers.
Conclusions: children from the family contact of tuberculosis 
form the high-risk group.
P60
Immunological parameters in patterns with 
tuberculosis
Anna Starshinova, Irina Dovgaliuk, Olga Yakunova
St.Petersburg Institute of Phthisiopulmonology, St. Petersburg, 
Russian Federati, ST.-PETRSBURG, Russian Federation
Objectives: identify changes in immune parameters in patterns in 
children with tuberculosis disease.
Materials and Methods: we examined 135 patients aged from 
3 to 14 years with suspicion of tuberculosis according to the X-ray 
results. They were examined during the years 2010-2012 in the 
children’s department of the Saint-Petersburg Institute for 
Phthisiopulmonology . The phthisiopulmonologic examination 
included: QuantiFERON-TB Gold (QFT-G), tuberculin skin test (TT) 
and computer tomography examination (CT). After phthisiopulm-
onology examination we divided patients in two groups. TB diag-
nosis was decide basing on clinical and Rx symptoms. The first 
group (I) (n=66; 48.8%) had no tuberculosis disease (control 
group). II group (n=69; 51.2 %) - with intrathoracic lymph nodes 
TB. Examination included: assessment of leucocytes’ subsets 
(CD3+, CD4+, CD8+, CD4 +/CD3+, CD8+, CD16+, CD20+, CD25+, 
CD95+, HLAII), cytokines (TNF-α, IL-2, IL-4, INF-γ) by complex of 
immunological tests ELISA (IgA, IgG, IgM).
Results: levels of CD3+ (1.74±0.08, p=0.03), CD25+ (0.57±0.03, 
p=0,04), HLAII (0.82±0.05, p=0.04) and the level of INF-γ 
(17421.22±2202.06 (I) vs. 21035.44±1432.53 (II) p=0.05) were 
significantly higher in II group compared to the control group (I). 
Specific antibodies titer was significantly higher in group II by the 
levels of the IgG antibodies (7.7% (I) vs. 22.9% (II), (p=0.05)), and 
IgM (25.6%(I) vs. 45.8 (II), p=0.05).
Conclusions: Assays of the CD3+, CD25+, HLAII, the level of INF-γ 
and specific antibodies (IgG, IgM) are the most informative tests 
for TB disease diagnosis in children.
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Palliative care for patients with COPD
Guðrún Jónsdóttir
Landspítali, REYKJAVÍK, Iceland
The aim of the study is to describe and explore how general 
clinical guidelines for palliative care recently introduced in 
Landspitali university Hospital can be utilized for the purpose of 
improving healthcare for patients with chronic obstructive 
pulmonary disease (COPD) in a pulmonary unit. The goal is that 
health care professionals taking care of people with COPD and 
their families apply the principles of palliative care to improve 
quality of life. Theoretical background of the implementation is the 
contingency model by Roland van Linge. In this model effective 
implementation consists of congruency between the intervention 
and the environment or existing practice. In this qualitative 
research two interviews were carried out with nurses (N=8) on a 
pulmonary unit at Landspitali university Hospital, as key 
informants, where barriers and successful solutions for the 
implementation of palliative care were identified. The themes that 
were analyzed from the interviews were confusion of concepts as 
regards palliative care and terminal care, that nurses were in 
disagreement with other health care professionals, e.g. physicians, 
about how to apply prinicples of palliative care in the unit as well 
as uncertainty of the course of the disease as hindering decision 
making for palliative care. Successful implementation was 
considered likely when health care workers work together as a 
team.
It is concluded that there is still considerable work to be done 
for clinical guidelines for palliative care to be successfully 
implemented in health care at the pulmonary unit. There is need 
for specialized palliative care for patients with COPD due to the 
complexity of the disease and the characteristics of course of the 
disease. Implementation of clinical guidelines in palliative care for 
patients with COPD needs to be based on specialized knowledge 
of the lung disease; it needs time and budget as well as 
amendments to the special needs of this patient group.
Referencer: 1. Yohannes, A.M. et al, Ten years of tiotropium: clinical impact and patient perspectives, International Journal of COPD 2013;8:117-125. 2. Sundhedsstyrelsens godkendte produktresumé af 19. juni 2012 for Spiriva® inhalati-
onspulver i kapsler: ”Farmakologiske egenskaber: I et 4-årigt studie sås en forbedring af lungefunktionen (FEV1). Forbedringen forblev konstant i alle 4 år. I behandlingsperioden sås en reduktion på 16% i risikoen for død.” 3. Casaburi R 
et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002;19:217-224. 4. O’Donnell DE et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in 
COPD. Eur Respir J 2004;23:832-840. 5. Tashkin DP et al; for the UPLIFT® Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008;359:1543-54. 6. Vogelmeier C et al; for the POET-COPD 
Investigators. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 2011;364:1093-1103. 7. Troosters T et al; for the UPLIFT® Study Investigators. Tiotropium as a first maintenance drug in COPD: secondary 
analysis of the UPLIFT® trial. Eur Respir J 2010;36:65-73. 8. Tonnel AB et al; for the TIPHON study group. Effect of tiotropium on health-related quality of life as a primary efficacy endpoint in COPD. Int J Chron Obstruct Pulmon Dis 2008;3:301-
310. 9. Casaburi R et al. Improvement in Exercise Tolerance With the Combination of Tiotropium and Pulmonary Rehabilitation in Patients With COPD. Chest 2005;127:809-817. 10. Maltais F et al. Improvements in Symptom-Limited Exercise 
Performance Over 8 h With Once-Daily Tiotropium in Patients With COPD. Chest 2005;128:1168-1178.
Spiriva® (tiotropium). Forkortet produktresumé. Indikationer: Tiotropium er en symptomlindrende bronkodilatator til vedligeholdelsesbehandling af kronisk obstruktiv lungesygdom (KOL). Kontraindikationer: Overfølsomhed overfor tio-
tropium, atropin eller dets derivater samt indholdsstoffet lactosemonohydrat (indeholder mælkeprotein). Bivirkninger*: Almindelige (1-10%): Mundtørhed er set hos ca. 4% af patienterne. Ikke almindelige (0,1-1%): Svimmelhed, hoved-
pine, smagsforstyrrelser, sløret syn, atrieflimren,  faryngitis, dysfoni, hoste, gastroesophageal reflux, constipation, oropharyngeal candidiasis, udslæt, dysuri, urinretention. Sjældne (mindre end 0,1%) bivirkninger samt bivirkninger med 
ukendt hyppighed, herunder angioødem, takykardi og paralytisk ileus, er anført i det fulde produktresumé. Særlige advarsler og forsigtighedsregler vedrørende brugen*: Bør ikke anvendes som initialbehandling ved akutte episoder af 
bronkospasmer, dvs. som akut behandling. I overensstemmelse med tiotropiums antikolinerge virkning skal tiotropium anvendes med forsigtighed til patienter med snævervinklet glaukom, prostatahyperplasi eller blærehalsobstruktion. 
Inhalerede lægemidler kan forårsage inhalationsinduceret bronkospasme. Hos patienter med moderat til svær nedsat nyrefunktion (kreatinin-clearance ≤ 50 ml/min) bør tiotropium kun anvendes, hvis fordelene opvejer den potentielle 
risiko. Tiotropium må ikke anvendes oftere end én gang dagligt. Interaktioner*: Der er ikke set bivirkninger ved anvendelse sammen med andre lægemidler inkl. sympatomimetiske bronkodilatatorer, methylxantiner, orale og inhalerede 
steroider. Samtidig indgift af andre antikolinerge midler er ikke undersøgt og kan derfor ikke anbefales. Graviditet og amning*: Bør ikke anvendes. Dosering: Inhalation af indholdet af 1 kapsel én gang dagligt med HandiHaler® på samme 
tidspunkt. Farmakologiske egenskaber: I et 4-årigt studie sås en forbedring af lungefunktionen (FEV1). Forbedringen forblev konstant i alle 4 år. I behandlingsperioden sås en reduktion på 16% i risikoen for død. Behandling med tiotropium 
reducerede risikoen for respirationssvigt med 19%. Lægemiddelformer: Inhalationspulver i kapsler. Pakninger og priser (uge 18-19/2013): Spiriva®, 30 kapsler med HandiHaler®: kr. 432,00; Spiriva®, 30 kapsler: kr. 415,00; Spiriva®, 90 
kapsler: kr. 1157,00 (Priserne er inkl. recepturgebyr). Dagsaktuel pris findes på www.medicinpriser.dk Udlevering: B. Tilskudsberettiget. Registreringsindehaver: Boehringer Ingelheim International GmbH. De med * markerede afsnit er 
omskrevet og/eller forkortet i forhold til det af Sundhedsstyrelsen godkendte produktresumé af 19.06.2012. Produktresuméet kan vederlagsfrit rekvireres fra den danske repræsentant Boehringer Ingelheim Danmark A/S, Strødamvej 52, 
2100 København Ø, tlf.: 39 15 88 88, Medicinsk Information eller via info.cop@boehringer-ingelheim.com 
Spiriva® Respimat® (tiotropium) Forkortet produktresumé. Indikationer: Tiotropium er en symptomlindrende bronkodilatator til vedligeholdelsesbehandling af kronisk obstruktiv lungesygdom (KOL). Kontraindikationer: Overfølsomhed over 
for tiotropium, atropin eller dets derivater eller over for et eller flere af hjælpestofferne. Bivirkninger: Almindelig (1-10%): Mundtørhed er set hos ca. 3,2% af patienterne - oftest mild og forbigående. Ikke almindelige (0,1-1%): Svimmelhed, 
hovedpine, atrieflimren, palpitationer, supraventrikulær takykardi, hoste, epitaxis, faryngitis, dysfoni, obstipation, oropharyngeal candidiasis, dysfagi, udslæt, pruritus, urinretention, dysuri. Sjældne (mindre end 0,1%) bivirkninger samt 
bivirkninger med ukendt hyppighed (frekvensen kendes ikke, men bivirkningen er ikke set hos 2.802 patienter), herunder glaukom, obstruktion af tarmene inkl. paralytisk ileus samt overfølsomhedsreaktioner (inkl. akutte reaktioner), er 
anført i det fulde produktresumé. Særlige advarsler og forsigtighedsregler vedrørende brugen*: Bør ikke anvendes som initialbehandling ved akutte episoder af bronkospasmer, dvs. som akut behandling. I overensstemmelse med tiotro-
piums antikolinerge virkning skal tiotropium anvendes med forsigtighed til patienter med snævervinklet glaukom, prostatahyperplasi eller blærehalsobstruktion. Inhalerede lægemidler kan forårsage inhalationsinduceret bronkospasme. 
Hos patienter med moderat til svær nedsat nyrefunktion (kreatinin-clearance ≤ 50 ml/min) bør tiotropium kun anvendes, hvis fordelene opvejer den potentielle risiko. Spiriva Respimat skal benyttes med forsigtighed hos patienter med 
kendt hjerterytmeforstyrrelse. Tiotropium (to pust på én gang) må ikke anvendes hyppigere end én gang dagligt. Interaktioner*: Der er ikke set bivirkninger ved anvendelse sammen med andre lægemidler inkl. sympatomimetiske bron-
kodilatatorer, methylxantiner, orale og inhalerede steroider. Samtidig indgift af andre antikolinerge midler er ikke undersøgt og kan derfor ikke anbefales. Graviditet og amning*: Bør ikke anvendes. Dosering: To pust inhaleres én gang om 
dagen på samme tidspunkt. Farmakologiske egenskaber*: Behandling med Spiriva Respimat resulterer i en signifikant forbedring af lungefunktion, dyspnø, livskvalitet, nedsat forbrug af p.n. medicin samt reduktion af KOL-eksacerbationer 
og hospitalsindlæggelser i forhold til placebo, hvor anden specificeret lungemedicin var tilladt. Lægemiddelformer: Inhalationsvæske, opløsning i patron. Pakninger og priser (uge 18-19/2013): Spiriva Respimat inhalationsvæske 2,5 
mikrogram, 1 patron med 60 pust: kr. 469,00. (Priserne er inkl. recepturgebyr). Dagsaktuel pris findes på www.medicinpriser.dk Udlevering: B. Tilskudsberettiget. Registreringsindehaver: Boehringer Ingelheim International GmbH. De med 
* markerede afsnit er omskrevet og/eller forkortet i forhold til det af Sundhedsstyrelsen godkendte produktresumé af 21.09.2012. Produktresuméet kan vederlagsfrit rekvireres fra den danske repræsentant Boehringer Ingelheim Danmark 
A/S, Strødamvej 52, 2100 København Ø, tlf.: 39 15 88 88, Medicinsk Information eller via info.cop@boehringer-ingelheim.com
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60 minutes more with iVAPS: helping overcome challenges in 
noninvasive ventilation (NIV) – initiation and adherence
Initiating patients on noninvasive ventilation (NIV) can be challenging. Getting them to accept therapy and stay 
on long-term NIV can be even harder.
ResMed’s automatic volume-assurance mode iVAPS (intelligent Volume-Assured Pressure Support)  can help 
overcome these challenges.  iVAPS is designed for easy set-up and  improved therapy acceptance.
60minutesmore
iVAPS makes the difference
www.resmed.com
VPAP ST-A
Stellar 150
ADVERT 60 minutes more - iVAPS.indd   3 31.01.13   09.47
Air is for everyone  
  and it’s yours to give 
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SERETIDE DISKUS 50/500 er ætlað til meðferðar hjá sjúklingum með langvinna lungnateppu, með FEV1 <60% af áætluðum gildum og 
sögu um endurteknar versnanir.
Seretide Diskus innöndunarduft, afmældir skammtar. Hver skammtur af Seretide Diskus gefur: 50 míkróg af salmeteróli (sem salmeterólxínafóat) og 100, 250 eða 500 míkróg af flútíkasónprópíónati. Ábendingar: Astmi: 
Seretide Diskus er ætlað til samfelldrar meðferðar gegn astma, þar sem samsett meðferð (langverkandi berkjuvíkkandi lyfs og barkstera til innöndunar) á við: þegar ekki næst nægileg stjórn á sjúkdómnum með notkun barkstera 
til innöndunar og stuttverkandi berkjuvíkkandi (beta-2-örvandi) lyfja eða þegar viðunandi stjórn á sjúkdómnum næst með notkun barkstera til innöndunar og langverkandi berkjuvíkkandi (beta-2-örvandi) lyfja. Langvinn 
lungnateppa: Seretide Diskus er ætlað til meðferðar á einkennum hjá sjúklingum með langvinna lungnateppu með FEV1 < 60% af áætluðu eðlilegu gildi (fyrir gjöf berkjuvíkkandi lyfs) sem hafa umtalsverð einkenni þrátt fyrir 
reglulega meðferð með berkjuvíkkandi lyfjum og sögu um endurtekna versnun. Skammtar og lyfjagjöf: Seretide Diskus er eingöngu ætlað til innöndunar. Ráðlagðir skammtar: Astmi: Fullorðnir og unglingar 12 ára og eldri: 
Einn skammtur með 50 míkróg salmeteról og 100 míkróg flútíkasónprópíónat, tvisvar sinnum á dag, eða einn skammtur með 50 míkróg salmeteról og 250 míkróg flútíkasónprópíónat, tvisvar sinnum á dag, eða einn skammtur 
með 50 míkróg salmeteról og 500 míkróg flútíkasónprópíónat, tvisvar sinnum á dag. Börn 4 ára og eldri: Einn skammtur með 50 míkróg salmeteról og 100 míkróg flútíkasónprópíónat, tvisvar sinnum á dag. Hámarksskammtur 
af flútíkasónprópíónati í Seretide Diskus, sem skráður er fyrir börn, er 100 míkróg tvisvar á dag. Upplýsingar varðandi notkun Seretide Diskus hjá börnum yngri en 4 ára, liggja ekki fyrir. Langvinn lungnateppa: Einn skammtur 
með 50 míkróg salmeteról og 500 míkróg flútíkasónprópíónat, tvisvar sinnum á dag. Frábendingar: Seretide Diskus er ekki ætlað sjúklingum með ofnæmi fyrir virku efnunum eða hjálparefninu Markaðsleyfishafi: 
GlaxoSmithKline ehf. Þverholti 14, 105 Reykjavík, Ísland, Sími 530 3700, Dagsetning endurskoðunar textans: 1. febrúar 2012. Upplýsingar um aukaverkanir, milliverkanir, varnaðarorð og önnur mikilvæg atriði 
má nálgast í sérlyfjaskrá –www.serlyfjaskra.is.
Pakkningar og verð (maí 2013). Seretide Diskus 50/100 míkróg/skammt innöndunarduft, 60 afmældir skammtar. R,G   6.442 kr. Seretide Diskus 50/250 míkróg/skammt innöndunarduft, 60 afmældir skammtar. R,G   9.940 kr.
Seretide Diskus 50/500 míkróg/skammt innöndunarduft, 60 afmældir skammtar. R,G 12.728 kr.
   Aukaverkanir má tilkynna á vef Lyfjastofnunar: www.lyfjastofnun.is/Aukaverkanir/tilkynna eða til GlaxoSmithKline í síma 530 3700.
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